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submitted this material, either in full or in part, for a degree at this or any other institution. 
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1.2 Abstract 
Until very recently the belief has been that cerebral 18F-fluoro-2-deoxy-D-glucose (FDG) 
uptake reaches a pattern resembling normal adulthood by approximately one year of age. 
This idea was based on studies published in the 1980’s and the dogma has been 
promulgated by repeated publications in various textbooks on nuclear medicine and 
neurology since then. Perhaps due to the limitations in performing cerebral FDG scans in 
normal children related to the associated radiation burden of PET CT imaging there has 
been no meaningful advancement in this area since these studies were published. 
 
This thesis aims to re-assess cerebral FDG uptake in children with the purpose of 
describing patterns during normal development and then apply this knowledge to scans 
performed in paediatric patients using qualitative, semi-quantitative (SUV) and statistical 
parametric mapping (SPM) techniques. To this end, Chapter 2 orientates the reader to the 
layout of the thesis as a whole, and provides readers unfamiliar with SPM the necessary 
theoretical background to understand the more technical chapters later in the thesis. 
 
Chapters 3 and 4 are concerned with describing normal cerebral FDG uptake in children. 
The results confirm that significant changes occur in regional cerebral FDG uptake 
throughout normal childhood development. 
 
Chapters 5 and 6 validate the dataset of normal subjects in preparation for SPM 
comparison to children with intractable epilepsy who have undergone surgery. SPM 
analysis is then applied to the pre-operative FDG scans in the epilepsy patients and the 
accuracy in predicting successful surgery is evaluated. Chapter 6 is an example of a 
single-subject versus group SPM analysis. 
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Chapters 7 and 8 analyse cerebral FDG scans in a group of children with 
Neurofibromatosis type 1 and compare the results with the dataset of normal subjects to 
reveal new findings in this common genetic disorder. Chapter 8 is an example of a group 
versus group SPM analysis. 
 
Chapter 9 then summarises the findings of the thesis and provides clinical context as to 
the importance of the results. The implications for future research in this area are 
discussed. 
 
This thesis forms a comprehensive body of work in a field lacking informative 
knowledge. The construction and comprehensive analysis of the highly unique dataset of 
cerebral FDG PET CT scans in neurologically normal children is a major advancement in 
the understanding of normal brain metabolism during human development. The 
demonstration of SPM analyses comparing this normal dataset to clinical scans 
exemplify the potential application of this technique to detect abnormal cerebral 
metabolism in children with any potential neurological disorder.  
 v
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1.12 Glossary / Abbreviations 
artefacts Supra-threshold voxels surviving an analysis that originate from non-
biological sources such as errors in normalisation or corrupted scans used in 
the analysis. 
 
cluster One or more adjoining voxels. 
 
corrected Corrected for multiple comparisons. 
 
custom template A normalisation template constructed from scans for a particlar analysis. 
Within the SPM software there are generic adult templates provided that are 
derived from various MRI sequences and PET and SPECT cerebral perfusion 
agents. 
 
FDG 18F-fluoro-2-deoxy-D-glucose. A glucose analogue bonded to a positron 
emitting nuclide, 18F. 
 
FWEc Family wise error rate (cluster) corrected for multiple comparisons. A 
method to adjust the statistical analysis for multiple comparisons at the 
cluster level.  The statistical inference arising from a FWEc corrected 
analysis is that there is evidence of a significant effect at at least one voxel 
within every supra-threshold cluster. 
 
FWEp Family wise error rate (peak) corrected for multiple comparisons. A method 
to adjust the statistical analysis for multiple comparisons at the voxel level.  
The statistical inference arising from a FWEp corrected analysis is that there 
is evidence of a significant effect at each and every supra-threshold voxel. 
 
local maxima The peak voxel or voxels within a particular cluster. 
 
local minima The trough voxel or voxels within a particular cluster. 
 
NF1 Neurofibromatosis Type 1 
 
normalisation Warping of a brain image to match a particular template image. 
 
normalisation bias A term describing the use of an inappropriate normaisation template that is 
more similar to a subset of brain images entered in to the analysis. The result 
is a systematic difference in normalisation between groups of images that can 
create artefacts on the output SPM map. 
 
PET CT Hybrid positron emission tomography and computed tomography imaging. 
 
pre-processing The manipulation of functional brain images prior to performing the 
statistical analysis. In general terms pre-processing is concerned with 
warping each brain image into the same steriotactic space and then 
smoothing the images to improve the statistical nature of the data prior to 
voxel-wise analysis. 
 
RFT Random field theory. A theory based on the geometry of three-dimensional 
images from which one can derive the expected topology of an image for a 
given smoothness. RFT is the underpinning theoretical construct behind FWE 
methods to correct for multiple comparisons in the analysis of functional 
brain images. 
 
specificity optimised Optimising the analysis, both the pre-processing parameters and statistical 
modelling, to reduce the chance of false positve findings i.e. to maximise the 
specificity of the analysis. 
 
SPM Statistical parametric mapping. The name of the most commonly used voxel-
 xix
based software for the anlaysis of functional brain images and often in 
common usage to refer to any process of voxel-wise satistical mapping of 
functional brain images. 
 
SPM map The actual output statistical image after applying a statistical threshold to an 
analysis. Often overlayed on an anatomical template to provide some spatial 
orientation to any surviving clusters. 
 
SUV Standardised uptake value. A unitless metric quantifying the intensity of 
tracer activity demonstrated on a PET scan image. The calculation 
incorporates the dose of the radiopharmaceutical administered, the physical 
decay of the radionuclide between administraton and scan, and a measure of 
the distribution of the radiopharmaceutical (usually body weight or body 
surface area). 
 
template The template used to warp (normalise) all of the images to, prior to statistical 
analysis. A key step in image pre-processing. 
 
topology The study of geometric shapes. In the context of fuctional brain image 
analysis topology generally refers to the three dimensional profile of a SPM 
map i.e. the peaks and troughs of the voxel values of the statistic making up 
the SPM map. 
 
voxel A volume unit of data within a brain image. 
  
 1
2 CHAPTER TWO: THESIS ORIENTATION  
 
2.1 Motivation 
The interpretation of cerebral 18F-fluoro-2-deoxy-D-glucose (FDG) PET CT scans in 
children is extremely challenging. In general, neurological pathology in children is less 
well studied than in adults and the physiologic patterns of FDG uptake in normal 
children are poorly established. 
 
The first major aim of this thesis is to describe patterns of cerebral FDG uptake in 
neurologically normal children. This is achieved by recruiting a high quality normal 
control dataset of cerebral FDG scans in neurologically normal children of various ages 
and performing a descriptive analysis using semi-quantitative (SUV) and qualitative 
methods. 
 
Scanning protocols may vary from facility to facility and also different PET scanners 
may produce variable image quality. These technical factors also contribute to the 
difficulties in accumulating knowledge on what may constitute a normal FDG scan in a 
child of a particular age. Such challenges may be partly overcome by the use of statistical 
methods to analyse cerebral PET images and allow meaningful differences in regional 
FDG uptake to be detected in children with neurological disorders. 
 
The second major aim of this thesis is to implement a voxel-based, whole brain analysis 
of the normal control dataset, and demonstrate the used of this technique to compare the 
dataset to scans performed in children with epilepsy and Neurofibromatosis Type 1. To 
achieve this, statistical parametric mapping using the software package called SPM 
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(Wellcome Trust Centre for Neuroimaging, Institute of Neurology, London, UK) is 
employed as the voxel-based technique to analyse the cerebral FDG scans. The 
comparative SPM analyses compares the normal control dataset to paediatric patients 
with epilepsy and Neurofibromatosis Type 1 (NF1), and are examples of single-subject 
versus group and group versus group SPM comparisons, respectively. 
 
2.2 Thesis structure 
 
Chapter 1 contains the front-section material of the thesis including the table of contents, 
list of figures and list of tables. 
 
Chapter 2, the current chapter, orientates the reader to the thesis structure and content. It 
also provides a review of the theory behind SPM as it applies to the analyses undertaken 
in subsequent chapters. The discussion is not intended as a comprehensive review of 
SPM but serves to provide sufficient background to readers without prior knowledge of 
statistical analysis of functional brain images to better understand the experimental 
design that is used in this thesis. 
 
The scientific analytical chapters are Chapters 3, 4, 5, 6, 7 and 8. 
 
Chapter 3 comprehensively describes the recruitment and analysis of the largest reported 
cohort of dedicated cerebral FDG scans in neurologically normal children. The 
introduction contains an extensive literature review relevant to the thesis as a whole, and 
highlights the deficiencies of the limited number of previously published reports on the 
topic. The analysis presented in this chapter has been published in modified form prior to 
submission of the thesis. 
 3
 
Chapter 4 uses SPM to descriptively analyse the normal control dataset. The data 
presented in Chapter 4 has also been published (in modified form) prior to submission of 
this thesis, and it is the first reported voxel-based descriptive analysis of cerebral FDG 
scans in neurologically normal children.  
 
Chapter 5 is a technical report detailing the process of determining SPM  “specificity 
optimised” parameters to use in the comparison of single-subject patient scans to the 
normal control dataset. The chapter culminates in the description of the most appropriate 
SPM settings (template smoothing, scan smoothing and voxel-level statistical thresholds) 
to reduce the chance of false positive findings, which are implemented in the analysis 
presented in Chapter 6. 
 
Chapter 6 is the first chapter that implements SPM to analyse paediatric patient scans, 
and utilises a large cohort of FDG scans performed in children with epilepsy. The 
hypothesis being tested is that focal hypo-metabolism detected by SPM analysis can 
guide surgical resection in children with medially intractable epilepsy.  
 
Chapter 7 uses standard qualitative and semi-quantitative (SUV) analyses to compare 
FDG scans in children with NF1 to the normal control dataset. The findings support 
those from the limited number of previously published reports in NF1 and new findings 
are also revealed. 
 
Chapter 8 implements SPM to compare the group of NF1 children to the normal control 
dataset. This chapter includes a technical analysis to determine the most appropriate SPM 
pre-processing parameters. A descriptive analysis of the children with NF1 using SPM is 
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also performed and the findings are contrasted against those from Chapter 4 where the 
same analysis was performed on the normal control dataset. 
 
Chapter 9 summarises the main results of the thesis and also provides commentary on the 
implications of the findings presented in the thesis and future directions. 
 
Chapter 10 is a list of the references cited in the thesis. 
 
2.3 PET CT imaging using 18F-FDG 
 
Hybrid imaging using positron emission tomography/computed tomography (PET CT) is 
a functional imaging modality which utilises positron emitting radionuclides, resulting in 
an in-vivo map of a particular molecular pathway [1, 2]. 
 
FDG is taken up into brain tissue via the same carrier-mediated diffusion mechanism as 
glucose and is phosphorylated by hexokinase to a substrate that is not further metabolised. 
It effectively becomes locked in the tissue and accumulates in the brain proportional to 
local cerebral metabolic rates of glucose utilisation [3]. FDG PET CT imaging provides 
an in-vivo map of the cerebral glucose utilisation and since the first FDG PET study in 
humans [4] it has become a major imaging modality in the investigation of neurological 
disorders. In adults the main non-oncologic use of cerebral FDG imaging is the 
investigation of neurodegenerative disorders but in paediatric patients the use is mainly 
in epilepsy. 
 
The interpretation of cerebral FDG scans primarily is by subjective visual assessment. 
Statistical methods for comparing a cerebral brain PET scan to a dataset of control 
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images are able to be performed and have become commonly used in the clinical 
evaluation of adult patients with suspected neurodegenerative disorders. Statistical 
analysis of cerebral FDG PET CT scan in children are not in routine clinical use and 
published reports are extremely limited, mainly due to the lack of a suitable normal 
control dataset. SPM is the most common software package used to analyse functional 
brain images in neuroscience research and is available free of charge (Wellcome Trust 
Centre for Neuroimaging, Institute of Neurology, London, UK).  
 
2.4 Statistical Parametric Mapping using SPM 
Whole brain voxel-wise analysis of FDG PET CT scans using SPM involves multi-step 
processing of the native reconstructed FDG scan (Figure 2.1). First there is the pre-
processing of the scans prior to statistical analysis. Pre-processing involves warping each 
image to the same stereotactic space (a process called “normalisation” in SPM parlance) 
and then smoothing the normalised scans by applying a Gaussian smoothing kernel. 
Following this, all of the scans are entered into a statistical model along with any 
covariates that are to be included in the analysis (the “[statistical] design matrix”. The 
investigator then stipulates which scans in the design matrix are to be compared (the 
“contrast matrix”). SPM then fits a general linear model based on the intensity within 
each and every voxel in the image and displays the output statistic (t-values in the case of 
a t-test comparison) as an image in three dimensions in the same stereotactic space as the 
brain volumes from which the data comes (ie. the output statistical parametric map, 
SPM). The output SPM map can then be thresholded based on a selected level of 
statistical evidence with only those voxels with more significant voxel intensities as 
shown on the SPM map. In SPM8 statistical thresholds are specified on the basis of a p-
value threshold, either uncorrected or corrected for multiple comparisons according to 
random field theory (RFT). The final SPM map can be viewed as a maximium intensity 
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projection (MIP) image, called ‘the glass brain” display in SPM, or overlayed on either 
tomographic slices or a surface rendered image of any other brain image that is in 
suitable electronic format. The SPM8 software contains a normal adult T1 cerebral MRI 
that is used in this thesis to overly the output SPM maps onto for both tomographic and 
surface rendered visualisations of the SPM results. 
 
 
Figure 2.1: Schematic of the steps involved in SPM analysis of FDG PET scans. 
Modified from [5]. The FDG PET scans are warped to match the stereotactic spaced of a normalisation 
template and then the normalised images are smoothed with a gaussian kernel. A statistical design matrix is 
set up including any covariated that are to be included in the linear modelling of the voxel-wise data. 
Contrasts are specific to compare the various conditions within the study group. An output statistical 
parametric map is produced and then thresholded according to a specified statistical limit, and after 
correcting for multiple comparisons (based on RFT) an output SPM may is produced from which 
inferences are made. 
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2.4.1 Pre-Processing 
2.4.1.1 Spatial Normalisation of Scans and the use of appropriate Normalisation 
Templates 
Spatial normalisation in SPM refers to the process of warping each FDG scan to the same 
template image. In this way all of the scans in the analysis fit the same stereotactic space 
and will allow the same voxel location to be compared across the entire dataset. 
Normalisation works best when the normalisation template is an image created from the 
same tracer as the type of tracer under investigation. There is evidence that scans in 
children are not accurately normalised when an adult template is used [6]. Therefore, the 
type of normalisation template that is used can potentially create artefacts in the resulting 
SPM images and selecting the most appropriate normalisation template has been 
carefully considered in this thesis. 
 
2.4.1.2 Image Smoothing 
Smoothing is required to overcome the inaccuracies of spatial normalisation between 
scans, to improve the signal to noise ratio of any underlying signal, and to improve the 
performance of the methods for correction for multiple comparisons in the statistical 
analysis. 
 
The smoothing process during SPM pre-processing can cause false SPM findings near 
the interface between tissues with very different voxel intensities, such as the boundaries 
between the ventricles and grey matter or at the edge of the brain surface [7]. Inspection 
of the output SPM maps is required to detect artefacts due to this phenomena and has 
been carefully considered during the technical evaluation of SPM pre-processing 
parameters when applied in this thesis. 
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2.4.2 Global Normalisation of Voxel Intensity 
The issue of variations in the voxel intensity due to variations in injected dose and 
variations in uptake time needs consideration. Voxel intensities can be scaled to overall 
brain FDG uptake in a procedure called global normalisation and this is often used in 
voxel-based analyses of FDG PET to account for differences in overall brain tracer 
uptake that can occur with different injected doses and uptake times. 
 
A potential problem arises if there is a correlation between the change in FDG uptake 
that we are interested in and the global signal. Voxel based analysis are less susceptible 
to this effect than analyses using large region-of-interest methods [8]. In essence, the 
larger the region from which you are collecting data from, the more chance that any 
changes in signal arising from this region may also effect the global signal and therefore 
be masked if uptake is scaled by the global signal during the analysis. 
 
2.4.3 Statistical analysis 
2.4.3.1 The Multiple Comparison Problem 
After pre-processing, a FDG brain scan may be made up of in excess of 200,00 voxels. 
The statistical modelling of the change in voxel-wise tracer intensity is applied at each 
and every voxel. This creates a problem of multiple statistical comparisons because if 
each voxel is treated as an independent data point then using standard statistical analysis 
with a p-value threshold of 0.05 would yield in excess of 10,000 (5% of 200,000) supra-
threshold false positive voxels in the absence of any true signal in the voxel wise data. 
This problem of multiple comparison requires some method to appropriately control the 
false positive rate. 
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Bonferroni correction for multiple comparisons treats each and every voxel as an 
independent data point. In reality there is a correlation between voxel intensities in 
nearby voxels, partly due to smoothing during image reconstruction and by image 
smoothing during SPM pre-processing in preparation for statistical analysis. The overall 
effect is that there are fewer independent observations in the image than there are voxels 
and a Bonferroni type correction for multiple comparisons is too strict for functional 
imaging analysis. 
 
Random field theory (RFT) is a theory related to the geometric configuration of three 
dimensional shapes and it has applications to the interpretation of images which contain 
random but spatially correlated variability in intensities such as cerebral PET scans [9]. 
RFT can be used to incorporate the spatially correlated nature of an FDG PET image to 
predict the geometric configuration of the image (ie. the topology) and if there are 
excursions beyond the predicted topology of the image then it provides evidence of non-
random, that is, statistically significant changes in FDG uptake. 
 
2.4.3.2 Voxel Level (FWEp) Correction for Multiple Comparisons 
SPM makes an estimate of the smoothness of the images being analysed and using voxel-
level correction for multiple comparisons (FWEp) according to RFT, adjusts the 
specified p-value threshold according to the expected topology of the image. The 
adjusted p-value threshold is now corrected for multiple comparisons and it is applied to 
each and every voxel to yield a whole brain voxel-level corrected (FWEp) SPM map [10, 
11]. 
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2.4.3.3 Cluster Level FWEc Correction for Multiple Comparisons 
Cluster level correction for multiple comparisons (FWEc ) also uses the RFT based 
family-wise error rate method. It evaluates, based on the size of any supra-threshold 
cluster, how likely cluster of this size or larger (based on a specified uncorrected p-value 
threshold) would have occurred by chance. If the cluster size is larger then that predicted 
could occur by chance at the cluster level corrected p<0.05 level, then the inference is 
that there is statistical evidence of at least one voxel within the supra-threshold cluster 
that is has altered intensity not due to chance, i.e. due to the underlying comparison. 
 
This approach means that detecting regions of the brain with a significant difference in 
intensity of tracer uptake does not depend on a single fixed p-value threshold, but 
examines the volume for significant clusters at any specified uncorrected p-value 
threshold. This method allows for increased sensitivity compared to voxel level FWEp 
correction but comes at a cost of spatial specificity i.e. the precision of the spatial 
localisation of the results. The spatial precision of the result is worse at more liberal 
uncorrected p-value thresholds because even if the supra-threshold clusters pass 
significance at the FWEc p<0.05 level, the clusters are very large and may involve large 
areas of the brain. 
 
2.4.4 Statistical Inference 
When using voxel level FWEp correction for multiple comparisons the inference is that 
there is evidence of a statistically significant difference in voxel intensities in each and 
every surviving supra-threshold voxel. However, with cluster level cFWEc correction for 
multiple comparisons the inference is that there is evidence for at least one voxel within 
each surviving supra-threshold cluster that has a significantly different intensity. 
Therefore, the spatial precision for cluster level FWEc results is poorer than voxel level 
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FWEp results, particularly if there are large FWEc clusters that cross over different 
functional areas of the brain or even spread to the contralateral side of the brain. 
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3 CHAPTER THREE: SUVMAX AND QUALITATIVE 
ANALYSIS OF NORMAL CEREBRAL FDG 
UPTAKE DURING CHILDHOOD 
3.1 Abstract 
Aims: Current understanding of cerebral FDG uptake during childhood originates from a 
small number of reports using patients with neurological abnormalities. Our aim is to 
describe cerebral FDG uptake in a dataset of FDG PET scans from children more likely 
to represent normal. 
 
Methods: We reviewed cerebral FDG PET scans in children up to 16 years with 
suspected/proven extra-cranial malignancies and the following exclusions: central 
nervous system metastases, previous malignancies, previous chemotherapy or 
radiotherapy, development of cerebral metastases during therapy, neurological conditions, 
taking antiepileptic medication or medications likely to interfere with cerebral 
metabolism and general anaesthetic within 24 hours. White matter, basal ganglia, 
thalamus and the cerebellar cortex were analysed using regional SUVmax, and the 
cerebral cortex, basal ganglia, thalamus and cerebellum were analysed using a regional 
relative uptake (RU) analysis compared to maximal cortical uptake. 
 
Results: Thirty scans were included (age range 11 months - 16 years, mean age 10 years 
five months). All regions showed increasing SUVmax with age. The parietal, occipital, 
lateral temporal and medial temporal lobes showed lower rates of increasing FDG uptake 
causing changing patterns of regional FDG uptake during childhood. The most intense 
cortical regions in early childhood are the parietal and occipital lobes. At approximately 
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seven years these regions have relatively less uptake than the frontal lobes and at 
approximately ten years these regions have relatively less uptake than the thalamus. 
 
Conclusions: Relative FDG uptake in the brain does not reach an adult pattern by one 
year of age but continues to change up to 16 years. The changing pattern is due to 
different regional rates of increasing cortical FDG uptake, which is less rapid in the 
parietal, occipital and temporal lobes than in the frontal lobes. 
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3.2 Introduction 
It is necessary to understand the normal patterns of FDG uptake during childhood to 
allow pathological alterations in brain metabolism to be identified. However, the current 
knowledge of cerebral glucose utilisation during normal childhood development using 
18F-fluoro-2-deoxy-D-glucose (FDG) PET has evolved from a very small number of 
clinical studies. Studies investigating cerebral FDG uptake in normal adults utilise 
healthy adult volunteers [12-14]. Due to ethical reasons studies addressing normal 
cerebral FDG uptake in children have to date been limited to patients with suspected 
neurological conditions. 
 
There have been three reports in children [12, 15, 16] and two reports in neonates and 
infants (up to 6 months of age) [17, 18] aiming to describe normal cerebral FDG uptake. 
All of the childhood studies involved children with neurological disorders [12, 15, 16] 
and a significant proportion were receiving anti-epileptic medications which have been 
proven in adult studies to alter cerebral glucose metabolism [19-21]. Of the two neonatal 
studies, one used patients with hypoxic ischaemic encephalopathy and hypoglycaemia 
[17, 18]. The validity of considering such patients as representative of “normal” is 
questionable. 
 
In the first systematic description of normal patterns of cerebral glucose utilisation 
Chugani et al described their findings in FDG PET scans performed in nine children 
ranging from five days to 18 months of age [15]. These patients were selected from over 
60 scans performed in children to evaluate suspected neurological conditions because 
their “status at the time of the procedure was judged to be nearly normal”. Six patients 
were scanned to assess seizures and three for the assessment of suspected Sturge-Weber 
Syndrome. Three had an abnormal EEG prior to the scan and six were on anti-epileptic 
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medication (phenobarbital, valproic acid and/or clonazepam). Five had normal cerebral 
CT imaging. 
 
The authors analysed changes in relative FDG uptake. Thalamic FDG uptake appeared 
“well developed” in all age groups and was chosen as the reference against which to 
normalise the uptake of the other regions of interest. The lenticular nuclei, primary visual 
cortex, anterior cingulate cortex, caudate, association visual cortex, sensorimotor cortex, 
transverse temporal gyrus, middle frontal gyrus, midbrain/brainstem and cerebellum 
were compared to the thalamus. While not explicitly stated it is presumed the authors 
used a region of interest analysis method to obtain ratios of uptake referenced to the 
thalamus.  
 
They found in their youngest patient (five weeks of age) that FDG uptake was highest in 
the thalamus, midbrain/brainstem, sensorimotor cortex and cerebellar vermis. By three 
months, uptake relative to the thalamus was increasing but still relatively low in the 
frontal and several association cortices, striatal uptake approached that of the thalamus 
and uptake was more uniform through the cerebellar cortex rather than concentrated in 
the vermis. By one year of age the authors considered relative cerebral uptake to appear 
similar to that in adults with prominent activity in the frontal and association cortices 
[15].  
 
Referencing regional cerebral glucose metabolism to the thalamus was justified by the 
authors quoting that their preliminary data showed absolute rates of thalamic glucose 
utilization to be high in their youngest patient aged five weeks old (23 umol/100g/min) 
and although they state that the thalamus did not seem to undergo significant change with 
advancing age, this data was not reported. The validity of this approach is questionable 
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given the existing evidence that thalamic FDG uptake is not static during childhood, 
either in absolute terms or relative to whole brain metabolism. 
 
In a study of 20 neonates being investigated for either hypoxic ischaemic encephalopathy 
or symptomatic hypoglycaemia, Kinnala et al calculated absolute rates of thalamic 
glucose utilisation to be low in the term infant (12 umol/100g/min) and increased during 
the first 6 months of age [17]. Further, in a study only incorporating children older than 
six years of age, Van Bogaert et al demonstrated that FDG uptake in the thalamus (and 
anterior cingulate cortex) relative to whole brain counts continues to increase until the 
third decade and then may progressively decline thereafter [12]. 
 
Chugani et al followed up their initial study by expanding their cohort to 29 children 
considered to be “reasonable representative of normal children”. They reported the 
changes in absolute values of local cerebral metabolic rates of glucose (lCMRGlc) 
throughout childhood [16]. Prior to our study, this analysis formed the most 
comprehensive published work on evaluating cerebral FDG uptake during childhood. 
Their patients ranged from five days to 15 years of age and all had had a transient 
neurological event. The indication for scanning was to evaluate a seizure disorder in the 
majority (21 patients), followed by possible Sturge-Weber Syndrome in five patients, and 
apnoea, visual hallucinations and tunnel vision each in one patient. Twenty-seven had a 
normal cerebral CT scan and six had a normal cerebral MRI scan. However, eight had an 
abnormal EEG and 18 were taking anti-epileptic medications at the time of the PET scan 
(phenobarbital, clonazepam, carbamazepine and/or phenytoin). Clinical follow up of the 
patients was carried out for between three months to ten years after the scan although the 
method for determining normal neurological development in their subjects is not reported 
[16]. Based on their data the authors concluded that whole brain FDG uptake is low at 5 
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days of age (their youngest patient studied) and increases to adult levels by about two 
years of age. They described FDG uptake continuing to increase to peak between the 
ages of four and nine years (at about twice that of normal adult levels) after which there 
was a decline to normal adult levels by about age 30 years. Superimposed on these global 
whole brain changes in absolute glucose FDG uptake were different patterns of regional 
relative uptake occurring over the first year of life. These patterns of changing relative 
uptake matched the findings of their earlier study [15] (although four patients in this very 
young age range were common to both reports) and remain based on a purely subjective 
assessment of the scans performed in seven children under the age of 12 months, five of 
these were receiving phenobarbitone at the time of the scan. Phenobarbitone and other 
anti-epileptic medications have been shown to significantly alter cerebral glucose 
metabolism [19-25]. 
 
Related studies investigating cerebral blood flow in children using PET and SPECT have 
shown evidence to support this peaking profile of absolute whole brain glucose 
utilisation in mid childhood as described by Chugani et al. One study using inhaled 
oxygen-15 showed a trend for increasing cerebral blood flow in the cortical, subcortical 
and cerebellar grey matter with age peaking in the 3-8 year age group significantly above 
normal adult levels, before reducing in the 8-16 yr age group [26]. Their study had a 
similar number of patients to ours and used quantitative measures of cerebral blood flow, 
however all of their patients in the older age group had moyamoya, which would be a 
strong potential confounder to their results [27]. Studies using inhaled or intravenously 
administered xenon-133 in children have shown variable associations of regional cerebral 
blood flow with age including low values at birth which rise to a peak in mid childhood 
followed by a gradual fall, and high levels in the first years of life which progressively 
decrease until adulthood [28, 29].  
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Interestingly the previous study by Kinnala et al, although involving patients of 
considerably younger age than Chugani et al, showed similar patterns of relative regional 
FDG uptake in association with post-conception age. They found at 43-48 weeks post-
conception (up to 2 months old by corrected gestational age) the most metabolically 
active regions in the brain were the brainstem and thalamus, followed by the cerebellum. 
Glucose uptake in the cerebral cortex was lower overall, about 50% of thalamic uptake, 
but was most prominent in the sensorimotor strip. This is very similar to the pattern 
described by Chugani et al [15, 16] in their youngest subject who was 5 weeks old. 
Kinnala et al described whole brain glucose metabolism continuing to increase with 
advancing age, but increasing more rapidly in the cerebral cortex so that by about six 
months of age the sensorimotor cortex had similar metabolic activity to the thalamus [17].  
 
Using a different PET radiopharmaceutical (11C-D-glucose) to measure rCMRGlc in six 
preterm infants, Powers et al performed a related study in neonates from 27 to 35 weeks 
gestation who were between four to seven days old at the time of the scan. All had 
cranial ultrasound scans; four were normal, one showed a small subependymal 
haemorrhage and one showed a small left intraventricular haemorrhage. There was no 
clinical evidence to suggest a perinatal hypoxic insult in any of the included patients. The 
primary objective of the study was to prove the feasibility of performing such studies on 
preterm infants to determine whole brain rates of glucose utilisation using a very small 
dose of the 11C-D-glucose tracer in this highly experimental setting [30]. They showed 
that whole brain CMRGlc in preterm infant was approximately one third of normal adult 
values. 
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Shi et al have published the most recent study of patterns of glucose utilisation in normal 
preterm and term neonates [18]. They performed FDG PET scans in seven preterm and 
nine term infants aged between three to 21 days after birth. Ten patients had a normal 
cerebral CT scans and six had a normal cerebral MRI scan. The authors state that the 
patients had no clinical neurological abnormalities and that FDG PET scans were 
performed solely for research purposes. Further clinical data on these patients are not 
provided and no mention is made of clinical follow up to ensure normal postnatal 
development of the patients. The authors used a regional SUV analysis of the thalamus, 
cerebellum, sensorimotor cortex, basal ganglia, frontal region, temporal region, occipital 
region and parietal region but it is not clear how regions of interest were constructed or if 
maximal SUV or mean SUV was recorded. Despite these omissions in reporting the 
study methodology, their findings were generally consistent with that of earlier studies 
and showed highest FDG uptake in the thalamus, cerebellum, basal ganglia and 
sensorimotor cortex, with global uptake lower in the preterm group. Other SPECT 
methods using iodine-123 iodoamphetamine have generally shown similar patterns in 
regional cerebral blood flow in infants, but with much less spatial resolution inherent in 
SPECT imaging [31]. 
 
General anaesthetic medications alter cerebral blood flow and metabolism [32] and 
therefore recent administration of general anaesthesia is an important consideration when 
looking at patients to include in a descriptive study of normal brain glucose metabolism. 
 
3.3 Aims 
The aim of our study was to recruit a high quality dataset of cerebral FDG PET/CT scans 
that represent a non-pathological state from which to describe the patterns of cerebral 
FDG uptake occurring during normal childhood. 
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3.4 Methods 
Approval was obtained from the hospital ethics committee to perform a retrospective 
review of dedicated cerebral FDG PET/CT scans. Patients referred for a whole body 
FDG PET/CT scan to stage proven or suspected extra-cranial malignancy undergo a 
dedicated cerebral scan acquisition in addition to a separate whole-body scan extending 
from the base of brain to the feet. A medical history is taken from each patient and their 
family prior to the scan. 
 
3.4.1 Scanning protocol 
PET/CT was performed on a Siemens Biograph16 HiRez PET/CT and reviewed on a 
Siemens e.soft workstation (Siemens Medical Solutions, Erlangen, Germany). Children 
fasted for 4–6 h before injection of 370 MBq (scaled to weight) of FDG and had blood 
glucose levels confirmed to be within the normal range. During a 30-minute uptake phase, 
the children rested in a dimly lit room, supine and with minimal stimulation followed by 
a 15-minute dedicated brain acquisition. If conscious sedation was required then 
50mg/kg of chloral hydrate was administered mid-way through the uptake phase. If a 
general anaesthetic was required then at the completion of the uptake phase and once the 
patient was positioned on the scanner an intravenous infusion of propofol was 
administered by a paediatric anaesthetist. 
 
3.4.2 Subject population 
An electronic database of patients who had an FDG PET/CT scan from June 2006 to July 
2010 was searched. Patients with a dedicated cerebral study were identified and the 
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electronic medical records were reviewed to determine eligibility based on the following 
criteria. 
 
Patients referred for a whole body FDG PET/CT scan investigating suspected or proven 
extra-cranial tumours were included. Exclusion criteria were the presence of central 
nervous system (CNS) metastases, previous malignancy, previous chemotherapy or 
radiotherapy, development of cerebral metastases during induction therapy, any 
neurological conditions (eg. developmental abnormalities, psychological or behavioural 
disorders, learning disorders, epilepsy, previous central nervous system infections), 
current use of antiepileptic medication or other medications likely to interfere with 
cerebral metabolism, and general anaesthesia within 24 hours prior to the FDG PET/CT 
scan. Qualifying scans were considered to represent cerebral FDG distribution for a 
normal child of their age at the time of the scan. 
 
3.4.3 Regional SUVmax analysis 
An ellipsoid volume of interest (VOI) thresholded at SUV 2.5 was placed over the 
caudate head, putamen and thalamus and the SUVmax was measured and recorded. White 
matter SUVmax was sampled from the centrum semiovale taking care to avoid the grey 
matter of the adjacent cerebral cortex and subcortical nuclei. The cerebellum was 
analysed by manually moving the ellipsoid VOI through the cerebellar grey matter to 
obtain the SUVmax in each cerebellar hemisphere. 
 
The cerebral cortex occupies such a large, irregular spatial profile such that using an 
ellipsoid VOI tool to sample regional SUV data was not able to reliably represent tracer 
uptake in each lobe. Therefore regional SUVmax analysis of the cerebral cortex was not 
performed but was considered in the regional relative uptake analysis described below. 
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3.4.4 Regional Relative Uptake (RU) 
Each scan was assessed independently by three readers who were all qualified Paediatric 
Nuclear Medicine Physicians (RHG, RU, DC (see acknowledgements)). The readers 
were blinded to patient details including age, indication for the scan and the results of the 
other readers. 
 
Eight regions were analysed: frontal lobe, medial temporal lobe, lateral temporal lobe, 
parietal lobe, occipital lobe, cerebellar hemisphere, thalamus and basal ganglia (caudate 
head and putamen combined). Each scan was viewed using a 10-step colour scale 
thresholded to the maximum cerebral cortical uptake.  The overall intensity of tracer 
uptake within each region expressed as a percentage relative to the maximal cortical 
uptake in 10% increments was assessed and recorded. 
 
3.4.5 Estimating SUVmax for cerebral cortical regions 
A calculation was performed to produce an estimated SUVmax to assign to each cerebral 
cortical region. Basal ganglia FDG uptake was qualitatively intense across the whole 
group of subjects and did not appear to change relative to maximal cortical uptake with 
age (see Regional Relative Uptake results below, and Figure 4). Therefore the basal 
ganglia structures were used as a reference from which to estimate the SUVmax to best 
represent uptake in each cerebral cortical region. The ratio of RU in each cortical region 
relative to the basal ganglia was calculated and multiplied by the basal ganglia SUVmax 
(visually derived from the plots of SUVmax against age in the caudate head and putamen, 
see Figure 3.2). 
ie. Estimated cortical region SUVmax 
  = (cortical region RU/basal ganglia RU) x (basal ganglia SUVmax) 
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These regional cortical SUVmax estimates were used to compare to the SUVmax data 
obtained directly from the FDG PET/CT scans in other regions. 
 
3.4.6 Statistical analysis 
Data analysis was carried out using SPSS v19 (IBM). 
 
A paired t-test on the difference in uptake between the corresponding left and right 
regions (right minus left) was used to evaluate the evidence for significant asymmetry for 
both the SUVmax and RU data. Scatterplots of regional SUVmax and RU against age were 
produced and inspected. Correlation and regression analysis were performed where 
appropriate, to investigate the relationship between regional FDG uptake and age. 
 
The data were categorised into four age groups (less that five years, five to ten years, ten 
to 15 years and greater than 15 years old) and statistical tests of non-equivalence were 
applied. If there was evidence of non-equivalence across the age groups then post-hoc 
testing between all age groups was performed. Non-parametric statistical tests (Kruscal-
Wallis and Mann-Whitney-U) were used due to the small numbers of children in each 
age group.  
 
Inter-reader agreement in the RU assessment was evaluated by intra-class correlation 
coefficient analysis with each reader classified as independent. 
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3.5 Results 
3.5.1 Patients included 
Forty three cerebral PET/CT scans were performed for the staging of suspected or proven 
extra-cranial malignancy during the review period.  Thirteen of these were excluded due 
to: an incidental caudate infarct, previous craniotomy for biopsy of a skull base tumour, 
previous malignancy, receiving a morphine infusion, receiving high dose corticosteroids, 
systemic lupus erythematosis, myelodysplastic syndrome, autism and five with a general 
anaesthetic within the previous 24 hours. 
 
There remained 30 eligible scans, 13 males and 17 females. The age range was 11 
months to 16 years. The mean age at the time of the scan was 10 years five months. 
Clinical details for the included children are presented in Table 1. 
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Table 3.1: Demographics of the included subjects. 
The age, sex and diagnosis of the included subjects are shown. 
Age 
(year, months) Sex Diagnosis 
0, 11 Malea Sacral yolk sac tumour, no metastases. 
1, 8 Femalea Introital embryonal rhabsomyosarcoma, no metastases. 
2, 1 Femalea Orbital Langerhan cell histiocytosis. 
3, 10 Femaleb Renal cell carcinoma, no metastases. 
4, 6 Malea Ewing sarcoma of great toe, lung metastases. 
4, 8 Malea Suspected neural crest tumour. No tumour found. 
7, 1 Male Adenopathy for investigation. Benign reactive lymph nodes. 
7, 5 Female Spitzoid melanoma of the calf, regional lymph node metastases. 
8, 0 Female Infrascapular epitheliod sarcoma, no metastases. 
8, 0 Female Maxillary rhabdomyosarcoma, regional lymph node metastases. 
8, 11 Male Suspected spinal tumor. Benign haemangioma. 
9, 6 Female Nodular sclerosing HLc, stage IV. 
10, 8 Female Fibular precursor B lymphoblastic lymphoma, skeletal 
metastases. 
10, 11 Female Suspected sarcoidosis. 
11, 6 Male Inguinal nodular lymphocyte predominant HLc. 
12, 1 Male Vertebral Langerhan cell histiocytosis. 
12, 7 Male Nodular sclerosing HLc mediastinum and supraclavicular fossa. 
12, 7 Female Thigh centroblastic diffuse large B cell lymphoma. 
12, 8 Female Paraspinal malignant peripheral nerve sheath tumour. 
12, 11 Female Nodular sclerosing HLc, stage four. 
13, 4 Female Supraclavicular lymphadenopathy, benign reactive lymphadenitis. 
13, 7 Male Inguinal nodular lymphocyte predominant HLc. 
14, 1 Female Kidney primitive neuroectodermal tumour. 
14, 2 Female Ovarian grade three immature teratoma, no metastases. 
14, 5 Male Calf undifferentiated high-grade sarcoma, lung metastases. 
15, 8 Male Shoulder soft tissue Ewing sarcoma, no metastases. 
15, 8 Female Eye extranodal marginal zone B cell lymphoma. 
15, 10 Female Mediastinal nodular sclerosing HLc. 
15, 11 Male Femoral osteosarcoma, lung metastases. 
16, 0 Male Cervical nodular lymphocyte predominant HLc. 
a Received oral sedation during the scan (see Scanning Protocol, Section 3.4.1) 
b Received general anaesthetic during the scan (see Scanning protocol) 
c Hodgkin Lymphoma 
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3.5.2 Regional SUVmax analysis 
Data was successfully collected from all 30 subjects. The results of the paired t-test for 
each region are presented in Table 2. There was no evidence of a difference between the 
left and right SUVmax for any region, therefore mean SUVmax of the corresponding left 
and right regions were used for the evaluation of the relationship between regional 
SUVmax and age. 
Table 3.2: SUVmax paired t-test results. 
There is no evidence of significant asymmetry in SUVmax between contralateral regions. 
Region Mean Difference (right minus left) in SUVmax (95% confidence interval) 
p-value 
White matter 0.13 (-0.004, 0.259) 0.056 
Thalamus -0.03 (-0.177, 0.109) 0.629 
Caudate -0.15 (-0.355, 0.051) 0.137 
Putamen -0.02 (-0.187, 0.143) 0.787 
Cerebellum -0.13 (-0.295, 0.043) 0.139 
 
Scatterplots of regional SUVmax (mean of left and right) against age are displayed in 
Figure 3.1. Each region showed a positive association of FDG uptake with age that 
appeared to approximate a linear relationship.
 
Figure 3.1: Scatterplots of regional SUVmax against age. 
On each plot are the Pearson’s correlation coefficients (r) and p value, r squared value (r2), univariate linear regression line with 95% prediction confidence interval, and linear 
regression equation. All regions show evidence of a linear association of SUVmax with age. 
Figure 3.2 shows the univariate linear regression lines for all regions plotted on the same 
axis. The order of highest to lowest regional SUVmax was consistent throughout the age 
range with the basal ganglia structures (putamen and caudate head) demonstrating the 
most intense uptake followed by the thalamus, cerebellum and white matter, respectively. 
All regions showed increasing SUVmax with age. The rates of increasing SUVmax with 
age were almost identical for the putamen (0.386 SUVmax units/year), caudate head 
(0.395 SUVmax units/year), thalamus (0.368 SUVmax units/year) and cerebellum (0.319 
SUVmax units/year). White matter had the lowest SUVmax throughout the age range 
studied and showed a much lower rate of increase over time (0.065 SUVmax units/year), 
compared to the other regions. 
 
Figure 3.2: Univariate linear regression lines for SUVmax against age. 
All regions plotted on the same axis. Similar rates of increasing FDG uptake with age are seen in basal 
ganglia, thalamus and cerebellum, producing a consistent relative relationship between these regions 
throughout childhood. The order from highest to lowest uptake is putamen, caudate, cerebellum, thalamus 
and white matter. 
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Figure 3.3 shows box-and-whisker plots of SUVmax for each age group and the results of 
the Kruscal-Wallis test. In those regions with evidence of a difference in SUVmax across 
the age groups (ie. Kruscal-Wallis p < 0.05) post-hoc testing between each age group 
was performed (Mann-Whiney U test). 
 
Figure 3.3: Box-and-whisker plots of regional SUVmax against age group. 
The p values for the Kruscal-Wallis test are shown. Age groups with evidence of a significant difference are indicated. SUVmax appears to increase with age in all regions. There is 
a trend for no significant difference in SUVmax between the 5-10yr and 10-16yr age groups suggesting a possible plateau in FDG uptake over this age range.
  
3.5.3 Regional Relative Uptake 
RU data was successfully collected for 28 subjects. There was good agreement in the 
assignment of RU between the three readers with the intraclass correlation coefficients 
for each region ranging from 0.48 in the right basal ganglia to 0.92 in the right thalalmus 
(see Table 3.3). The mean RU of the three readers in each region was used in further 
analysis. 
 
Table 3.3: Intra-class correlation coefficients for RU. 
All regions show good to excellent agreement for the RU assessment by the three readers. 
Region Intraclass correlation coefficient 
Right frontal lobe 0.71 
Left frontal lobe 0.83 
Right lateral temporal lobe 0.75 
Left lateral temporal lobe 0.63 
Right medial temporal lobe 0.69 
Left medial temporal lobe 0.61 
Right parietal lobe 0.71 
Left parietal lobe 0.67 
Right occipital lobe 0.83 
Left occipital lobe 0.78 
Right cerebellum 0.86 
Left cerebellum 0.85 
Right thalamus 0.92 
Left thalamus 0.92 
Right basal ganglia 0.48 
Left basal ganglia 0.50 
 
The results of the paired t-test for each region is presented in Table 3.4. There was no 
evidence of significant asymmetry in RU between any of the regions. Similar to the 
SUVmax data, the mean of the left and right RU for each region was used as the variable 
for the evaluation of the relationship between regional RU and age. 
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Table 3.4: RU paired t-test results. 
There is no evidence of significant asymmetry in RU between contralateral regions 
Region Mean difference 
(right minus left) in mean RU (95% confidence limit) 
p-value 
Frontal 1.5 (-1.6, 4.7) 0.320 
Lateral temporal 0.5 (-0.9, 1.9) 0.490 
Medial temporal 0    (-1.0, 1.0) 1.000 
Parietal 3.0 (-0.2, 6.1) 0.062 
Occipital 0.1 (-1.0, 1.1) 0.813 
Cerebellum 0.1 (-0.6, 0.9) 0.745 
Thalamus 0.7 (-0.02, 1.5) 0.056 
Basal ganglia 2.0 (-0.6, 4.7) 0.131 
 
The scatterplots of regional RU against age for each region are shown in Figure 3.4. 
There was no apparent visual association of RU with age in the frontal lobe, thalamus, 
basal ganglia or cerebellum, confirmed by non-significant Pearson’s correlation 
coefficients. Visually there appeared to be a negative association of RU with age in the 
parietal lobe, lateral temporal lobe, medial temporal lobe and occipital lobe. The 
Pearson’s correlation coefficients indicated evidence of a moderate correlation in the 
parietal and occipital lobes, and a mild correlation in the lateral and medial temporal 
lobes. In those regions with evidence of a linear relationship between RU and age the 
univariate linear regression line and the 95% prediction confidence intervals are shown. 
For those regions with no evidence of an association between RU and age the mean RU 
and the 95% prediction confidence intervals are shown. 
Figure 3.4: Scatterplots of regional 
relative uptake against age. 
Indicated on each plot are the associated 
Pearson’s correlation coefficients and p 
value. In those regions with evidence of a 
linear association between RU and age 
(p<0.05) the univariate linear regression 
line (bold line) with 95% prediction 
confidence intervals are shown. For those 
regions with no evidence of an association 
between RU and age (p>0.05) the mean 
RU (thin line) with 95% prediction 
confidence intervals are shown. There is 
markedly reducing RU with age in parietal 
and occipital lobes, and mildly reducing in 
lateral and medial temporal lobes. No 
significant relationship between RU and 
age was seen in the frontal lobes, thalamus, 
basal ganglia or cerebellum.
  
Figure 3.5 shows the univariate regression lines for the parietal, occipital, medial 
temporal and lateral temporal lobes, and the mean RU for the frontal lobe, basal ganglia, 
thalamus and cerebellum plotted on the same axis. The regions without an association 
between RU and age in order from highest to lowest RU were the basal ganglia, frontal 
lobe, thalamus and cerebellum. There was a very similar pattern of reducing RU with age 
in the parietal and occipital lobes. Both show very high RU at birth and progressively 
reduce to a level between the thalamus and lateral temporal lobe at age 16 years. The 
lateral and medial temporal lobes show a lower rate of reducing RU and remain at a level 
between the thalamus and cerebellum, and lower than the cerebellum throughout the age 
spectrum, respectively. 
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Figure 3.5: Univariate regression and mean lines for RU against age. 
Univariate regression lines and mean relative uptake for regions with an association of RU with age and no 
association with age, respectively, are shown plotted on the same axis. There is a clearly different 
trajectory of relative FDG uptake in parietal and occipital lobes, and less markedly in lateral and medial 
temporal lobes. These cortical regions have reducing FDG uptake compared to maximum cortical uptake 
and are responsible for the different pattern of relative FDG uptake seen during childhood. 
 
Box-and-whisker plots demonstrating the distribution of RU for each age group in each 
region are shown in Figure 3.6. The p values for the Kruscal-Wallis test in each region 
are shown and where there was evidence of non-equality within the age groups (ie. 
Kruscal-Wallis p < 0.05), post-hoc Mann-Whitney-U testing between each age group 
was performed. The age groups with evidence of a significant difference are indicated. 
 
Figure 3.6: Box-and-whisker plots of 
relative uptake against age. 
The p-values for the Kruscal-Wallis test are 
shown and age groups with evidence of a 
significant difference are indicated. There is a 
trend for reducing RU with age in parietal, 
lateral temporal and occipital lobes.
 3.5.4 Estimates of SUVmax in the cerebral cortical regions 
At age one and 16 years, the RU values for the cortical regions and basal ganglia were 
visually extracted from the extrapolated regression lines in Figure 3.4. In a similar 
fashion the SUVmax values at age one and 16 years were extrapolated from the regression 
lines in Figure 3.1. The SUVmax linear regression lines of the basal ganglia structures (the 
caudate head and putamen) are very close together (see figure 2) and therefore 
classification of basal ganglia SUVmax was taken as the approximate mid point between 
these two lines and extracted visually from Figure 3.2. 
 
Given that there appeared to be an approximate linear relationship of SUVmax to age in 
all the regions analysed, the relationship of SUVmax to age in the cortical regions was also 
assumed to be approximately linear. This assumption is supported by the appearance of 
the scatterplots of the cortical RU findings, which visually appear approximately linear 
(see Figure 3.4). The calculation of estimated SUVmax in the cortical regions was 
performed for age one and 16 years as described in the methods section (see Table 3.5), 
plotted on a graph and joined with a straight line to produce an estimate of the expected 
change in cortical SUVmax with age. The composite graph (see Figure 3.7) shows the 
relationship between (measured or estimated) SUVmax and age in the cortical and 
subcortical regions, the cerebellum and white matter. 
 
Table 3.5: Calculation of RU and SUVmax estimates for the cortical regions. 
The results of the basal ganglia RU and SUVmax data visually extracted from Figures 3.5 and 3.2 are 
indicated, as well as the calculated SUVmax estimates for the cortical regions. 
 At age 1 yr At age 16 yrs 
Region 
RU 
(%, visually 
extracted from 
figure 3.5) 
RU Ratio 
(relative to 
basal 
ganglia) 
SUVmax 
RU 
(%, visually 
extracted from 
figure 3.5) 
RU Ratio 
(relative to 
basal ganglia) 
SUVmax 
Basal ganglia 94 1 5.4* 94 1 11.2* 
Frontal 81 0.86 4.7# 81 0.86 9.7# 
Parietal/Occipital 89 0.95 5.1# 68 0.72 8.1# 
Lateral temporal 67 0.71 3.8# 59 0.63 7.0# 
Medial temporal 48 0.51 2.8# 42 0.45 5.0# 
* mid point of putamen and caudate SUVmax extracted visually from Figure 3.2 
# calculated by: [RU Ratio] x [basal ganglia SUVmax] 
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Figure 3.7: Plot of SUVmax against age for all regions analysed and FDG PET scans in children 
aged 5, 9 and 15 years old. 
The relationship of SUVmax against age is shown for all regions analyzed (A). Estimated SUVmax for the 
cortical regions are shown in color and were extrapolated from the results of the relative uptake analysis in 
reference to measured basal ganglia SUVmax (see methods). Although all regions show increasing 
SUVmax with age, the rate of increase is lowest in parietal and occipital lobes. Parietal/occipital SUVmax 
is higher than the frontal lobes up until approximately 7 years (solid arrow). After approximately 10 years 
of age (open arrow), parietal/occipital SUVmax becomes lower than thalamus. FDG PET scans are shown 
for subjects aged 5, 9 and 15 years of age (B). Transaxial slices through the high frontal and parietal lobes 
(upper panels) and at the level of the basal ganglia (lower panels) are displayed. Image intensity is not 
scaled equally between subjects but are set at levels to highlight the relative differences in regional FDG 
uptake within each subject. In the five year old child the parietal lobes have more intense FDG uptake than 
frontal lobes which in turn are more intense than thalamus. In the nine year old child parietal lobe FDG 
uptake has become less intense than frontal lobes but remains above that of thalamus. At 15 years of age 
the parietal lobe FDG uptake has become less intense than the thalamus. 
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3.6 Discussion 
The analyses presented in this chapter indicate that regional cerebral FDG uptake during 
childhood does not reach a pattern resembling that of an adult by one year of age as 
reported by Chugani et al [15, 16] but continues to change throughout childhood. 
Although FDG uptake appears to increase in all areas of the brain with increasing age, 
there appears to be regionally specific differences in the rate of increasing uptake that is 
responsible for the changing relative regional patterns that occur with age. Our findings 
are derived from the largest reported cohort of dedicated cerebral FDG PET/CT scans in 
children, none of whom had preceding neurological events. These results have important 
implications for the correct interpretation of paediatric cerebral FDG PET/CT scans. 
 
Semi-quatitative FDG uptake (ie. SUVmax) in the subcortical nuclei, white matter and 
cerebellar cortex showed approximately linearly increasing FDG uptake occurring 
through to age 16 years, the upper age limit in our cohort (Figure 2). The analysis did 
not reveal a peak in FDG uptake between the ages of 4 and 9 years, as has suggested by 
the previous literature [16]. Also, the data showed that there is a consistent relative 
pattern of FDG uptake in the subcortical nuclei and cerebellum throughout childhood. 
The putamen consistently demonstrates the highest uptake followed by the caudate head, 
thalamus and cerebellum respectively. These regions have very similar rates of 
increasing semi-quantitative uptake with age and therefore their relative relationship 
remains constant as overall whole brain FDG uptake increases with age. As expected, 
white matter FDG uptake was much lower than subcortical and cerebellar grey matter, 
and showed increasing uptake with age but at a much slower rate. 
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There are ongoing changes in relative cortical FDG uptake occurring throughout 
childhood, in contradistinction to previous reports stating “a pattern of glucose utilisation 
resembling that seen in adults [was] established in infants 7.5 month’s, 1 year, and 1.5 
years old” [16] and “By 1 year [of age], the lCMRGlc pattern resembled that seen in 
adults” [15].  
 
The RU analysis included cortical regions that were not part of the SUVmax analysis and 
showed a clear difference in the trajectory of parietal, occipital and temporal lobe FDG 
uptake realtive to the other parts of the brain (Figure 3.5). These cortical regions (ie. 
essentially the whole cerebral cortex excluding the frontal lobes) showed reducing RU 
occurring with age. It needs to be emphasised that although our findings support 
markedly reducing FDG uptake with age in these regions relative to maximal cortical 
uptake, combining the RU findings with the SUVmax data indicate that absolute FDG 
uptake is likely to in fact be increasing in these regions, albeit at a slower rate than 
elsewhere in the brain (Figure 7). It can be surmised that we saw three different profiles 
of increasing grey matter FDG uptake with age. The most rapid rate of increase in the 
frontal lobe, basal ganglia, thalamus and cerebellum, slightly lower rates of increase in 
the lateral and mesial temporal lobes, and the lowest rates of increase in the parietal and 
occipital lobes (Figure 3.7). 
 
The changing pattern of cortical FDG uptake during normal childhood can be explained 
by the differentially more rapid increase in frontal lobe FDG uptake (paralleling that of 
the subcortical nuclei and cerebellum) compared to the remainder of the cerebral cortex. 
The pattern is such that in early childhood up until approximately seven years of age, the 
parietal and occipital lobes show the most intense FDG uptake (probably initially as 
intense as the basal ganglia) followed by the frontal lobes, lateral temporal lobes and 
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medial temporal lobes, respectively. After the age of approximately seven years, uptake 
in the frontal lobes have increased more rapidly than the rest of the cerebral cortex to be 
more intense that the parietal and occipital lobes. After approximately 10 years of age 
thalamic uptake has increased in line with frontal lobe activity to become more intense 
than the parietal and occipital lobes. The medial temporal lobe consistently shows the 
lowest degree of FDG uptake in the cerebral cortex followed by the lateral temporal lobe. 
Both of these regions parallel the slower rate of increasing FDG uptake seen in the 
parietal and occipital lobes. Cerebellar FDG uptake begins at a level approximately the 
same as the medial temporal lobe and although it follows the more rapidly increasing 
FDG uptake profile with age, uptake remains lower than the lateral temporal lobe. 
 
Concerning the lateral and mesial temporal lobes, both show similar rates of increasing 
FDG uptake with age, marginally slower than the frontal lobes but higher than the 
parietal and occipital lobes. Therefore the relative difference between lateral and mesial 
temporal lobe FDG uptake remains essentially constant throughout childhood with the 
medial temporal lobe demonstrating 30-35% lower FDG uptake than the lateral temporal 
lobe. 
 
A similar pattern of regional cortical perfusion occurring with age has been reported 
using technetium-99m ethylcysteinate dimer SPECT in children. When referenced to 
cerebellar perfusion, cortical perfusion generally appeared to reduce with age but was 
most marked the parietal and lateral occipital lobes [33]. 
 
The changing pattern of cerebral FDG uptake, and by inference the different regional 
rates of glucose utilisation, is likely reflecting the changing regional metabolic demands 
throughout childhood. Hypotheses can be drawn connecting the developmental processes 
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occurring at different ages in an attempt to explain observed changes in regional cerebral 
FDG uptake [34]. For example, tasks controlled by frontal lobe processes continue to 
improve throughout adolescence whereas task performance supported by the posterior 
cortex are static during this time [35]. This type of regionally specific functional 
development might have relevance to the more rapidly increasing frontal cortex 
metabolism we observed in our study when compared to the other cortical regions. 
 
Total grey matter volume in children reaches a peak at approximately seven to 12 years 
of age [36, 37] and then declines through late childhood. While these findings might 
suggest that markers of metabolism such as FDG uptake should follow the same pattern, 
cortical volume alone may be a poor predictor of underlying metabolic activity. Cortical 
synaptic density peaks during the first year of life followed by a complex process of 
synaptic pruning occurring through into adulthood [38]. This pruning process may 
contribute to regional changes in metabolic activity through the activity of cells other 
than neurons, such as microglial cells [39]. Synaptic pruning therefore may be a factor 
contributing to the increasing FDG uptake over this time period of reducing synaptic 
density. 
 
Volumetric changes in the brain are also regionally specific. While the volume of grey 
matter in the frontal and parietal regions peak at around 12 years of age, temporal grey 
matter peaks at 16-17 years and occipital grey matter continues to increase through to age 
20 [40]. Clearly regional volumetric changes and regional changes in FDG uptake during 
childhood, as shown in our study, do not correlate and point to the importance of factors 
in addition to neuronal volume in contributing to regional metabolic activity. 
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Our study was a univariate analysis of the effect of age on regional FDG uptake. More 
complex multiple regression analysis adjusting for important variables such as regional 
brain volumes, age specific neurocognitive assessment, physical growth parameters and 
perhaps relevant genetic factors might tease out a more refined description of the 
regional cerebral glucose patterns associated with normal development. 
 
Part of our analysis was to semi-quantify regional cerebral glucose metabolism using 
SUVmax analysis. We acknowledge that SUVmax is not a substitute for direct quantitative 
measures of regional metabolic rates of glucose utilisation and is subject to considerable 
variability not able to be controlled for in clinical studies [41]. However, SUV analysis 
does allow scans performed in a clinical setting, where procedures required for absolute 
quantification such as arterial blood sampling are not practical or reasonably able to be 
performed, to be semi-quantitatively compared albeit with added non-adjusted statistical 
variability. This different method of quantification probably contributes to the 
differences we saw in our study compared to previous reports [15, 16, 34]. However, 
current PET/CT scanners have greater spatial resolution than those used at the time of 
these reports 25 years ago and allow regional differences in uptake to be more accurately 
assessed qualitatively. Therefore, our findings on the qualitative analysis that show 
relative regional patterns of FDG uptake continue to change throughout childhood and do 
not reach a typical adult pattern at one year of age may be more robust that previous 
reports. 
 
Our youngest subject was 11 months old and the results from our study therefore cannot 
be reasonably extrapolated to children younger than a year of age where there may be 
more profound changes occurring in regional measures of absolute cerebral FDG uptake. 
The previously published reports in this very young age group have relatively few 
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subjects [15-18] and all except one [18] used infants with potential neurological 
disturbances and/or receiving medications likely to perturb cerebral FDG uptake. More 
research is required in this very young age group. 
 
3.7 Conclusion 
We have described the pattern of cerebral FDG uptake occurring during childhood 
development in the largest dataset of patients that are more likely to represent normal 
brain metabolism than previous published reports. We are the first to describe that the 
relative pattern of cortical FDG uptake does not reach a typical adult pattern by one year 
of life, but continues to change throughout childhood. This changing pattern of FDG 
uptake is likely due to the different regional rates of increasing FDG uptake occurring 
with age. While subcortical grey matter and the cerebellum maintain a consistent relative 
pattern of FDG uptake with age, the cerebral cortex shows a changing pattern of relative 
regional uptake driven by the highest rate of increase in FDG uptake in the frontal lobes, 
followed by the lateral and mesial temporal lobes, and then the parietal and occipital 
lobes which have the lowest rates of increasing FDG uptake. 
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4 CHAPTER FOUR: APPLICATION OF 
STATISTICAL PARAMETRIC MAPPING IN 
CEREBRAL FDG PET CT SCANS IN 
NEUROLOGICALLY NORMAL CHILDREN 
4.1 Abstract 
Aims: The changing pattern of relative cerebral 18F-fluoro-2-deoxy-D-glucose (FDG) 
uptake that occurs during normal childhood development is not completely understood. 
 
Methods: Using SPM8 we undertook a voxel-based analysis of dedicated cerebral FDG 
scans in 28 children ranging in age from 11 months to 16 years to examine the effects of 
age on regional FDG uptake. The subjects included were children with suspected or 
proven extra-cranial malignancies without central nervous system metastases and no 
previous or current therapies or medical conditions likely to interfere with cerebral 
metabolism. The included cerebral FDG scans were considered to represent normal 
cerebral FDG distribution in a child of their age at the time of the scan. 
 
Results: When normalised to whole brain mean uptake, the voxel-based analysis showed 
increasing FDG uptake with age in the premotor and prefrontal cortices, insula cortex, 
cingulate cortex, basal ganglia, thalamus, cerebellum and in small areas of the inferior 
temporal lobes and left Heschl’s gyrus. These findings correlate with analysis of the 
same data that used qualitative and maximal standardised uptake value (SUVmax) analysis 
techniques, presented in Chapter 3. 
 
Conclusions: This data provide more regionally specific information and further support 
the conclusion that relative cerebral FDG uptake in children has not reached a typical 
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adult pattern by approximately one year of age but in fact changes throughout childhood. 
The results speak to the importance of using age-matched data or adjusting for age in the 
statistical analysis of studies comparing paediatric cerebral FDG scans to a control 
dataset to avoid bias due to different age distributions in the groups of subjects studied. 
The areas of increasing FDG uptake with age probably relate to underlying neuronal 
processes linked to normal neurodevelopment including key resting state networks. 
 
4.2 Introduction 
Cerebral FDG distribution during normal childhood development is not completely 
understood. The classical description of regional FDG uptake in children reaching a 
normal adult pattern by approximately one year of age [15, 16, 42] has been challenged 
by recent reports [43, 44]. Regional FDG uptake has been shown to increase more 
rapidly in the frontal and temporal lobes, than in the parietal lobes to give the changing 
relative appearance in regional brain FDG uptake during normal childhood development 
[43]. 
 
It is vital to understand the expected changing patterns of normal cerebral FDG uptake 
during childhood to accurately identify abnormalities in cerebral metabolism in children 
of various ages. Voxel based analysis techniques may be more susceptible to bias if aged 
matched data is not used or if age is not adjusted for in the analysis. The aim of this study 
was to implement a voxel-based analysis of a previously reported high quality dataset of 
cerebral FDG scans that are likely to accurately represent normal children [43], to 
investigate the hypothesis that there is increasing relative FDG uptake with age in all 
cerebral regions except the parietal and occipital regions. 
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4.3 Aims 
The aim of this chapter is to perform a voxel-based whole brain analysis of cerebral FDG 
PET CT scans in a dataset of neurologically normal children to evaluate for regions of 
increasing FDG uptake occurring with age. 
 
4.4 Methods 
Approval for the study was obtained from the hospital ethics committee. 
 
4.4.1 Subjects 
The clinical details of the included subjects have been more fully described in Chapter 3 
and published elsewhere [43]. Briefly, the dataset consisted of the dedicated cerebral 
FDG PET-CT scan of 28 children referred for a whole-body FDG PET-CT scan to stage 
proven or suspected extra-cranial malignancies with the following exclusion criteria: the 
presence of central nervous system metastases, previous malignancy, previous 
chemotherapy or radiotherapy, development of cerebral metastases during induction 
therapy, any neurological conditions (e.g. developmental abnormalities, psychological or 
behavioural disorders, learning disorders, epilepsy, previous central nervous system 
infections), current use of antiepileptic medication or other medications likely to interfere 
with cerebral metabolism, and general anaesthesia within 24 hours prior to the FDG 
PET-CT scan. These scans were considered to closely represent normal cerebral FDG 
distribution in a child of their age at the time of the scan. The age range was 11 months to 
16 years, and the mean age at the time of the scan was 10 years 5 months (Figure 4.1). 
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Figure 4.1: Age histogram of the included subjects. 
 
4.4.2 PET imaging and reconstruction protocol 
Children fasted for 4–6 hours and had blood glucose levels confirmed to be within the 
normal range before injection of 370 MBq of FDG scaled to body surface area using a 
weight based nomogram. During an approximate 30 minute uptake period, the children 
rested in a dimly lit room, supine and with minimal stimulation. A 15 minute dedicated 
brain acquisition was performed followed by a whole body scan acquisition from the 
base of brain to toes. 
 
PET-CT was performed on a Siemens Biograph16 HiRez PET-CT scanner (Siemens 
Medical Solutions, Erlangen, Germany) with field of view of 500mm in width and 
160mm in axial length. CT attenuation correction was used with a source rotation speed 
of 0.5 sec/rotation at 80 kV. Siemens proprietary CT dose modulation protocol 
(“Caredose”) was used to modulate the CT tube current from a maximum of 100 mA. 
 
All PET scans were decay corrected and reconstructed using an iterative reconstruction 
algorithm based on ordered-subset expectation maximization (OSEM; 8 iterations, 16 
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subsets) with scatter correction and measured attenuation correction. OSEM images 
underwent a 4.1 mm full-width-at-half-maximum Gaussian postsmoothing. 
 
4.4.3 SPM pre-processing and analysis 
Spatial pre-processing and statistical analyses were performed using the “PET & VBM” 
module of SPM8 (Wellcome Trust Centre for Neuroimaging, Institute of Neurology, 
London, UK), which was implemented using Matlab 7.12.0 (R2011a, MathWorks Inc., 
Sherborn, MA). 
 
4.4.3.1 Creation of a custom template for spatial normalisation 
The dataset of cerebral FDG scans used in this chapter span a wide pediatric age range 
with considerable differences in overall size and spatial configuration of their brains. A 
systematic difference in the normalisation process applied to the scans in an analysis is 
termed “normalisation bias” and has the potential to occur if an adult template was used 
that would more closely match the spatial profile of the older children compared to the 
younger children. Normalisation bias can lead to spurious results on the resulting SPM 
maps. Other potential problems caused by using inappropriate templates generated from 
adults or created from a different tracer to that being studied have been described in the 
literature [6, 45]. The PET template provided with SPM8 is derived from a cerebral 
blood flow agent, 15O-H2O, and the patients in our normal control dataset were scanned 
using the glucose metabolism agent 18F-FDG. The issues related to the problems using an 
adult based template or a template based on a tracer other than FDG that are relevant to 
our findings are more comprehensively discussed in the Discussion section of this 
chapter. These issues motivated the creation of a custom pediatric FDG template for the 
SPM analysis reported in this chapter. 
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A custom FDG PET template for pre-processing was created using the entire dataset as 
follows. Using the “Normalise: Est and Wri” module, the reconstructed scans were each 
spatially normalized to the SPM8 “PET” template and written out using a bounding box 
dimension of -90:91 -126:91 -72:109. The remainder of the default parameters in this 
module were unchanged. The “Smooth” and “ImCalc” modules of SPM8 were used to 
smooth the images with an 8mm Gaussian kernel and then to calculate the mean overall 
image, respectively. This mean, smoothed image was used as the custom template for 
spatial normalisation of the original reconstructed scans. 
 
The use of our custom template would likely produce more accurate SPM maps that 
using a template derived from a different tracer. We did perform a preliminary analysis 
using the SPM8 PET template directly and resulted in a very similar pattern of 
significant voxels. We felt that the inclusion of a comparison of these results to those 
achieved using our custom pediatric FDG template was not necessary and would add 
unnecessary length to the manuscript. We feel that such a comparison is not required 
given the existing evidence indicating that using the adult 15O-H2O SPM PET template 
would be considered inferior to the custom pediatric 18F-FDG template we created for 
this purpose. 
 
The “Normalise: Est and Wri” module, was then used to spatially normalize each original 
reconstructed FDG PET scan to the custom template which was written out using a 
bounding box dimension of -90:91 -126:91 -72:109 with voxel sixe of 2x2x2mm. The 
remainder of the SPM8 default parameters were unchanged. 
 
In this way all reconstructed FDG PET scans were normalized to the MNI standard space 
(Montreal Neurological Institute, McGill University, Montreal, Canada) with a voxel size 
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of 2x2x2mm.  Normalized images were then smoothed with an 8mm isotropic Gaussian 
kernel to increase signal-to-noise ratio and to adjust for anatomical structural differences 
and inaccuracies in the normalization process between subjects. These normalized and 
smoothed images were used as the input scans for model specification and estimation 
within SPM8. 
 
4.4.3.2 Relative threshold masking 
Image masking is required to remove extra-cerebral voxels from the images prior to the 
statistical analysis. There are two main reasons as to why masking is important. Firstly, 
the methods for multiple comparison correction lead to a more sensitive analysis if fewer 
voxels are analysed and secondly, there are statistical instabilities that occur within 
regions that have very low variability in voxel intensity (viz. low statistical variance). For 
instance, within the PET scan field of view in the space outside of the head there is very 
little if any voxel signal and the variability (variance) in these voxels is close to zero. The 
calculated t statistics that form the SPM map are “proportional to the magnitude of the 
differences [in the voxel signal], divided by the square root of the residual variance” [46] 
ie. the greater the voxel difference between groups in a two-sample t-test the greater the 
t-statistic; and the lower the variability in the voxel signal within each group the greater 
the t-statistic. This can lead to false positive supra-threshold voxels extending a long way 
into the space outside of the head and is prevented by masking [7]. If an overly 
aggressive mask is used than this increases the chance of excluding from the analysis 
voxels correlating to areas of interest potentially containing physiologically relevant 
signal [47]. 
 
Within SPM, masking methods include using an MNI atlas based explicit brain mask or 
relative threshold masking. Relative threshold masking masked out the lowest intensity 
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voxels that are presumed to be extracerebral. The masking threshold can be specified 
relative to global voxel intensity. Due to our concerns about inaccurate normalisation to 
MNI space (comprehensively covered in the discussion) we opted to proceed with a 
relative threshold mask. Relative threshold masks are commonly used in voxel-wise 
analysis of PET scans [ref]. 
 
Selecting the threshold for relative threshold masking becomes a balance between using a 
high, relatively more restrictive threshold to effectively remove non-relevant, extra-
cerebral tissue but no so strict as to exclude potentially relevant brain tissue from the 
analysis. 
 
When implemented in SPM, relative threshold masking effectively takes the intersection 
of all of the subjects non-masked voxels to be analysed. Thus if there was an included 
subject with a grossly abnormal brain not adequately corrected for during the 
normalization process, for instance with a previous surgical resection, then that part of 
the brain masked out on this subject would be excluded from the whole analysis. In this 
case the exclusion of a potentially large part of the brain from the analysis may not be 
readily apparent on the resulting SPM map and necessitates that each subjects relative 
threshold mask is carefully inspected as part of the SPM method. 
 
Different relative masking thresholds were trialled (0.8, 0.6, 0.4, 0.2 and 0 (no threshold)) 
to evaluate the effect of different thresholds on the resulting SPM map. 
 
4.4.3.3 Modelling the effect of age using SPM 
The “Basic models” module was used to create a one-sample t-test with age as a 
covariate. Relative threshold masking was implemented to remove extra-cerebral tracer 
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uptake and 0.8 was used as the threshold because it appeared to most accurately mask out 
extra-cerebral signal while retaining all of the relevant intra-cerebral voxels compared to 
more liberal thresholds. Proportional normalization was used as the global normalisation 
procedure to account for the variability of injected dose of FDG and uptake times. The 
remainder of the SPM8 default parameters in this module were unchanged. 
 
A one-sample t-test was performed to detect areas of the brain that show increasing FDG 
uptake with age. Computationally this operation is the same as a linear regression with 
age as the explanatory variable. Multiple comparison correction was performed at the 
voxel level using a familywise error (FWE) corrected peak threshold of p<0.05. A cluster 
extent threshold of k=50 was used to exclude single voxel effects and small clusters that 
might not be biologically credible. A 50-voxel cluster equates to 0.4 cm3 of neural tissue 
in the scan after normalization to standard MNI space. 
 
Significant clusters were localized using visual inspection of the resulting suprathreshold 
voxels displayed on the glass brain, displayed on the “render_SPM96” surface rendered 
brain and overlayed on the “avg152T1” and “single_subj_T1” cross sectional images 
provided within SPM8. The Automated Anatomical Labelling (AAL) toolbox for SPM 
[48] was implemented to quantify the distribution of significant clusters using the 
“cluster labelling” module and also used to aid in localising the regions containing 
suprathreshold voxels. 
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4.5 Results 
4.5.1 Relative threshold masking 
As expected there was increasing inclusion of extra-cerebral voxels with the lower 
thresholds (Figure 4.2). This was most apparent inferior to the orbitofrontal cortex where 
there was significant “bleeding” of included extra-cerebral voxels into the ocular region 
with the lower thresholds. This may be due to FDG uptake in the extra-occular muscles. 
When applying uniform statistical thresholds for the SPM analysis (FWE corrected at 
0.05 with extent threshold of 50 voxels) across the different relative masking thresholds, 
significant voxels also “bled” into the ocular region on the resulting SPM maps with the 
more liberal relative thresholds (Figure 4.3). It is important to note that with the more 
strict 0.8 and 0.6 relative thresholds there was some masking out of voxels in the lateral 
ventricle/periventricular white matter region, however there were no suprathreshold 
voxels in this region on the SPM map when using the more liberal relative threshold 
masks (0.4, 0.2 and 0) where these voxels were included in the SPM analysis. Therefore 
the use of the strict 0.8 threshold was the most appropriate and did not remove relevant 
voxels within the brain that would survive the analysis, but successfully removed 
irrelevant extracerebral voxels that would. The 0.8 threshold was used for relative 
threshold masking and all results in this chapter are generated with the use of this mask. 
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Figure 4.2: Differences in relative threshold masks. 
A comparison of different relative threshold masks overlaid on a T1 single subject template is shown. The 
red region is the 0.8 threshold margin, blue region are the extra included voxels at threshold 0.6, green is 
0.4, pink is 0.2, and yellow is without threshold masking. The red 0.8 mask contours quite tightly to the 
external surface of the brain but excludes some voxels in the region of the periventricular white matter and 
pons. Using the more liberal thresholds of 0.6 (blue) and 0.4 (green) captures the whole brain volume but 
at a cost of including some extra-cerebral voxels in the periphery, especially in the inferior frontal region 
and anterior to the brainstem at the base of the brain. The 0.2 threshold (pink) and without any masking 
(yellow) shows dramatic inclusion of large amounts extra-cerebral voxels in the base of skull, orbital and 
scalp regions. 
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Figure 4.3: Differences in SPM maps when using different relative threshold masks. 
A comparison of the resulting SPM maps when using the different relative threshold masks overlaid on a 
T1 single subject template is shown. The red region is SPM map when using the 0.8 threshold, blue is the 
extra supra-threshold voxels using 0.6, green is using 0.4, pink is using 0.2, and yellow is without using 
threshold masking. There were no more intra-cerebral supra-threshold voxels identified when using 
thresholds more liberal than 0.8 (red). The only difference appears to be the inclusion of extra-cerebral 
supra-threshold voxels extending out to the region of the medial extra-ocular muscles in the 0.6 (blue), 0.4 
(green) and 0.2 (pink) thresholds; and the scalp/anterior eye region in the case of not applying a relative 
threshold mask (yellow). This comparison confirms that with the use of the strictest 0.8 threshold there are 
no relevant intra-cerebral voxels falsely excluded from the analysis. 
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4.5.2 SPM results 
Figure 4.4 shows the output from the SPM analysis and includes technical information 
about the SPM method and results. The SPM8 glass brain display, the statistical model 
and contrast matrices, and the statistical output are displayed. These results reveal 11 
clusters comprising a total of 28,524 suprathreshold voxels surviving peak FWE p<0.05 
and cluster extent thresholding of 50 voxels. The most significant voxel was at MNI 
coordinates 6, 28, 44 in the right mesial frontal cortex. 
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Figure 4.4: SPM output showing areas of increasing FDG uptake with age. 
The glass brain display, statistical model and contrast matricies, and SPM8 output of the analysis of 
regions that show evidence of increasing FDG uptake with age are shown. Statistical thresholding 
consisted of a FWE corrected voxel level threshold of p<0.05 and cluster extent threshold of 50 voxels. 
The most significant voxels are in the mesial frontal lobe (MNI coordinates 6, 28, 44 and -2, 22, 60) and 
anterior cingulate cortex (MNI coordinate -4, 32, 22). In this SPM output figure the statistical design 
matrix and contrast matrix is shown, the glass brain display provides visual expression of the distribution 
of the significant clusters, and the text below the glass brain shows the voxel statistical and cluster extent 
thresholds applied and the corresponding T score threshold. The statistics table gives detail on the MNI 
coordinates of local maxima, total cluster sizes and voxel/resl dimensions of the pre-processed scan 
volumes. 
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AAL labelling identified 95% of the supra-threshold voxels to be within AAL specified 
regions. The distribution of supra-threshold voxels are described in Table 4.1.  
 
Voxels with evidence of increasing FDG uptake with age are shown in Figure 4.5A 
overlayed on a single subject surface rendered brain (“render_SPM96” in SPM8) and in 
Figure 4.5B overlayed on a single subject T1 MRI (“single_subj_T1” in SPM8) in 
selected transaxial slices. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 4.1 (following page): Results of AAL labelling of supra-threshold regions. 
There were 28,524 surviving supra-threshold voxels and 95% of these voxels were 
within AAL specified regions. The percent of each AAL specified region containing 
supra-threshold voxels are shown. If 10% or more of a specified AAL region contained 
supra-threshold voxels, then this was considered to provide reasonable evidence of 
involvement of this region (see Discussion). 
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Table 4.1: Results of AAL labelling of supra-threshold regions. 
(see table legend on previous page) 
 AAL specified region 
% of region containing 
suprathreshold voxels 
 LEFT RIGHT 
Central region 
Precentral gyrus 14 5 
Postcentral gyrus - - 
Rolandic operculum 9 14 
Frontal lobe 
Lateral surface   Superior frontal gyrus, dorsolateral 33 38 
Middle frontal gyrus 23 47 
Inferior frontal gyrus, opercular part 10 16 
Inferior frontal gyrus, triangular part 2 8 
Medial surface   Superior frontal gyrus, medial 63 68 
Supplementary motor area 49 37 
Paracentral lobule 1 - 
Orbital surface   Superior frontal gyrus, orbital part 44 61 
Superior frontal gyrus, medial orbital 54 66 
Middle frontal gyrus, orbital part 19 71 
Inferior frontal gyrus, orbital part 17 39 
Gyrus rectus 40 42 
Olfactory cortex 22 5 
Temporal lobe 
Lateral surface   Superior temporal gyrus 2 1 
Heschl gyrus 10 2 
Middle temporal gyrus - - 
Inferior temporal gyrus 7 7 
Parietal lobe 
Lateral surface   Superior parietal gyrus - - 
Inferior parietal - - 
Angular gyrus - - 
Supramarginal gyrus - - 
Medial surface   Precuneus 1 1 
Occipital lobe 
Lateral surface   Superior occipital gyrus - - 
Middle occipital gyrus - - 
Inferior occipital gyrus - - 
Medial and inferior surfaces   Cuneus - - 
Calcarine fissure and surrounding cortex - - 
Lingual gyrus - - 
Fusiform gyrus - - 
Limbic lobe 
Temporal pole: superior temporal gyrus 2 2 
Temporal pole: middle temporal gyrus 2 10 
Anterior cingulate and paracingulate gyri 53 55 
Median cingulate and paracingulate gyri 34 48 
Posterior cingulate gyrus 28 24 
Hippocampus - - 
Parahippocampal gyrus - - 
Insula  28 28 
Sub cortical grey nuclei 
Amygdala - - 
Caudate nucleus 33 27 
Lenticular nucleus, putamen 15 5 
Lenticular nucleus, pallidum 43 20 
Thalamus 23 28 
Cerebellum 
crus I of cerebellar hemisphere 12 9 
crus II of cerebellar hemisphere 39 28 
Lobule III of cerebellar hemisphere - - 
lobule IV, V of cerebellar hemisphere - - 
Lobule VI of cerebellar hemisphere - - 
lobule VIIB of cerebellar hemisphere 32 36 
lobule VIII of cerebellar hemisphere 12 14 
lobule IX of cerebellar hemisphere - - 
lobule X of cerebellar hemisphere (flocculus) - - 
Lobule I, II of vermis - - 
Lobule III of vermis - - 
Lobule IV, V of vermis - - 
Lobule VI of vermis - - 
Lobule VII of vermis - - 
Lobule VIII of vermis - - 
Lobule IX of vermis - - 
Lobule X of vermis (nodulus) - - 
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Figure 4.5: Surface rendered and transaxial slice display of SPM results. 
A. Voxels with evidence of increasing FDG with age overlayed on a single subject surface rendered brain 
(“SPM96” in SPM8). From left to right, the top row shows the left and right mesial surfaces, the second 
row shows posterior and anterior surfaces, the third row shows the right and left lateral surfaces, and the 
bottom row shows the inferior and superior surfaces. There is increasing uptake with age in the bilateral 
frontal lobes (more extensively on the right), cingulate gyrus, striatum, thalamus, cerebellum and small 
areas of the inferior temporal lobes. B: Voxels with evidence of increasing FDG with age overlayed on 
selected axial slices of a single subject T1 MRI (“single_subj_T1” in SPM8) to show relevant deep grey 
matter structures. Images are displayed in neurological convention with the left side of the brain situated on 
the left side of the image. Increasing uptake with age is seen in the frontal lobes, insular cortex, medial 
superior frontal gyrus, cingulate cortex, thalamus and striatum. The numbers in the top left corner of each 
image represents the z axis co-ordinate of the slice in MNI space (images created using xjView SPM 
toolbox (http://www.alivelearn.net/xjview)). The corresponding t-value colour bar is in the bottom right 
corner of the figure. 
 
The frontal lobes contained extensive regions of suprathreshold voxels. There was 
extensive bilateral involvement of the supplementary motor area, medial, dorsolateral 
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and orbital parts of the superior frontal gyri. There was bilateral involvement of the 
middle frontal gyri, more extensively on the right. The bilateral inferior frontal gyri were 
less extensively involved apart from the right orbital part and both opercular parts. The 
posterior border of the suprathreshold clusters appeared to follow the precentral sulcus 
and its medial continuation, the anterior border of the paracentral lobule, so that the 
precentral gyrus was largely excluded (see Figures 4.4 and 4.5). 
 
The insula cortex was involved bilaterally and there was extensive involvement of the 
cingulate gyrus involving the anterior, middle and posterior divisions. Compared to the 
frontal lobes, there was much less extensive involvement of the temporal lobes with only 
small regions of the inferior temporal gyrus containing suprathreshold voxels and the left 
Heschl’s gyrus. There were no suprathreshold voxels in the mesial temporal structures 
and there were no areas of the parietal or occipital lobes involved. In the subcortical 
regions suprathreshold clusters were seen involving the striatum and thalami; and there 
was also involvement of the cerebellar cortex, mainly in the region of the vermal lobules 
of crus II and lobule VIIB as identified on the AAL labelling output (see Table 4.1 and 
Figure 4.5). 
 
The SPM voxel response describes the voxel intensity of FDG uptake after proportional 
normalization to whole brain uptake. Scatterplots of the voxel response against age are 
shown for local maxima in selected representative regions (see Figure 4.6). Regions 
selected were the right mesial frontal cortex, left anterior cingulate cortex, left 
cerebellum, left caudate nucleus and the right inferior temporal cortex. The positive 
linear association of FDG uptake with increasing age can be clearly seen in each of these 
regions.  
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Figure 4.6: Scatterplots of voxel response in the mesial frontal cortex, anterior cingulate cortex, 
cerebellum, caudate nucleus and inferior temporal cortex. 
The SPM voxel response describes voxel-wise intensity of FDG uptake after proportional normalization to 
whole brain activity. Proportional normalization is a method of accounting for global variability in uptake 
between subjects due to irregular administered doses of FDG and non-uniform uptake times. The voxel 
response plotted against age is shown for local maxima voxels in selected representative regions. On each 
scatterplot the linear regression line has been included along with a graphic to show the location of the 
voxel being depicted on the plot. There is a clear positive linear association of globally normalized FDG 
uptake with age in each of these regions. 
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4.6 Discussion 
In this voxel-based analysis of 28 children ranging in age from 11 months to 16 years, we 
have shown that when normalised to whole brain mean uptake there is increasing FDG 
uptake with age in the bilateral frontal lobes, insular cortex, cingulate cortex, striatum, 
thalamus and cerebellum; and smaller less extensive regions in the inferior temporal 
lobes and left Heschl’s gyrus. 
 
These results broadly correlate with the results from the qualitative and maximal 
standardised uptake value (SUVmax) analysis of the same dataset of scans (Chapter 3) 
where the changes in relative cerebral FDG uptake were shown to be due to different 
rates of increasing FDG accumulation in various regions.  The most rapid rate of increase 
was in the frontal lobes, basal ganglia, thalamus and cerebellum; lower rates of increase 
were seen in the temporal lobes; and the lowest rates of increase were in the parietal and 
occipital lobes. The report of these findings have been published [43]. The use of an atlas 
within MNI space (AAL) with the SPM analysis has potentially added more anatomical 
precision to the identification of regions demonstrating increasing FDG uptake with age. 
 
Using SPM, when proportionally normalized to global brain uptake, the voxel-based 
analysis shows increasing uptake with age most extensively in the frontal lobes, the 
striatum, thalamus and cerebellum. The involved regions of the frontal lobes are probably 
more accurately specified to the prefrontal and premotor cortices because the primary 
motor cortex (the precentral gyrus) appeared largely uninvolved. These regions match 
those that showed the highest rate of increase with age on the SUVmax analysis from 
Chapter 3, notwithstanding the spatial limitations of the SUVmax method. For example, 
there were small areas of the inferior temporal gyri and the left Heschl’s gyrus identified 
on the current voxel-based study showing increasing uptake with age that were not 
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apparent on the SUVmax assessment. An explanation for this apparent discordance is that 
the SUVmax analysis did not have the spatial specificity to separate the superior, middle 
and inferior temporal gyri. These regions were grouped together in the subjective 
analysis as a much larger region, the “lateral temporal lobe”. The voxel-based analysis 
estimates only 7% of the inferior temporal gyri and 10% of the left Heschl’s gyrus were 
involved (see Table 4.1). It is likely that on the previous study this relatively small 
amount of signal was lost within the lower rate of increasing FDG uptake in the 
remaining “lateral temporal lobe” region. Secondly, on the SUVmax analysis the parietal 
and occipital lobes had the lowest rates of increasing FDG uptake with age and in fact, 
when assessed subjectively and relative to maximal cortical uptake these regions to 
showed reducing uptake with age [43]. The results from the current voxel-based analysis 
are in agreement and show no voxels in the parietal or occipital lobes showing evidence 
of increasing uptake with age when normalised to whole brain uptake. 
 
4.6.1 Biological basis for the results 
The regional changes in cerebral FDG uptake that we have described in the current study 
provide a biomarker for changing regional rates of cerebral glucose utilization. These 
regions probably signal underlying neuronal activity and provide insight into the 
potential neural centres responsible for childhood neurodevelopment. For example, 
putative frontal lobe tasks show improvement during childhood and adolescence and 
correlate to the predominately frontal lobe distribution of increasing relative FDG uptake 
in in the SPM analysis [35]. 
 
Frontal and parietal grey matter volume has been shown to peak at approximately 12 
years of age, temporal grey matter at 16 to 17 years, and occipital grey matter at 20 years 
[40]. Such regional volumetric changes in cortical grey matter do not appear to correlate 
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with the regions with increasing FDG uptake. Therefore, it is likely that processes other 
than changes in cortical grey matter volume are contributing to regional glucose 
utilization. Possibilities include synaptic pruning or other glial processes that are known 
to change with age during childhood [38, 39]. 
 
The maturing of resting state networks is another possible contributing factor. Functional 
MRI studies in adults have identified the sustained activation of networks involving the 
dorsal anterior cingulate/medial superior frontal cortex and the bilateral anterior 
insula/frontal operculum during a range of independent goal directed tasks [49, 50]. 
These regionally specific activations have been posed as a common core network in the 
implementation of task directed behaviours and maybe these networks are undergoing 
maturation during childhood development to contribute to our results that show highly 
significant voxels in these areas. Functional MRI studies in children have suggested that 
there is a shift in resting state connectivity from being dominated with constrained local 
networks towards more spatially distant networks as children age [51]. Such a 
developmental pattern may also be contributing to the increasing activation occurring 
with age in the regions identified on the SPM analysis, suggesting that distant 
connectivity between frontal, striatal, thalamic, cerebellar and inferior temporal circuitry 
is linked to normal childhood neurodevelopment. 
 
4.6.2 Global (proportional) normalisation 
As was mentioned in Chapter 3, the subjects included in the normal dataset did not 
undergo invasive blood sampling to permit the gathering of quantitative PET data. Hence, 
we used a global normalization procedure within SPM8 to account for the global 
differences in cerebral FDG uptake between subjects that result from various factors 
including unequal uptake times and differences in dose administered to each subject. 
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To demonstrate the importance of using a global normalization procedure a non-globally 
normalized analysis was performed and unsurprisingly, yielded no supra-threshold 
surviving voxels. The reason for this finding can be visually depicted. The globally 
normalized and non-globally normalized voxel response scatterplots from the most 
significant voxel in the right mesial frontal cortex, MNI coordinates [6, 28, 44] are 
shown in Figures 4.7, 4.8, 4.9 and 4.10. It can be seen that the variability in the voxel-
based signal is massively increased by not using global normalization and the signal due 
to the effect of age is lost within this added variability. Figures 4.7 and 4.8 are the plots 
with the same narrow Y axis scale and show that without global normalization the voxel 
response variability is so dramatically increased that there are no non-globally 
normalized data points within the total voxel response range for the globally normalized 
data. Figures 4.9 and 4.10 are the same data displayed with an expanded range on the Y 
axis and show the extreme variability introduced in the non-global normalization data 
which obliterates the linear association with increasing age. 
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Figure 4.7: Scatterplot of voxel response WITH global normalisation, narrow Y axis scale. 
Data is from the peak voxel in the right mesial frontal lobe and shows a clear positive linear association 
between globally normalized FDG uptake and age. 
 
 
Figure 4.8: Scatterplot of voxel response WITHOUT global normalisation, narrow Y axis scale. 
Data from the same peak voxel in the right mesial frontal lobe and displayed with the same Y axis scale 
shows no non-global normalization data within the range of the global normalization data. This is due to 
the greatly increased variability without global normalisation of the data. 
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Figure 4.9: Scatterplot of voxel response WITH global normalisation, expanded Y axis scale. 
Data from the same peak voxel in the right mesial frontal lobe now displayed with an expanded Y axis 
scale shows the linear relationship between normalised FDG uptake and age. 
 
Figure 4.10: : Scatterplot of voxel response WITHOUT global normalisation, expanded Y axis scale. 
Data from the same peak voxel in the right mesial frontal lobe and displayed with the same expanded Y 
axis scale. The data can now be visualised and shows that the greatly increased variability in the non-global 
normalization data has obliterated the linear association between FDG uptake and age. 
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Using the construct of global normalization if there are voxels that have a strong 
association with any global change in uptake that occurs with age, then they will not be 
identified in such a globally normalized analysis. It follows that our results could have 
hypothetically arisen in the situation of reducing uptake in the parietal and occipital lobes 
in concert with reducing global brain uptake, and actually static uptake in the voxels 
identified as increasing with age in the frontal lobes, cerebellum and elsewhere. Such 
artefactual false results arising from a global normalization paradigm make intuitive 
sense and have been previously proposed in the literature [52-54]. This scenario is not 
likely to be the case and would be at odds with the literature supporting globally 
increasing quantitative measures of absolute cerebral glucose utilisation until 
approximately 10 years of age [16, 42] and increasing semi-quantitative measures of 
FDG uptake through to 16 years of age [43]. Also, recall that the results from this SPM 
analysis are voxel-based changes in FDG uptake relative to mean overall brain uptake (ie. 
“global normalization”). Therefore, it does not imply that the areas of the brain not 
showing an increase with age on the SPM map (ie. the parietal and occipital lobes) are 
not increasing with age in absolute terms, but rather that these areas are not increasing in 
uptake beyond the increase in global whole brain uptake. 
 
4.6.3 Comparison with related literature 
A previous study used SPM96 to investigate the effect of age on cerebral FDG uptake in 
a cohort of patients ranging in age from six to 38 years old. Nineteen patients were in the 
age range 6 to 15 years. All of these children had epilepsy and abnormalities on their 
EEG, and 14 were taking anti-epileptic medication. The authors concluded that when 
proportionally normalised to total counts and over the entire age range from six to 38 
years, there was a polynomial expression that best modelled the effect of age on FDG 
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uptake which increased most prominently in the thalamus and anterior cingulate cortices; 
and less extensively in the insular, posterior cingulate, frontal and post central cortices, 
the basal ganglia and brain stem [12]. This association appeared near linear in their 
patients within the pediatric age range and increased to reach a peak at approximately 30 
years after which there was reducing uptake. The results from this previous report share 
common findings with the SPM voxel-based analysis where notably the most significant 
voxels showing an increase in FDG uptake with age are in the mesial frontal lobe and 
anterior cingulate cortex (see Figures 4.4 and 4.4). 
 
Age associated changes in cerebral FDG uptake have been previously studied in 87 deaf 
children using SPM99 [55]. The authors found evidence of linearly increasing FDG 
uptake with age in the bilateral inferior prefrontal and orbitofrontal cortex, and the right 
dorsomedial frontal cortex. Several technical factors are notably different in their study 
compared to the SPM voxel-based analysis reported in this chapter. The authors appeared 
to use an adult MNI template for image pre-processing rather than a custom paediatric 
template, they used grand mean scaling as the global normalisation procedure rather than 
proportional normalisation, and they used an uncorrected peak voxel threshold of 
P<0.0005 with no correction for multiple comparison at the cluster level. Our analysis 
revealed a similar but more extensive pattern of increasing FDG uptake with age in the 
frontal lobes in addition to subcortical grey matter and temporal lobes (see Results). 
Their study also showed reducing FDG uptake with age in the inferior temporal gyrus 
and white matter of the internal capsule. The current SPM study did not show any 
significant areas with evidence of decreasing FDG uptake with age using the same strict 
statistical thresholds that were used for detecting increasing FDG uptake with age (data 
not presented).  
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The differences in the SPM pre-processing and statistical parameters, and the probable 
cerebral metabolic derangements associated with deafness in their patients are possible 
explanations for the more extensive areas of increasing FDG uptake shown in our results 
which used children without hearing impairment. 
 
4.6.4 Multiple comparison correction 
In the current SPM study, I corrected for multiple comparisons at the voxel level 
according to the principle of Gaussian random fields using a stringent voxel level 
statistical threshold, namely familywise error correction with P<0.05 [10]. Peak voxel 
level correction for multiple comparisons using familywise error rate correction are 
generally considered to be extremely strict and has been shown to result in a low 
sensitivity in detecting relevant hypometabolic regions when applied to individual patient 
scans compared with a control group in adult patients with frontal lobe epilepsy [56]. We 
used this strict threshold in combination with a cluster extent threshold of 50 voxels (0.4 
cm3 of neural tissue after normalisation to MNI space) to minimise the likelihood of false 
positive suprathreshold voxels surviving the analysis and therefore our results are much 
more likely to be true positive findings rather than a spurious result due to random 
chance. 
 
4.6.5 Issues with spatial normalisation 
A possible source of error in my SPM analysis relates to inaccurate spatial normalisation. 
Muzik et al have shown that SPM normalization procedures using FDG PET scans may 
produce significant errors in children under the age of six years [6]. Their study used an 
earlier version of SPM (SPM96) and assessed the accuracy of normalizing pediatric FDG 
scans in children with intractable epilepsy to the adult “PET” template provided with 
SPM96. There are two important factors in relation to inaccurate normalisation of FDG 
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brain scans in young children, firstly, the “PET” template provided within SPM is based 
on adult brains and secondly, the PET tracer used in the creation of this template was the 
cerebral perfusion agent [15O]H2O and not [18F]FDG (SPM8, Wellcome Trust Centre for 
Neuroimaging, Institute of Neurology, London, UK). To address these issues we created 
a custom normalization template incorporating the entire range of ages within our dataset 
of FDG brain scans. Using the entire dataset in this way reduces the potential for 
systematic differences in the accuracy of normalisation (ie. reduces normalisation bias) 
that may be more accurate in the older aged subjects if the adult “PET” template within 
SPM was used. We also generated a template based on the same PET tracer as the 
subjects being studied, [18F]FDG. It has been previously shown in adult studies that using 
normalisation templates based on PET tracers different to the scans being studied 
produces noticeably different SPM maps and also that when a custom-made tracer 
specific normalization template is used the resulting SPM map is similar to that produced 
when using structural MRI based normalisation [45]. 
 
4.6.6 Improved spatial localisation 
In my SPM analysis I used the Automated Anatomical Labelling (AAL) toolbox for SPM 
to aid in identifying the location of significant voxels [48]. This SPM add-on utility uses 
the segmentation of spatially normalised high resolution T1 cerebral MRI scans in a 
single adult subject. Errors in attributing the correct region of the brain based on single 
subject atlases are prone to occur due to physiologic variation in gyral patterns between 
subjects [57, 58]. Due to this effect our study may be susceptible to misslocalisation at 
the gyral level and compounded by potentially less accurate spatial normalisation to MNI 
space in our pediatric subjects, however the extent of the suprthreshold clusters 
particularly in the frontal lobes, would be considered to provide reasonable regional 
specificity. I took an empiric approach and regarded a threshold of 10% of the AAL 
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region to provide compelling enough evidence to assume involvement of that region and 
allow sensible generalized discussion of the results without overstating the accuracy of 
the regional localization of each and every suprathrashold voxel. I feel it is important to 
provide the whole AAL results table containing the percentage of each AAL region 
containing significant voxels so that the reader can assess for themselves the degree of 
regional distribution of the suprathreshold voxels (see Table 1). Inspection of Table 1 
shows that there is a striking consistency in that the frontal lobes are extensively 
involved as is the cerebellum, insula, striatum and thalamus, with less extensive 
involvement of the temporal lobes; and a clear exclusion of the parietal and occipital 
lobes. 
 
Image smoothing is a required as part of the SPM method and has an effect on the spatial 
resolution of localizing suprathreshold voxels. The degree of smoothing and its effect on 
the spatial resolution of SPM is discussed in the next chapter.  
 
4.6.7 Representation of normal 
The patients used in the current SPM analysis is the same as that used in Chapter 3 and 
were not normal subjects. They all underwent an FDG PET-CT scan for suspected or 
proven malignancy but none of them had a significant neurological condition. Although 
it is difficult, if not impossible to prove, we consider the scans analysed in our study are 
more likely to represent normal cerebral FDG uptake compared to children with 
clinically relevant neurological conditions necessitating the need for evaluation by FDG 
PET-CT. Previous FDG SPM studies in children have compared various patient groups 
with “pseudo-control” groups consisting of patients with clinically significant 
neurological abnormalities necessitating a cerebral FDG scan but with normal MRI 
findings [59, 60] or have used an adult control dataset [61-63]. Such control groups are 
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clearly suboptimal and we propose that a dataset such as the one used in my current study 
is more valid. The only way to confirm that the dataset used in my study is truly 
representative of a normal dataset would be to compare these patients to children without 
extracranial malignancies and without neurological disorders. Due to ethical 
considerations related to subjecting normal children to the radiation burden associated 
with 18F-FDG scans, this type of comparison is unlikely to ever be performed. 
 
4.7 Conclusion 
When normalised to global brain uptake, there is increasing FDG uptake with age in the 
premotor and prefrontal cortices, insula cortex, cingulate cortex, basal ganglia, thalamus, 
cerebellum and small areas of the inferior temporal lobes and left Heschl’s gyrus. These 
findings correlate to the results of the SUVmax analysis from Chapter 3, and provide 
further evidence that cerebral FDG uptake undergoes regionally specific changes 
throughout childhood. These age-related changes underline the importance of using age-
matched data or adjusting for age in the statistical analysis of studies comparing pediatric 
cerebral FDG scans to a reference dataset. The areas of increasing FDG uptake with age 
probably relate to underlying neuronal processes linked to normal neurodevelopment 
including key resting state networks. This SPM analysis provides a more quantitative 
approach with potentially more spatial specificity that the SUVmax analysis from Chapter 
3. It is an important proof of principle demonstration in the use of general linear 
modelling within SPM to describe whole brain voxel-by-voxel age related changes in 
regional 18F-FDG uptake. The analysis provides a methodological basis for the 
comparison of clinical 18F-FDG scans in children with neurological disorders to the 
normal dataset.  
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5 CHAPTER FIVE: SPECIFICITY OPTIMISATION 
OF SPM PARAMETERS FOR SINGLE-SUBJECT 
VERSUS GROUP COMPARISONS  
5.1 Abstract 
Aims: SPM analysis may produce false positive supra-threshold voxels. Paediatric scans 
may be more susceptible to false positive results particularly if an inappropriate adult 
control group is used or if scans have been excluded from the control group on the sole 
basis of containing outlying voxel intensities.  The aim of this chapter is to utilise the 
high quality dataset of dedicated cerebral FDG scans described in Chapters 3 and 4, to 
determine specificity optimised template smoothing, scan smoothing and statistical 
thresholds to limit the risk of false positive results when comparing the dataset to scans 
in patients with neurological disturbances in a single-subject versus group analysis. 
 
Methods: Each scan in the normal control dataset was compared against the remaining 
scans in a single-subject versus group SPM analysis. Voxel-level and cluster-level 
correction for multiple comparison correction, and analyses looking for hypo and hyper-
metabolism were considered separately. Any surviving supra-threshold voxels were 
considered to represent false positive findings. The combination of template smoothing 
(0mm, 8mm, 16mm or 24mm) and scan smoothing (0mm, 8mm, 16mm or 24mm) that 
resulted in the fewest number of false positive results were considered the specificity 
optimised pre-processing parameters. These parameters were used in SPM pre-
processing to determine the most liberal p-value threshold separately for hypo and hyper-
metabolism where there were no false positive results across the entire dataset. These 
statistical thresholds were considered the specificity optimised statistical thresholds and 
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in combination with the specificity optimised pre-processing parameters constituted the 
specificity optimised SPM setup to minimise false positive results. 
 
Results:  With voxel-level correction for multiple comparisons the specificity optimised 
SPM parameters were: 16mm template smoothing, 16mm scan smoothing and FWEp 
corrected p<0.094 for hypo-metabolism; and 0mm template smoothing, 0mm scan 
smoothing and FWEp corrected p<0.00012 for hyper-metabolism. 
 
With cluster-level correction for multiple comparisons the specificity optimised SPM 
parameters were: 16mm template smoothing, 24mm scan smoothing and uncorrected 
p<0.05-0.00005 for hypo-metabolism and 24mm template smoothing, 24mm scan 
smoothing and uncorrected p <0.05-0.0000005 for hyper-metabolism. 
 
Conclusions:  Specificity optimised SPM parameters have been determined for hypo and 
hyper-metabolism using both voxel-level FWEp and cluster-level FWEc correction for 
multiple comparisons. The specificity optimised statistical threshold for hyper-
metabolism were more strict than for hypo-metabolism, suggesting that there is more 
variability in regional increases in FDG uptake which may relate to more variable 
cerebral activation during the tracer uptake phase. The hypo-metabolism specificity 
optimised parameters will be used in the SPM analysis of scans in children with epilepsy 
presented in Chapter 6. 
5.2 Introduction 
The cerebral FDG scans that have been examined and characterised in Chapters 3 and 4, 
comprise the largest reported group of dedicated cerebral FDG scans in neurologically 
normal children. Whole-brain, voxel-wise statistical analysis of FDG PET CT scans is a 
technique that when combined with a suitable control dataset can be useful to identify 
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abnormal cerebral metabolism without the need for an a priori hypothesis of a region 
with altered metabolism. Such voxel-wise statistical comparisons can be used to assess 
the effect of a variable of interest on voxel-wise activity in a group of subjects (such as 
subject age in Chapter 3), to perform single-subject versus group or group-versus-group 
comparisons, and also to perform single-subject paired studies [64].  
 
Published reports using SPM to analyse functional nuclear medicine cerebral scans in 
children are sparse. Studies exist using SPM to compare cerebral perfusion studies in 
children with autism to non-autistic mental retardation [65, 66]; analysing cerebral FDG 
PET to assess the effect of age in a cohort of deaf children [55], to compare a group of 
children with epilepsy and aggressive features to an adult control dataset [61], and to 
compare a very small group of children with Neurofibromatosis Type 1 to non-NF1 
children with extra-cranial malignancies [67]. There have been single-subject versus 
group comparisons with SPM in pediatric epilepsy but the control groups have consisted 
either of adults [68, 69] and/or children with seizure disorders [59, 60] limiting the 
validity of the comparisons. As was shown in Chapters 3 and 4, there are regional 
changes that occur in brain FDG uptake throughout normal childhood, and therefore 
adult control datasets are clearly suboptimal. The two studies that used children with 
non-lesional epilepsy as a control group both excluded potential control subjects on the 
basis of SPM results from an internal comparison to the other “normal” contenders. A 
potential control subject was excluded if deviations in FDG uptake were found [59, 60]. 
Artificially and arbitrarily reducing the variability in a control dataset of cerebral FDG 
scans in this manner brings into question the validity of such a control dataset. 
 
The purpose of the analysis presented in this chapter is to validate the SPM database of 
28 cerebral FDG scans performed in neurologically normal children (described in 
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Chapter 4) for use as the control dataset for single-subject versus group SPM 
comparisons. As this group of subjects is defined as the entire normal control dataset all 
28 scans were retained, regardless of the presence of apparent statistical outliers during 
the validation process. This approach does not artificially reduce the variability in the 
dataset and contributes to reducing the chance of false positive results when comparing 
to other single-subject scans. Similarly, the validation process described below is a 
“specificity optimized” method targeted at reducing the chance of producing false 
positive findings in subsequent single-subject versus group comparisons.  
 
The SPM specificity optimized analysis employed a leave-one-out validation paradigm 
[70]. This technique systematically compares each subject in the dataset against the 
remaining subjects using a two-sample t-test within SPM. By definition the dataset 
comprises cerebral FDG PET scans in neurologically normal children of varying ages, 
and therefore any significant findings were considered to represent false positive results. 
Analyses aimed at detecting increased and decreased FDG uptake, ie. hyper-metabolism 
and hypo-metabolism, were considered separately as were results based on voxel level 
(FWEp) and cluster level (FWEc) correction for multiple comparisons (see Chapter 2 and 
“Optimising statistical thresholds” below for further explanation of the methods for 
correction for multiple comparisons in SPM). 
 
The validation process involved evaluation of the specificity optimised template 
smoothing parameters, scan smoothing parameters, and voxel-based statistical thresholds. 
Further introduction to these key elements of the SPM process are now provided, prior to 
the detailed description of the validation process in the Methods section. 
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5.2.1 Optimising template smoothing and scan smoothing 
5.2.1.1 Template Smoothing 
Recall from Chapter 2 that one of the initial pre-processing steps in performing an SPM 
analysis of FDG PET scans is the normalisation of each scan to a common reference 
template. In this way each scan is in register with each other and data from spatially 
concordant voxels across the entire dataset can then be analysed. As has been more fully 
discussed in Chapter 4, there are published studies that highlight the importance of using 
an appropriate normalisation template [45] and that pediatric brain images are not 
adequately normalised when using an adult template, particularly in children less than six 
years of age [6], to reduce the chance of normalisation bias affecting the resulting SPM 
maps. Hence the custom normalisation template created from the entire dataset of normal 
control subjects (described in Chapter 4) was used as the template for the analysis 
presented in this chapter. 
 
SPM uses a method of minimizing the sum of squares difference between a scan and the 
chosen template using both affine and non-linear warping. The degree of smoothing of 
the normalisation template potentially has an impact on the accuracy of normalisation 
and the subsequent SPM map. Technical detail of the normalisation process is beyond 
the scope of this thesis but further information can be found in the SPM8 manual [46]. 
The degree of smoothing of the custom template is an important parameter to consider in 
the assessment of specificity optimised pre-processing parameters. 
 
5.2.1.2 Normalisation differences produced by templates of different smoothness 
The differences in scan warping by using normalization templates of different 
smoothness can be demonstrated in an analysis of a single subject. Four different custom 
FDG normalization templates were generated from the dataset, each with a different 
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degree of smoothing (see Methods: SPM pre-processing and analysis). Each was applied 
to the same subject, PID11, a 16 year old male. There was no further smoothing of each 
resulting normalized scan. Using the “Imcalc” module within SPM the normalized scans 
were then subtracted from each other to show a “difference image” and a 0.8 relative 
threshold mask was applied to remove extra-cerebral voxels. This “difference image” is a 
visual representation of differences in the voxel-by-voxel intensities between the two 
images and the results are displayed in Figure 5.1. Each difference image is shown with 
the same grey scale window threshold settings in SPM (-20,000, 20,000) to allow visual 
comparison between the images. The darker shades of grey represent negative values and 
the lighter shades represent positive values. When the same normalization template scan 
image is subtracted from itself, depicted by the cells on the downward diagonal, the 
resulting image is entirely made up of “zeros” and therefore not visible. Note also that 
the difference images diagonally opposite the zero value images are the inverse of each 
other, that is, light/white voxels on one image correspond to dark/black voxels on the 
other image. This occurs because these opposite difference images are formed from 
opposite mathematical subtractions. For example, the bottom left cell is the scan 
normalised to template 8mm minus the scan normalised to template 16mm. The resulting 
“difference image” is the inverse of the diagonally opposite difference image at the top 
right which is the scan normalised to template 16mm minus the scan normalised to 
template 8mm. 
 
Figure 5.1 shows that there are differences in warping parameters when using 
normalization templates of different smoothness. It cannot be assumed that the intensity 
of the light and dark voxels, which more precisely represent the magnitude of the 
numerical difference in voxel values, correlates to increasing voxel misalignment. 
However, the inherent smoothness of the underlying PET scan would imply that with 
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mild to moderate levels of misalignment as common voxels move more beyond their 
region of similar intensity voxels, a higher magnitude of difference would result and 
produce more lighter or darker shades on the difference image. Based on this underlying 
theoretical concept, the largest difference (ie. the difference images with more intense 
lightly or darked shaded voxels) appears to be between the two most extreme template 
smoothing kernels, 0mm and 24mm. One might predict that there could be more extreme 
values on the difference image at regions close to the interface between high and low 
level voxel intensities, such as the surface of the cortex at the boundary of the mask 
where even a small amount of misalignment could overlap a low intensity previously 
masked voxel with a very high intensity voxel in the cerebral cortex. There is some 
visual evidence of this with a visible “rind” of extreme voxel difference values, most 
noticeable in the difference images using the 24mm smoothed template, and there are 
also similar dark and light intensity difference voxels extending deeper in the cortex and 
deep brain structures. These differences in warping during the normalization process 
have the potential to alter the voxel-to-voxel statistics when applied across the dataset 
and ultimately produce variable results in SPM maps. Therefore the effects of template 
smoothing on producing false positive results are investigated in this chapter and the 
specificity optimised template smoothing parameters are systematically evaluated. 
 
Normalization based on high-resolution structural imaging such as MRI is more accurate 
than PET tracers such as FDG and has been used to assess the accuracy of normalisation 
based on PET images alone [6]. None of the subjects in the normal control dataset had a 
cerebral MRI scan from which the accuracy of normalization based on the custom FDG 
template could be assessed. I therefore incorporated different degrees of smoothing of the 
custom FDG normalisation template within the paradigm of the leave-one-out validation 
process (see Methods below) to assess the performance of each template in limiting false 
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positive findings. In this manner the specificity optimised degree of template smoothing 
was determined. 
 
 
Figure 5.1: Difference image matrix of subject PID11 when normalized to four custom normalization 
templates with different smoothing. 
Axial slices are shown through the centre of the volume at the level of the basal ganglia at the z-axis MNI 
coordinate 18.0mm. Template smoothing is indicated across the top of the figure and down the left hand 
side. The images in the matrix are the difference images ie. the image in each cell represents the image of 
PID11 normalized to the template indicated on the left hand side minus the image of PID11 normalised to 
the template indicated on the top. The images were created in the “Imcalc” module in SPM and the 
difference images are all manually scaled to the same window (-20,000 20,000) and displayed in grey scale. 
The dark shades represent negative values and the lighter shaded represent positive values. The actual 
custom templates each smoothed with the four different smoothing kernels are shown in the template 
smoothing results summary Table 5.10. 
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5.2.1.3 Scan smoothing 
The degree of smoothing applied to the scans in the dataset is a critically important 
parameter to evaluate. To understand the reasons for this it is necessary to briefly explain 
some further theory behind the SPM methodology. Scan smoothing is a process that 
contributes to overcoming limitations in the functional normalisation of the scans, to 
improve the signal-to-background ratio of voxels with abnormal FDG uptake and 
perhaps most critical of all, has effects on the SPM method of correction for multiple 
comparisons. These three areas are now discussed. 
 
5.2.1.4 Scan smoothing to improve functional alignment between scans 
Even after normalization of the brain scans to an appropriate normalisation template, 
there remains residual between-subject variability in both structurally and functionally 
homologous regions. For example, although the major sulci are very consistent between 
subjects the minor sulci maintain a large degree of variability from subject to subject [71-
76]. The normalization process does not overcome these physiologic, structural 
differences at the minor sulci level. There are computational processes to more finely 
match the anatomy of subjects brain scans at this level but these run the risk of “over-
fitting” and applying unrealistic deformations of the native brain scan creating false 
anatomical structures as a result of forcing a particular brain scan to match a particular 
template [77]. After normalisation, smoothing of the scans before proceeding to voxel-
wise statistical analysis mitigates the residual variability between subjects due to these 
factors. Smoothing brings common structural and functional regions of the brain into 
more close alignment between subjects prior to voxel-wise statistical analysis, but comes 
at a consequence of reducing the anatomical precision. 
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5.2.1.5 Scan smoothing to improve signal-to-noise ratio 
Technical aspects related to the acquisition and reconstruction of FDG PET scans result 
in both random, independent voxel-to-voxel noise and also non-independent voxel-to-
voxel ie. spatially correlated, noise. Spatially correlated noise is related to resolution of 
the PET scanner. Biological factors related to physiologic variability in FDG uptake 
throughout the brain also contribute to noise. This variability in PET signal is probably 
spatially correlated because the noise signal coming from biological process in the 
underlying brain are likely to span several, if not many, voxels in the reconstructed image. 
If there is a biological signal of interest in addition to the noise present in the scans being 
analysed, then this signal is also likely to be spread over several adjacent voxels. This 
degree of spatial dependence is related to the voxel size of the reconstructed image and 
the biological extent of the brain region from which the signal arises. An image with a 
small voxel size and extensive area of signal from the brain would produce a larger 
degree of spatial dependence than an image with a larger voxel size and less extensive 
area of signal from the brain. From a statistical perspective and according to the matched 
filter theorem, smoothing of the voxel wise data would reduce the signal variability due 
to random noise and increase the signal to noise ratio in any region with increased or 
decreased PET signal [78]. The signal of interest present in FDG PET data may be low in 
magnitude compared to statistical noise and methods to increase the signal to noise ratio 
such as increasing the number of subjects in the analysis and smoothing of the scans are 
both considerations in SPM analysis. 
 
5.2.1.6 Scan smoothing to apply Random Field Theory methods of multiple 
comparison correction 
As has been more comprehensively discussed in Chapter 2, Random Field Theory (RFT) 
underpins the SPM method of correcting the analysis for multiple comparisons. The 
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concept of the resel and its relationship to RFT FWE correction was introduced in 
Chapter 2, and recall that scan smoothing has a direct impact on resel size which in turn 
effects both voxel and cluster level FWE statistical thresholds. The degree of scan 
smoothing via the influence on resel size and statistical thresholds therefore has a direct 
influence on false positive findings at both voxel level and cluster level correction for 
multiple comparison. 
 
5.2.2 Smoothing summary 
To summarise, scan smoothing is a requirement to improve the alignment of 
anatomically and functionally homologous regions between subjects, to increase the 
signal to noise ratio of areas of abnormal tracer uptake, and allows RFT methods to 
correct for multiple comparisons across a whole brain analysis. Scan smoothing comes at 
a cost of compromising the spatial accuracy of the findings. In this chapter scan 
smoothing parameters are investigated systematically to determine the optimal scan 
smoothing parameters to limit false positive findings within the paradigm of a leave-one-
out validation process (see Methods below). In this manner the specificity optimized 
degree of scan smoothing was determined. 
 
5.2.3 Optimising statistical thresholds 
Recall from Chapter 2 that SPM results can be corrected for multiple comparisons and 
specified at either the voxel level or cluster level. Voxel level results have a higher 
degree of spatial specificity and infer that there is evidence of a significant finding in 
each and every supra-threshold voxel. Cluster level results have a lower degree of spatial 
specificity and infer that there is evidence of a significant finding in at least one voxel 
within each supra-threshold cluster. Also recall that when using voxel level correction 
analysis a corrected voxel level statistical threshold (ie. a corrected p-value cut point) is 
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specified in SPM and applied to the statistic image at each and every voxel to determine 
the presence of significant supra-threshold voxels. This is compared to cluster level 
correction where first an uncorrected voxel level statistical threshold (ie. an uncorrected 
p-value cut point) is specified and applied to the statistic image at each and every voxel, 
followed by a FWE corrected cluster extent threshold (FWEc p<0.05) applied to every 
cluster to ultimately determine the presence of significant supra-threshold clusters. 
 
A key difference in the processing of a cluster level corrected analysis compared to a 
voxel level corrected analysis is that cluster level significance can be assessed across 
many different uncorrected voxel level thresholds. Ultimately, and dependent on the resel 
size and voxel size of the statistic images, it is the change in cluster size relative to the 
uncorrected voxel level threshold that determines whether or not a particular cluster at a 
particular uncorrected voxel level threshold passes significance. Put another way, if a 
cluster increases in size sufficiently beyond that expected based on the specified 
uncorrected voxel threshold (according to RFT), then it will pass significance on a FWEc 
corrected cluster level. It is therefore important to assess cluster level corrected 
specificity optimized parameters at multiple different uncorrected voxel level thresholds. 
 
Determining specificity optimised voxel level corrected thresholds is a less complex 
process. FWEp thresholds (ie. corrected p-value cut points) can be varied and any supra-
threshold voxels pass significance on a FWEp corrected voxel level basis. 
 
5.3 Aims 
The aims of this chapter were to determine the optimal template smoothing and scan 
smoothing parameters, and to perform an empiric validation of statistical thresholds to 
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protect against false positive findings (ie. “specificity optimised” parameters) in single-
subject versus group analyses using SPM. 
The hypotheses are that template smoothing and scan smoothing have an effect on false 
positive findings, and that suitable specificity optimised statistical thresholds can be 
determined for both voxel level and cluster level corrected SPM analyses, to protect 
against false positive findings. Validation testing will be performed separately for 
analyses targeted at detecting reduced or increased FDG uptake compared to the dataset. 
 
The dataset of cerebral FDG scans to be used in this analysis is the largest reported 
dataset in neurologically normal children and the ensuing results form the basis for SPM 
comparison with single-subject scans in children with epilepsy presented in the following 
chapter. 
 
5.4 Methods 
5.4.1 Subjects and PET imaging protocol 
The normal dataset of 28 pediatric cerebral FDG scans described in Chapter 4 was 
analysed using SPM. Detailed description of the included subjects and PET imaging 
protocol are described in Chapters 3 and 4. 
 
5.4.2 SPM pre-processing and analysis 
Spatial pre-processing and statistical analyses were performed using the “PET & VBM” 
module of SPM8 (Wellcome Trust Centre for Neuroimaging, Institute of Neurology, 
London, UK), which was implemented using Matlab 7.12.0 (R2011a, MathWorks Inc., 
Sherborn, MA). 
 
 89
The SPM parameters investigated were two pre-processing parameters (normalization 
template smoothing and scan smoothing) and voxel level statistical thresholds (further 
described below). 
 
Four different custom, FDG specific normalization template were constructed from all of 
the scans in the dataset in the same way as described in Chapter 4. All scans were first 
normalized to the default PET template available within SPM and then these normalized 
scans were smoothed with four different Gaussian smoothing kernels (0x0x0mm (no 
smoothing), 8x8x8mm, 16x16x16mm, and 24x24x24mm). Each of the differently 
smoothed datasets were combined using the “Imcalc” module within SPM and the mean 
image was calculated and written out using a bounding box dimension of -90:91 -126:91 
-72:109 and a voxel size of 2x2x2mm. This produced a mean, spatially normalised image 
for each of the smoothing kernels composed from the whole dataset. These four mean 
images were the four custom, FDG normalization templates at different Gaussian 
smoothing kernels (ie. normalization templates at 0x0x0mm(no smoothing), 8x8x8mm, 
16x16x16mm and 24x24x24mm) and were each used to normalise the native 
reconstructed PET scans from each subject during SPM image pre-processing. 
 
After each template was used to spatially normalize the dataset, the “Smooth” module in 
SPM was used to smooth each normalized scan with four different Gaussian kernels of 
the same dimensions as the smoothing kernels applied to the templates (0x0x0mm(no 
smoothing), 8x8x8mm, 16x16x16mm, and 24x24x24mm). Therefore (4x4) 16 different 
template and scan smoothing combinations were used to evaluate the specificity 
optimised SPM image pre-processing template and scan smoothing parameters (see 
Table 5.1). 
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Table 5.1: The 16 different template and scan smoothing combination. 
The 16 different combinations of the four normalization template smoothing and scan smoothing are 
shown. Each of the 16 different combinations were applied to the entire dataset used in the specificity 
optimization evaluation process. 
  Template smoothing 
  0x0x0mm 8x8x8mm 16x16x16mm 24x24x24mm 
Scan 
smoothing 
0x0x0mm Temp0.Scan0 Temp8.Scan0 Temp16.Scan0 Temp24.Scan0 
8x8x8mm Temp0.Scan8 Temp8.Scan8 Temp16.Scan8 Temp24.Scan8 
16x16x16mm Temp0.Scan16 Temp8.Scan16 Temp16.Scan16 Temp24.Scan16 
24x24x24mm Temp0.Scan24 Temp8.Scan24 Temp16.Scan24 Temp24.Scan24 
For each combination, “Temp#” denotes the normalization template smoothing kernel and 
“Scan#” demotes the scan smoothing kernel. 
 
The “Normalise: Est and Wri” module was used to normalize the scans for each 
particular template taking care to match the “Source Image Smoothing” to the “Template 
Image Smoothing”. Apart from the template and scan smoothing parameters under 
investigation, the remainder of the SPM default parameters were unchanged and the 
resulting normalized and smoothed images were written out using a bounding box 
dimension of -90:91 -126:91 -72:109 with a voxel size of 2x2x2mm. In this manner there 
were 16 different datasets produced, each composed of all the scans from the normal 
dataset pre-processed with a different combination of normalization template smoothing 
and scan smoothing (see Table 5.1). 
 
For each of these datasets, the “Basic models” module in SPM was used to create a 2-
sample t-test comparing each scan to the remaining scans within the dataset in a leave-
one-out validation process, similar to that described by Signorini et al [70]. Chapter 4 
proved that regional changes in FDG uptake occur with age and therefore age was 
incorporated as a covariate in the SPM design matrix. As was done in the SPM analysis 
in Chapter 4, relative threshold masking of 0.8 was implemented to remove extra-
cerebral tracer uptake and proportional normalisation was used as the global 
normalisation procedure to account for global differences in whole brain tracer uptake in 
part arising from variability in injected dose of FDG and uptake times. The variance was 
set to “Equal” and the remainder of the SPM8 default parameters in this module were 
unchanged. 
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5.4.3 Specificity-optimised template smoothing and scan smoothing 
The comparison of all 28 control subjects’ scans individually against the remaining 27 
scans in the dataset, using each of the 16 different pre-processing template/scan 
smoothing combinations, and for both hypo and hyper-metabolism yielded (28x16x2) 
896 individual 2-sample t-test SPM maps. Voxel level and cluster level statistical 
thresholds were set at the SPM default levels of FWEp p<0.05 and FWEc p<0.05 at an 
uncorrected voxel threshold of p<0.001, respectively. The template smoothing that 
resulted in the fewest false positive results was considered the specificity-optimized 
template. When using this determined specificity-optimized template, the scan smoothing 
that resulted in the fewest false positive results was considered the specificity-optimized 
scan smoothing parameter. 
 
5.4.4 Specificity-optimized statistical thresholds 
Once the specificity optimized template and scan smoothing parameters were determined, 
they were used in the SPM pre-processing for detecting both hypo and hyper-metabolism 
with voxel level and cluster level correction for multiple comparisons. The SPM results 
using these specificity-optimised pre-processing parameters were used to determine 
specificity-optimized statistical thresholds. 
 
In the case of voxel level correction for multiple comparisons, the most liberal (ie. 
highest p-value) FWEp p-value threshold (with a precision of two significant figures) at 
which there were no false positive results was determined for each scan in the leave-one-
out validation process. The FWEp p-value threshold at which there were no false positive 
voxels across the whole dataset was deemed the specificity-optimized statistical 
threshold for a voxel level corrected analysis. 
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In the case of cluster level correction for multiple comparisons, the leave one out 
validation process was repeated using uncorrected voxel level p-value thresholds ranging 
in increments from 0.000,000,01 up to 0.5. The number of supra-threshold clusters at the 
cluster corrected FWEc default level of p<0.05 at each specified uncorrected voxel level 
threshold was determined for each scan compared against the remaining dataset. The 
upper and lower limits of the uncorrected voxel level p-value where there were 
significant clusters at the FWEc p<0.05 level across the entire dataset was called the 
“false positive p-value window”. Uncorrected voxel level p values outside of the “false 
positive p-value window” were deemed the specificity optimized statistical thresholds for 
a cluster level corrected analysis. 
5.5 Results 
5.5.1 Specificity optimized template smoothing and scan smoothing 
5.5.1.1 Hypo-metabolism: voxel level FWEp corrected analysis 
On the FWEp voxel level corrected analysis, 37/448 maps had decreased FDG uptake 
with clusters ranging in size from one voxel to 704 voxels (Table 5.2). The non-
smoothed template had a total of 1,308 suprathreshold voxels, 8mm had 306 voxels, 
16mm had 27 voxels and 24mm had 1,085 voxels. When grouped according to degree of 
scan smoothing (Table 5.3) the analyses with no scan smoothing had 18 suprathreshold 
voxels, 8mm had 39 voxels, 16mm had 220 voxels and 24mm had 2,449 voxels. The 
16mm template had the lowest number of FP voxels (27) and when using this template 
the 16mm scan smoothing had the lowest number of suprathreshold voxels (0) 
compared to 3 suprathreshold voxel with the non-smoothed scans, 9 voxels with the 
8mm smoothing and 15 voxels with 24mm smoothing (Table 5.2).  
 
  
Table 5.2: Hypo-metabolism, FWEp corrected specificity-optimised results – grouped by template smoothing. 
Results for the template smoothing and scan smoothing specificity-optimised procedure; hypo-metabolism using voxel level FWEp correction for multiple comparisons are shown. 
Results are grouped by template smoothing. The subjects forming the normal control dataset are listed in the first column indicated by their patient identification number (PID). The 
results of their leave-one-out two-sample t-test validation procedure are indicated under the column headings corresponding to the relevant template smoothing and scan smoothing 
parameters. The numbers in the cells represent the size, in voxels, of any supra-threshold cluster(s) for that subject’s leave-one-out two-sample t-test. A cell containing no numbers 
indicates no surviving supra-threshold voxels for that combination of template smoothing and scan smoothing. The 16mm smoothed template had the lowest total number of supra-
threshold voxels (27) and when this template was used, the 16mm scan smoothing had the lowest number of supra-threshold voxels (0). 
 
Template smoothing (x, y, z; mm)
Scan smoothing (x, y, z; mm) 0mm 8mm 16mm 24mm 0mm 8mm 16mm 24mm 0mm 8mm 16mm 24mm 0mm 8mm 16mm 24mm
PID
1
10 1 2 2 2 9
102 12
11 1 1
12 1
13
16 1
2
28
31 3
34 1 9 5 1 15, 14 371
49 12
52 60, 32 507 163
67 1 4 1 4 20
68
69
72
73
78
79
8 704 131 1 3 27
80 54, 25 519
81
82
86 1
87 1 2
90
93 3
subtotals 3 2 92 1211 3 9 0 294 3 9 0 15 9 19 128 929
total per template smoothing
0mm 8mm 16mm 24mm
1308 306 27 1085
 
 
 
Table 5.3: Hypo-metabolism, FWEp corrected specificity-optimised results – grouped by scan smoothing. 
Results for the template smoothing and scan smoothing specificity-optimised procedure; hypo-metabolism using voxel level FWEp correction are shown. Results are grouped by 
scan smoothing. 
 
Scan smoothing (x, y, z; mm)
Template smoothing (x, y, z; mm) 0mm 8mm 16mm 24mm 0mm 8mm 16mm 24mm 0mm 8mm 16mm 24mm 0mm 8mm 16mm 24mm
PID
1
10 1 2 2 2 9
102 12
11 1 1
12 1
13
16 1
2
28
31 3
34 1 9 5 1 15, 14 371
49 12
52 60, 32 507 163
67 1 1 4 4 20
68
69
72
73
78
79
8 1 704 131 3 27
80 54, 25 519
81
82
86 1
87 1 2
90
93 3
subtotals 3 3 3 9 2 9 9 19 92 0 0 128 1211 294 15 929
total per scan smoothing
0mm 8mm 16mm 24mm
18 39 220 2449
 5.5.1.2 Hypo-metabolism: cluster level FWEc corrected analysis 
On the FWEc cluster level corrected analysis, 54/448 maps had decreased uptake (Table 
5.4) The non-smoothed template had 19 suprathreshold clusters, 8mm had 18 clusters, 
16mm had 17 clusters and 24mm had 22 clusters (Table 5.4). When grouped according 
to scan smoothing (Table 5.5) the analyses with no scan smoothing had 44 
suprathreshold clusters, 8mm had 13 clusters, 16mm had 11 clusters and 24mm had 8 
clusters. The 16mm template had the lowest number of FP clusters (17) and using this 
template the 24mm scan smoothing had the lowest number of suprathreshold clusters (2) 
compared to 9 suprathreshold clusters with the non-smoothed scans, and 3 
suprathreshold clusters with both the 8mm and 16mm smoothing (Table 5.4).  
 
The minimum FWEc suprathreshold cluster size ranged from 58 voxels in the non-
smoothed scans to 14,552 voxels in the 24mm smoothed scans (Table 5.4). When 
grouped according to template, the minimum suprathreshold cluster size was similar 
across the different templates (Table 5.4). These were 61, 58, 62 and 67 voxels for the 
0mm, 8mm, 16mm and 24mm smoothing kernels, respectively, and in all templates the 
minimum suprathreshold cluster size occurred with the 0mm scan smoothing. When 
grouped according to degree of scan smoothing the minimum suprathreshold cluster size 
increased as the smoothing increased (Table 5.5). Minimum suprathreshold size was 58, 
310, 1108 and 1709 voxels for 0mm, 8mm, 16mm and 24mm scan smoothing kernels, 
respectively. 
Table 5.4: Hypo-metabolism, FWEc corrected specificity-optimised results – grouped by template smoothing. 
Results for the template smoothing and scan smoothing specificity-optimised procedure; hypo-metabolism using cluster level FWEc correction for multiple comparisons are shown. 
Results are grouped by template smoothing. The subjects forming the normal control dataset are listed in the first column indicated by their patient identification number (PID). The 
results of their leave-one-out two-sample t-test validation procedure are indicated under the column headings corresponding to the relevant template smoothing and scan smoothing 
parameters. The numbers in the cells represent the number of supra-threshold cluster(s) for that subject’s leave-one-out two-sample t-test using an uncorrected voxel p<0.001 and 
FEWc p<0.05. A cell containing no numbers indicates no surviving FWEc supra-threshold clusters for that combination of template smoothing and scan smoothing. The 16mm 
smoothed template had the lowest total number of FWEc supra-threshold clusters (17) and when this template was used, the 24mm scan smoothing had the lowest number of FWEc 
supra-threshold clusters (2). 
 
Template smoothing (x, y, z; mm)
Scan smoothing (x, y, z; mm) 0mm 8mm 16mm 24mm 0mm 8mm 16mm 24mm 0mm 8mm 16mm 24mm 0mm 8mm 16mm 24mm
PID
1
10 1 1 1
102 1 1
11 3 2 1 1
12
13
16 1
2
28 1
31
34 1 3 2 2 1 1
49
52 2 1 1 1 2 1 1 1 1 1 1
67 1 1 3 1 3 3 1 1
68
69
72
73
78
79
8 2 2 1 1 1 1 2 1 1 2 1 1 2 2 1 1
80 1
81
82
86 2
87
90
93
subtotals 11 4 2 2 11 3 3 1 9 3 3 2 13 3 3 3
total clusters per template
min cluster size 61 322 3011 2877 58 516 1186 14552 62 310 1108 2141 67 330 1319 1709
min cluster size per template
19 18 17 22
0mm 8mm 16mm 24mm
61 58 62 67
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Table 5.5: Hypo-metabolism, FWEc corrected specificity-optimised results – grouped by scan smoothing. 
Results for the template smoothing and scan smoothing specificity-optimised procedure; hypo-metabolism using cluster level FWEc correction are shown. Results are grouped by 
scan smoothing. 
Scan smoothing (x, y, z; mm)
Template smoothing (x, y, z; mm) 0mm 8mm 16mm 24mm 0mm 8mm 16mm 24mm 0mm 8mm 16mm 24mm 0mm 8mm 16mm 24mm
PID
1
10 1 1 1
102 1 1
11 3 2 1 1
12
13
16 1
2
28 1
31
34 1 3 2 2 1 1
49
52 2 2 1 1 1 1 1 1 1 1 1
67 1 3 3 3 1 1 1 1
68
69
72
73
78
79
8 2 1 1 2 2 1 2 2 1 2 1 1 1 1 1 1
80 1
81
82
86 2
87
90
93
subtotals 11 11 9 13 4 3 3 3 2 3 3 3 2 1 2 3
total clusters per scan smoothing
min cluster size 61 58 62 67 322 516 310 330 3011 1186 1108 1319 2877 14552 2141 1709
min cluster size per scan smoothing
8mm 16mm 24mm
44
0mm
13 11 8
58 310 1108 1709
5.5.1.3 Hyper-metabolism: voxel level FWEp corrected analysis 
On the FWEp voxel level corrected analysis, 72/448 maps had suprathreshold voxels 
with clusters ranging in size from one voxel to 599 voxels (Table 5.6). The non-
smoothed template had 697 suprathreshold voxels, 8mm had 1,236 voxels, 16mm had 
2,041 voxels and 24mm had 1,638 voxels. When grouped according to the degree of scan 
smoothing (Table 5.7) the analyses with no scan smoothing had 248 suprathreshold 
voxels, 8mm had 370 voxels, 16mm had 1,942 voxels and 24mm had 3,052 voxels. The 
non-smoothed template had the lowest number of FP voxels (697) and using this 
template no scan smoothing resulted in the lowest number of suprathreshold voxels (50) 
compared to 82 suprathreshold voxel with the 8mm smoothing, 258 voxels with the 
16mm smoothing and 307 voxels with 24mm smoothing (Table 5.6).  
 
 
 
Table 5.6: Hyper-metabolism, FWEp corrected specificity-optimised results – grouped by template smoothing. 
Results for the template smoothing and scan smoothing specificity-optimised procedure; hyper-metabolism using voxel level FWEp correction for multiple comparisons are shown. 
Results are grouped by template smoothing. The subjects forming the normal control dataset are listed in the first column indicated by their patient identification number (PID). The 
results of their leave-one-out two-sample t-test validation procedure are indicated under the column headings corresponding to the relevant template smoothing and scan smoothing 
parameters. The numbers in the cells represent the size, in voxels, of any supra-threshold cluster(s) for that subject’s leave-one-out two-sample t-test. A cell containing no numbers 
indicates no surviving supra-threshold voxels for that combination of template smoothing and scan smoothing. The 0mm smoothed template had the lowest total number of supra-
threshold voxels (697) and when this template was used, the 0mm scan smoothing had the lowest number of supra-threshold voxels (50). 
  
Template smoothing (x, y, z; mm)
Scan smoothing (x, y, z; mm) 0mm 8mm 16mm 24mm 0mm 8mm 16mm 24mm 0mm 8mm 16mm 24mm 0mm 8mm 16mm 24mm
PID
1
10 15 25 17 29 26 2 18
102 2
11 17 21 247 254 32 42 355 430 22 73 309 381 35 69 241 599
12 16
13
16 9 32 4 2 4 7
2 1 3
28 1 2 1
31 1 3 2 3
34 3 4 5 12 5 104 132 1 7 118 233
49 103 191 5 300 505 54 142 77
52 18
67
68
69
72 1
73
78
79
8 2 7 19 11 154 1 30
80
81
82
86
87 1 8 5 2
90
93
subtotals 50 82 258 307 63 71 470 632 67 87 713 1174 68 130 501 939
total per template smoothing 697 1236 2041 1638
0mm 8mm 16mm 24mm
 100
 
 
 
 
Table 5.7: Hyper-metabolism, FWEp corrected specificity-optimised results – grouped by scan smoothing. 
Results for the template smoothing and scan smoothing specificity-optimised procedure; hyper-metabolism using voxel level FWEp correction. Results are grouped by scan 
smoothing. 
 
Scan smoothing (x, y, z; mm)
Template smoothing (x, y, z; mm) 0mm 8mm 16mm 24mm 0mm 8mm 16mm 24mm 0mm 8mm 16mm 24mm 0mm 8mm 16mm 24mm
PID
1
10 15 17 26 18 25 29 2
102 2
11 17 32 22 35 21 42 73 69 247 355 309 241 254 430 381 599
12 16
13
16 9 2 4 7 32 4
2 1 3
28 1 1 2
31 1 3 2 3
34 3 5 5 1 4 7 12 104 118 132 233
49 5 54 103 300 142 191 505 77
52 18
67
68
69
72 1
73
78
79
8 2 1 7 19 11 154 30
80
81
82
86
87 1 8 2 5
90
93
subtotals 50 63 67 68 82 71 87 130 258 470 713 501 307 632 1174 939
total per scan smoothing
8mm 16mm 24mm
248 370 1942 3052
0mm
5.5.1.4 Hyper-metabolism: cluster level FWEc corrected analysis 
On the FWEc cluster level corrected analysis, 57/448 maps had increased uptake (Table 
5.8). The non-smoothed template had 34 suprathreshold clusters, 8mm and 16mm both 
had 39 clusters, and 24mm had 32 clusters (Table 5.8). When grouped according to 
degree of scan smoothing (Table 5.9) the analyses with no scan smoothing had 98 
suprathreshold clusters, 8mm had 29 clusters, 16mm had 12 clusters and 24mm had 5 
clusters. The 24mm template had the lowest number of FP clusters (32) and using this 
template the 24mm scan smoothing had the lowest number of suprathreshold clusters (1) 
compared to 23 suprathreshold clusters with the non-smoothed scans, 5 clusters with 
8mm smoothing, and 3 clusters with 16mm smoothing (Table 5.8). 
 
The minimum FWEc suprathreshold cluster size ranged from 58 voxels in the non-
smoothed scans to 12,123 voxels in the 24mm smoothed scans (Table 5.8). As was seen 
in the hypometabolism analysis, when grouped according to template, the minimum 
suprathreshold cluster size was similar across the different templates. These were 61, 58, 
60 and 69 voxels for the 0mm, 8mm, 16mm and 24mm smoothing kernels, respectively, 
and in all templates the minimum suprathreshold cluster size occurred with the 0mm scan 
smoothing. When grouped according to degree of scan smoothing the minimum 
suprathreshold cluster size increased as the smoothing increased (Table 5.9). Minimum 
suprathreshold size was 58, 306, 880 and 2423 voxels for 0mm, 8mm, 16mm and 24mm 
scan smoothing kernels, respectively. 
 
  
Table 5.8: Hyper-metabolism, FWEc corrected specificity-optimised results – grouped by template smoothing. 
Results for the template smoothing and scan smoothing specificity-optimised procedure; hyper-metabolism using cluster level FWEc correction for multiple comparisons are shown. 
Results are grouped by template smoothing. The subjects forming the normal control dataset are listed in the first column indicated by their patient identification number (PID). The 
results of their leave-one-out two-sample t-test validation procedure are indicated under the column headings corresponding to the relevant template smoothing and scan smoothing 
parameters. The numbers in the cells represent the number of supra-threshold cluster(s) for that subject’s leave-one-out two-sample t-test using an uncorrected voxel p<0.001 and 
FEWc p<0.05. A cell containing no numbers indicates no surviving FWEc supra-threshold clusters for that combination of template smoothing and scan smoothing. The 24mm 
smoothed template had the lowest total number of FWEc supra-threshold clusters (32) and when this template was used, the 24mm scan smoothing had the lowest number of FWEc 
supra-threshold clusters (1). 
 
Template smoothing (x, y, z; mm)
Scan smoothing (x, y, z; mm) 0mm 8mm 16mm 24mm 0mm 8mm 16mm 24mm 0mm 8mm 16mm 24mm 0mm 8mm 16mm 24mm
PID
1
10 3 1 3 2 2 2 2
102
11 11 3 1 1 11 3 1 1 16 3 1 1 12 2 2 1
12 2 1 1 1 1 1
13
16 6 2 7 2 4 2 4 1
2 2 2
28 1
31
34 1 1 1 1 1
49 1 1 2 2 1 1 1
52
67
68
69
72
73
78
79
8 1
80
81
82
86 1
87 1 1 1
90
93
subtotals 24 6 2 2 26 9 3 1 25 9 4 1 23 5 3 1
total clusters per template
min cluster size 61 320 1526 2423 58 342 1211 12123 60 331 880 11574 69 306 1016 8903
min cluster size per template
0mm 8mm 16mm 24mm
61 58 60 69
34 39 39 32
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Table 5.9: Hyper-metabolism, FWEc corrected specificity-optimised results – grouped by scan smoothing. 
Results for the template smoothing and scan smoothing specificity-optimised procedure; hyper-metabolism using cluster level FWEc correction are shown. Results are grouped by 
scan smoothing. 
Scan smoothing (x, y, z; mm)
Template smoothing (x, y, z; mm) 0mm 8mm 16mm 24mm 0mm 8mm 16mm 24mm 0mm 8mm 16mm 24mm 0mm 8mm 16mm 24mm
PID
1
10 3 3 2 2 1 2 2
102
11 11 11 16 12 3 3 3 2 1 1 1 2 1 1 1 1
12 2 1 1 1 1 1
13
16 6 7 4 4 2 2 2 1
2 2 2
28 1
31
34 1 1 1 1 1
49 1 1 2 1 1 2 1
52
67
68
69
72
73
78
79
8 1
80
81
82
86 1
87 1 1 1
90
93
subtotals 24 26 25 23 6 9 9 5 2 3 4 3 2 1 1 1
total clusters per scan smoothing
min cluster size 61 58 60 69 320 342 331 306 1526 1211 880 1016 2423 12123 11574 8903
min cluster size per scan smoothing
0mm 8mm 16mm 24mm
29 12 5
58 306 880 2423
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5.5.1.5 Results summary for specificity optimised template smoothing and scan 
 smoothing 
Table 5.10 shows the summary for the specificity-optimised template smoothing results. 
An axial slice through the level of the basal ganglia is shown for each degree of template 
smoothing and the appearance of the different normalisation templates can be 
appreciated. 
 
Table 5.10: Results of the specificity-optimised template smoothing analysis. 
For hypo-metabolism the 16mm smoothed template had the fewest false positive voxels in the voxel level 
FWEp corrected analysis and also the fewest number of false positive clusters in the cluster level FWEc 
corrected analysis. For hyper-metabolism the 0mm, non-smoothed template had the fewest false positive 
voxels in the voxel level FWEp corrected analysis and the 24mm smoothed template had the fewest 
number of false positive clusters in the cluster level FWEc corrected analysis. 
 
 
 
Table 5.11 shows the summary for the specificity-optimised scan smoothing results. An 
axial slice through the level of the basal ganglia is shown for each degree of scan 
smoothing applied to a normalised scan of a selected normal control subject (PID11, 16 
yr old boy). The appearance of the different degrees of scan smoothing is readily 
apparent. 
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Table 5.11: Results of the specificity optimized scan smoothing analysis. 
When using the specificity optimized normalization template (16mm), for hypo-metabolism the 16mm 
scan smoothing had the fewest false positive voxels in the voxel level FWEp corrected analysis and the 
24mm scan smoothing had the fewest number of false positive clusters in the cluster level FWEc corrected 
analysis. When using the specificity optimized normalization templates (0mm for voxel level correction 
and 24mm for cluster level correction), for hyper-metabolism the 0mm, non-smoothed scans had the fewest 
false positive voxels in the voxel level FWEp corrected analysis and the 24mm scan smoothing had the 
fewest number of false positive clusters in the cluster level FWEc corrected analysis. 
 
 
 
 
 
 
105 
  
5.5.2 Specificity optimised statistical thresholds 
5.5.2.1 Hypo-metabolism: voxel level FWEp corrected analysis 
The results of the leave-one-out testing procedure for determining the voxel level 
corrected FWEp specificity optimized threshold for hypo-metabolism is shown in Figure 
5.2. Across the entire dataset the specificity optimized voxel-level FWEp corrected 
threshold was 0.094. 
 
Figure 5.2: Hypo-metabolism, FWEp corrected specificity-optimised statistical threshold results. 
Specificity optimized statistical threshold results for detecting hypo-metabolism with voxel level FWEp 
correction for multiple comparisons are shown. The 2-sample t-test results of the leave-one-out validation 
procedure are shown for each subject compared against the remaining dataset. The previously determined 
specificity optimized pre-processing parameters were used (16x16x16mm template smoothing, 
16x16x16mm scan smoothing). The results for each subject are displayed in ascending age order from left 
to right on the x-axis. FWEp corrected voxel p-value is depicted on the y-axis in log scale. For each subject 
the bar represents the FWEp corrected voxel p values where there were supra-threshold voxels. It can be 
seen that each subject had a different FWEp corrected p-value threshold beyond which there were no 
supra-threshold voxels. Across the entire dataset, the hypo-metabolism specificity optimized voxel level 
corrected FWEp p-value threshold was 0.094. False positive results were seen with p-values more liberal 
(ie. greater) than this.  
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5.5.2.2 Hypo-metabolism: cluster level FWEc corrected analysis 
The results of the leave-one-out testing procedure for determining the cluster level 
corrected FWEc threshold for hypo-metabolism is shown in Figure 5.3. When examining 
for hypo-metabolism there were 2/28 scans that had significant clusters. Across the 
whole dataset the false positive (uncorrected) p value window at a cluster level corrected 
FWEp p<0.05 threshold was 0.000 05 - 0.05. 
 
 
Figure 5.3: Hypo-metabolism, FWEc corrected specificity-optimised statistical threshold results. 
Specificity optimized statistical threshold results for detecting hypo-metabolism with cluster level FWEc 
correction for multiple comparisons are shown. The 2-sample t-test results of the leave-one-out validation 
procedure are shown for each subject compared against the remaining dataset. The previously determined 
specificity optimized pre-processing parameters were used (16x16x16mm template smoothing, 
24x24x24mm scan smoothing). The results for each subject are displayed in ascending age order from left 
to right on the x-axis. The y-axis shows the uncorrected voxel p-value thresholds that were tested in 
ascending order. For each subject the blue portion of the bar represents the uncorrected voxel p-value 
thresholds where there were no supra-threshold voxels, the green portion of the bar represents the 
uncorrected voxel p-value thresholds where there were supra-threshold voxels but no clusters that were 
significant at the FWEc p<0.05 level, and the red portion of the bar represents the uncorrected voxel p-
value thresholds where there were supra-threshold voxels forming clusters that were significant at the 
FWEc p<0.05 level. Across the entire dataset, the “false positive p-value window” for detecting hypo-
metabolism with cluster level FWEc correction for multiple comparisons was 0.000,05 – 0.05. The 
uncorrected p-values outside of this window are the specificity optimized uncorrected p-value thresholds 
for cluster level correction for multiple comparisons, where no false positive clusters occurred.   
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5.5.2.3 Hyper-metabolism: voxel level FWEp corrected analysis 
The results of the leave-one-out testing procedure for determining the voxel level 
corrected FWEp specificity optimized threshold for hyper-metabolism is shown in Figure 
5.4. Across the entire dataset the specificity optimized voxel-level FWEp corrected 
threshold was 0.000 12. 
 
Figure 5.4: Hyper-metabolism, FWEp corrected specificity-optimised statistical threshold results. 
Specificity optimized statistical threshold results for detecting hyper-metabolism with voxel level FWEp 
correction for multiple comparisons are shown. The 2-sample t-test results of the leave-one-out validation 
procedure are shown for each subject compared against the remaining dataset. The previously determined 
specificity optimized pre-processing parameters were used (0x0x0mm template smoothing, 0x0x0mm scan 
smoothing). The results for each subject are represented in ascending age order from left to right on the x-
axis. FWEp corrected voxel p-value is depicted on the y-axis in a log scale. For each subject the bar 
represents the FWEp corrected voxel p-values where there were supra-threshold voxels. It can be seen that 
each subject had a different FWEp corrected p-value threshold beyond which there were no supra-
threshold voxels. Across the entire dataset, the hyper-metabolism specificity optimized voxel level 
corrected FWEp p-value threshold was 0.000 12. False positive results were seen with p-values more 
liberal (ie. greater) than this.  
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5.5.2.4 Hyper-metabolism: cluster level FWEc corrected analysis 
The results of the leave-one-out testing procedure for determining the cluster level 
corrected FWEc threshold for hyper-metabolism is shown in Figure 5.5. When 
examining for hyper-metabolism there were 5/28 scans that had significant clusters. 
Across the whole dataset the false positive (uncorrected) p-value window at a cluster 
level corrected FWEp p<0.05 threshold was 0.000 000 5 - 0.05. 
 
 
Figure 5.5: Hyper-metabolism, FWEc corrected specificity-optimised statistical threshold results. 
Specificity optimized statistical threshold results for detecting hyper-metabolism with cluster level FWEc 
correction for multiple comparisons are shown. The 2-sample t-test results of the leave-one-out validation 
procedure are shown for each subject compared against the remaining dataset. The previously determined 
specificity optimized pre-processing parameters were used (24x24x24mm template smoothing, 
24x24x24mm scan smoothing). The results for each subject are displayed in ascending age order from left 
to right on the x-axis. The y-axis shows the uncorrected voxel p-value thresholds that were tested in 
ascending order. For each subject the blue portion of the bar represents the uncorrected voxel p-value 
thresholds where there were no supra-threshold voxels, the green portion of the bar represents the 
uncorrected voxel p-value thresholds where there were supra-threshold voxels but no clusters that were 
significant at the FWEc p<0.05 level, and the red portion of the bar represents the uncorrected voxel p-
value thresholds where there were supra-threshold voxels forming clusters that were significant at the 
FWEc p<0.05 level. Across the entire dataset, the “false positive p-value window” for detecting hyper-
metabolism with cluster level FWEc correction for multiple comparisons was 0.000,000 5 – 0.05. The 
uncorrected p-values outside of this window are the specificity optimized uncorrected p-value thresholds 
for cluster level correction for multiple comparisons, where no false positive clusters occurred. 
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5.5.3 Specificity optimised parameters: results summary 
The final specificity optimized template and scan smoothing parameters, and specificity 
optimized voxel level FWEp corrected statistical thresholds for hypo and hyper-
metabolism are shown in Table 5.12. The specificity optimized template and scan 
smoothing parameters and uncorrected p-value false positive windows for cluster level 
FWEc correction for both hypo and hyper-metabolism are shown in Table 5.13. 
 
Table 5.12: Voxel level FWEp corrected specificity optimized parameters. 
 Template smoothing Scan smoothing FWEp p-value threshold 
Hypo-metabolism 16mm 16mm 0.094 
Hyper-metabolism 0mm 0mm 0.000 12 
 
 
Table 5.13: Cluster level FWEc corrected specificity optimized parameters. 
 Template smoothing Scan smoothing 
Uncorrected voxel p-
value false positive 
window 
Hypo-metabolism 16mm 24mm 0.000 05 – 0.05 
Hyper-metabolism 24mm 24mm 0.000 000 5 – 0.05 
 
5.6 Discussion 
The validation process described in this chapter has identified specificity optimised 
template smoothing, scan smoothing and statistical thresholds to apply in single-subject 
versus group SPM analysis. Different specificity optimised parameters have been 
determined for analyses directed at detecting hypo or hyper-metabolism in single-subject 
scans and also when applying either voxel level FWEp or cluster level FWEc correction 
for multiple comparison. 
 
As well as determining these specificity optimised parameters the results of the 
validation process provide an insight into the topology of normal variations in FDG 
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uptake to be expected in cerebral FDG PET CT scans in children without neurological 
conditions. 
 
5.6.1 Specificity optimized template and scan smoothing 
In the FWEp voxel level corrected analysis for hypo-metabolism, the 16mm template 
clearly outperformed the other templates with 27 false positive suprathreshold voxels in 
total compared to 1308, 306 and 1085 for the 0mm, 8mm and 24 mm smoothed 
templates, respectively. The improved performance of the 16mm smoothed template 
appeared to be primarily due to the performance in the two most highly smoothed scan 
groups. When using the 16mm template, the 16mm/24mm scan smoothed groups had 
only 0/15 suprathreshold voxels compared to 92/1211, 0/294 and 128/929 voxels when 
using the 0mm, 8mm and 24mm smoothed templates, respectively. This was quite 
different to the hypermetabolism FWEp analysis where the 0mm template was superior 
with 697 total suprathreshold voxels compared to 1236, 2041 and 1638 voxels for the 
8mm, 16mm and 24mm templates, respectively. Similar to the hypo-metabolism analysis, 
the superior performance of the 0mm template also appeared to be due to the reduced FP 
findings mainly in the more highly smoothed scan groups. When using the 0mm template, 
the 16mm/24mm scan smoothed groups had 258/307 suprathreshold voxels compared to 
470/632, 713/1174 and 501/939 voxels for the corresponding 16mm/24mm scan 
smoothed groups when using the 8mm, 16mm and 24mm smoothed templates, 
respectively. These results show that the better performing templates were identified 
mainly through the improved performance with the more highly smoothed scans and 
suggests that increased scan smoothing may amplify subtle performance differences 
between the templates with FWEp correct analyses. 
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Why should a particular normalisation template perform differently in the same dataset 
when using SPM to detect hypo or hype-metabolism? The differences that result when 
using differently smoothed normalisation templates to normalize the same scan (Figure 
5.1) appear diffusely throughout the brain and are not more prominently at the interface 
with CSF spaces, the outside of the brain or around any particular structures. These 
diffuse differences suggest a whole brain phenomenon. Correction for multiple 
comparisons in SPM is based on RFT (see Chapter 2), which in turn is intimately related 
to both intrinsic scan smoothness (ie. prior to further applied smoothing during pre-
processing) and the topography of the scans being analysed. The smoothness of an FDG 
PET scan image is fixed regardless of the analysis, however normal variability in hypo-
metabolism may a different topology to normal variation in hyper-metabolism. Such a 
difference in the topologies of globally normalised decreased or increased FDG uptake 
could be an explanation for the requirement of differently smoothed templates to limit FP 
findings for either hypo or hyper-metabolism. I am not aware of any published literature 
investigating the topology of variable FDG uptake in cerebral FDG PET scans in 
children to support or refute this hypothesis. 
 
The specificity optimised templates when using an FWEc corrected analysis was the 
same for hypo-metabolism (16mm) but different for hyper-metabolism (0mm for FWEp 
and 24mm for FWEc). FWEc assessment of significance is based on cluster size but 
FWEp assessment of significance is based on peak cluster height (see Chapter 2). 
Therefore in a similar way to producing different results for hypo versus hyper-
metabolism analyses, the differences in the topology of globally normalised variations in 
FDG would be expected to produce different results based on FWEc versus FWEp (viz. 
cluster size versus voxel peaks) correction for multiple comparisons. 
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The hyper-metabolism analysis had a much higher FP rate that the hypo-metabolism 
analysis. 
Across all of the template and scan smoothing combinations and at the fixed FWEp 
statistical threshold of p<0.05 there were two times more FP suprathreshold voxels in the 
hyper-metabolism analysis (5612 voxels) compared to the hypo-metabolism analysis 
(2726 voxels). More FP clusters were also detected using FWEc analysis in the hyper-
metabolism analysis (144 clusters) compared to the hypo-metabolism analysis (86 
clusters). These differences indicate that there is considerably more variability in globally 
normalised increases in FDG uptake than decreases in FDG uptake in normal children. 
Regions of increasing FDG uptake are likely influenced by activation during the tracer 
uptake period. Such physiologic activations would be expected to be more variable from 
subject to subject due to environmental stimulation during uptake and also individual 
patient factors (medications, level of anxiety, age). These factors could explain the higher 
variability in voxel-wise globally normalised increases in FDG uptake compared to 
decreases in FDG uptake. 
 
Scan smoothing seems to be a more important factor than template smoothing in 
reducing FP findings particularly when using FWEc cluster level correction. With FWEc 
correction in both the hypo and hyper-metabolism analysis there was little variation in 
the total number of suprathreshold clusters between the different templates. For the 
templates with 0mm, 8mm, 16mm and 24mm smoothing, the total number of 
suprathreshold clusters for hypo-metabolism were 19, 18, 17 and 22; and for hyper-
metabolism were 34, 39, 39 and 32, respectively. When grouped by scan smoothing 
however (Tables 5.5 and 5.9), there was a clear pattern of reducing total number of 
suprathreshold clusters and increasing in the minimum suprathreshold cluster size that 
occurred with increasing scan smoothing. This pattern was consistent within both the 
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hypo and hyper-metabolism analysis. This pattern is expected based on the RFT method 
of correcting for multiple comparisons at the cluster level because for a given 
uncorrected voxel statistical threshold increasing levels of smoothness results in 
increasing resel size and therefore progressively larger clusters are required to pass 
significance. Although the specificity optimized templates for cluster level FWEc 
correction were different for hypo and hyper-metabolism, the specificity optimized scan 
smoothing was consistent and as expected was the highest degree of smoothing, 24mm. 
 
One might expect that smoothing of the scans would reduce the number of false positive 
voxels in the FWEp corrected analysis. Looking at the total number of suprathreshold 
FWEp corrected voxels per degree of scan smoothing for both hypo and hyper-
metabolism (Tables 5.3 and 5.7) it can be seen that there is a clear increase in false 
positive voxels with increasing scan smoothing. The explanation is that the underlying 
statistical noise is not random on a voxel-by-voxel basis, that is, there is spatial 
dependence in the underlying noise. Smoothing would also amplify the spatially 
correlated noise to random noise ratio from these regions, as well as the true signal to 
random noise that may be present in any single-subject versus group SPM analysis. 
Given that the dataset being analysed is by definition a group of normal control subjects, 
there is no underlying true signal of either increased or decreased FDG uptake and any 
spatially correlated variations in FDG uptake are therefore also by definition spatially 
correlated noise. The process of scan smoothing in the specificity optimisation validation 
procedure overall is a balance between reducing the effect of non-spatially correlated 
noise with more smoothing and minimising the effect of spatially correlated noise by less 
smoothing. The balance between these factors is different for hypo or hyper-metabolism, 
and for FEWp or FWEc correction for multiple comparisons, as shown by the differing 
specificity optimised scan smoothing parameters for each situation. For example when 
 115
using their respective specificity optimized normalization templates, the hypo-
metabolism FWEp analysis produced a specificity optimized scan smoothing of 16mm 
compared to 0mm (no scan smoothing) for hyper-metabolism (Table 5.12). This implies 
that the topology of globally normalized areas of reduced FDG uptake in the dataset 
contained more random, spatially independent noise to allow a fair degree of scan 
smoothing to be applied before false positives emerged. In contrast, the topology of 
globally normalized areas of relatively increased FDG uptake may have more 
physiologically based, spatially dependent noise (ie. activation during the uptake phase) 
that restricted the amount of scan smoothing before false positive findings emerged. 
 
Regardless of the mechanism, this chapter has shown that in order to optimally limit the 
FP rate in a single-subject versus group SPM analysis, different template smoothing, 
scan smoothing and statistical thresholds need to be applied depending on the detection 
of hypo or hyper-metabolism and either FWEp or FWEc methods to correct for multiple 
comparisons. Clearly, a single SPM set up does not effectively function for all types of 
analyses, at least within the confines of the analysis of FDG PET CT scans in children. 
 
5.6.2 Specificity optimised statistical thresholds 
The specificity optimised voxel level FWEp statistical threshold for detecting hypo-
metabolism was more liberal than for detecting hyper-metabolism (p<0.094 compared to 
p<0.00012, respectively). The results for specificity optimised cluster level FWEc 
statistival thresholds followed a similar pattern. Hypo metabolism had a narrower false 
positive window (uncorrected p<0.000,05 to 0.05) compared to hyper-metabolism 
(uncorrected p<0.000,000,5 to 0.05). These findings support the conclusion that there is 
more variability in globally normalised increases in FDG uptake such that a stricter 
statistical threshold (ie. a lower p-value threshold) is required when performing single-
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subject versus SPM analysis, to limit FP results. The other interpretation is that there is 
less variability in globally normalised decreases in FDG uptake such that a more liberal 
threshold (ie. a higher p-value threshold) can be used when performing single-subject 
versus SPM analysis, yet also limit FP results. 
 
The main strength of this analyse is the large size of the dataset being analysed and also 
that the scans were dedicated cerebral FDG acquisitions rather that the brain portion of a 
whole body scan protocol. The only two previously published single-subject versus 
group SPM studies that have used a pediatric control dataset have used “pseudo-control” 
groups consisting of scan performed in children with seizures [59, 60] and no studies 
have been published that have examined the effect of template smoothing or scan 
smoothing, or the application of various statistical thresholds, to limits FP findings. 
 
The validation process was applied to the whole brain with no a priori regions of interest. 
If a particular region of the brain was being specifically examined for abnormal FDG 
uptake then the validation procedure could be repeated but limiting the analysis to that 
particular brain region. In this way a more liberal statistical threshold may arise that can 
be used studies targeting a particular, a priori region of interest with the benefit of 
increased power to detect statistical differences while still limiting FP findings. 
 
The validation procedure described in this chapter has not been previously described in 
pediatric FDG PET CT scans, most likely due to lack of a suitably large control dataset. 
My dataset involved a relatively large number of subjects with no known neurological 
abnormalities, although they were not truly normal in that each subject had suspected or 
proven extra-cranial malignancies (see Chapter 2 for a full description of subjects). There 
are two published adult reports that show the presence of extra-cranial lung cancer or 
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lymphoma may alter cerebral metabolism as seen on FDG scans [79, 80] and therefore it 
is possible that the validation of my dataset may perform differently in children without 
cancer. A dataset of truly normal children, without underlying malignancy, inflammatory 
conditions or neurological abnormalities is unlikely to ever be realised due to the 
radiation burden associated with FDG PET CT scans. Empirically, a dataset of pediatric 
aged scans, in pediatric patients with suspected or proven extra-cranial malignancies 
would be much more appropriate than a dataset of scans in adults when comparing 
against a scan in a child with a potential neurological disorder. 
 
5.7 Conclusions 
In this chapter, a rigorous validation procedure has been carried out using a single-
subject versus group SPM analysis on the largest reported group of dedicated cerebral 
FDG PET CT scan in neurologically normal children. Template smoothing, scan 
smoothing, and statistical thresholds have been determined that limit the FP results, ie. 
“specificity optimised” parameters. Different specificity optimised parameters have been 
evaluated for use in detecting hypo and hyper-metabolism, and with the application of 
both voxel level and cluster level correction for multiple comparisons. 
 
The different specificity optimised parameters have provided insight into the different 
topological patterns of globally normalised increases and decreases in FDG uptake that 
occur during resting state cerebral FDG scans in children. 
 
These specificity optimised parameters can be used in the single-subject versus group 
SPM analyses in children with suspected neurological abnormalities and will be 
employed in Chapter 6 for the evaluation of cerebral FDG PET CT scans in children with 
epilepsy.  
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6 CHAPTER SIX: APPLICATION OF STATISTICAL 
PARAMETRIC MAPPING IN CHILDREN WITH 
MEDICALLY INTRACTABLE EPILEPSY 
 
6.1 Abstract 
Aims: Very few published studies exist that use SPM to evaluate cerebal FDG scans in 
paediatric patients with medically intractable epilepsy prior to surgery, largely due to 
lack of a suitable control dataset. The aim of this chapter is to implement SPM analyses 
of the pre-operative cerebral FDG scan in children who subsequently underwent 
resective epilepsy surgery. The hypothesis is that SPM identification of a hypo-metabolic 
focus localising to the subsequent surgical resection zone (SRZ) will predict a good 
response to surgery as measured by improved seizure control. 
 
Methods: Using the hypo-metabolism specificity optimised SPM parameters determined 
in Chapter 5, a single-subject versus group SPM analysis was performed on the pre-
operative cerebral FDG scan in 61 children with medically intractable epilepsy that 
subsequently underwent resective epilepsy surgery. SPM results were categorised 
according to the strength of the result in localising a hypo-metabolic focus to the SRZ. 
The diagnostic test performance of SPM localising a hypo-metabolic focus to the SRZ in 
predicting good post-operative seizure control was evaluated (sensitivity (SN), specificity 
(SP), positive (PLR) and negative likelihood ratios (NLR), positive (PPV) and negative 
predictive vales (NPV), and area under the curve (AUC) of the receiver operator 
characteristic (ROC) curve). 
Results: SPM localising a hypo-metabolic focus to the SRZ had a very high specificity 
for predicting good post-operative seizure control. There were persisting false negative 
 119
results that could be attributable to unidentified electrical seizure activity during the FDG 
uptake phase. SPM performed best with FWEp correction for multiple comparisons and 
including all patients the diagnostic test metrics were: SN 38%, SP 93%, PLR 5.4, NLR 
0.7, PPV 95%, NPV 31%, AUC of ROC curve 0.638. The diagnostic test performance of 
SPM was maximised in patients with extra-temporal resections after excluding those 
with EEG or clinical seizures during FDG uptake.  
 
Conclusions: As a stand-alone test, SPM performs moderately well in predicting that a 
planned surgical resection site will result in improved post-operative seizure control. The 
poor sensitivity may be due to the large proportion of patients who did not have scalp 
surface EEG recorded during FDG uptake to allow detection of subclinical electrical 
seizure activity that would disrupt cerebral FDG uptake. This analysis is the largest 
reported cohort of dedicated FDG scans in childhood epilepsy and is the only SPM study 
in children that uses a true paediatric control dataset consisting of children with no 
neurological abnormalities. The results indicate that SPM analysis of pre-operative FDG 
PET scans when used as a complementary test with other imaging modalities is useful 
when localising a hypo-metabolic focus to the planned SRZ, to confirm the high chance 
of post-operative benefit. 
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6.2 Introduction 
The thesis thus far has descriptively analysed the largest reported dataset of dedicated 
cerebral FDG PET scans in neurologically normal children. The results clearly 
demonstrate changing patterns of FDG uptake that occur with age during childhood. The 
statistical parametric mapping (SPM) specificity analysis presented in the previous 
chapter has systematically determined the template smoothing, scan smoothing and 
statistical thresholds, using both voxel-level and cluster-level correction for multiple 
comparisons, to minimise the chance of producing false positive results in a single-
subject versus group comparison. This chapter applies these specificity optimised SPM 
parameters in the analysis of paediatric patients with medically intractable epilepsy. 
 
Neuroimaging in paediatric epilepsy involves the complementary use of multiple 
imaging modalities including FDG PET, structural and functional MRI, CT and cerebral 
perfusion scans [81, 82]. One purpose of multimodality neuroimaging in children with 
epilepsy is to determine surgical candidacy in medically intractable cases. Early papers in 
adults suggested hypo-metabolism as seen on FDG PET could predict seizure freedom 
after invasive EEG guided surgery [83, 84] and that inter-ictal FDG PET appeared to be 
more useful for this purpose than PET scans of cerebral perfusion [85, 86].  
 
Surveys of physicians managing children with refractory epilepsy have shown that 
cerebral FDG PET scan impact clinical management in approximately half of patients, 
principally in supporting the suitability for surgical intervention [87]. When carefully 
selected, the response to epilepsy surgery is comparable between paediatric patients and 
adults [88]. 
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Early descriptions of FDG PET in paediatric patients with epilepsy suggested the 
potential benefit of inter-ictal pre-operative assessment to guide surgery [89]. Visual 
assessment of cerebral FDG scans is the most common method of interpretation [90] but 
semi-quantitative analysis using a region-of-interest approaches have been shown to be 
more sensitive than visual assessment in children with epilepsy [91]. Published reports 
using SPM to analyse cerebral FDG scans in children with seizure disorders are sparse 
and all have used sub-optimal control datasets made up of cerebral FDG scans performed 
in adult volunteers, paediatric patients with epilepsy but visually normal FDG scans (so 
called “pseudo-control” subjects), or children with another neurological condition [6, 59-
61, 68, 69, 92, 93]. Three of these studies have used group versus group comparisons 
comparing six epileptic children with aggression to epileptic children without aggressive 
features [61], comparing 13 children with temporal lobe epilepsy to 17 adults control 
subjects [6], and comparing 30 children with drug resistant generalised seizures to 12 
adult controls [68]. 
 
There have been five published studies using a single-subject versus group SPM analysis 
in paediatric epilepsy, similar to the analysis presented in this chapter. The largest 
published study individually compared FDG PET scans in 47 children with epilepsy to a 
“pseudo-control” dataset of 24 children also with epilepsy but no apparent visual 
abnormalities on their FDG scan [60]. Hypo-metabolic foci detected with SPM were 
compared to a reference standard of visually detected regions of reduced FDG uptake 
and/or localising features on EEG. This study therefore was a test of agreement between 
SPM and visual assessment, with no attempt to use SPM to predict a meaningful clinical 
endpoint such as post-operative outcome. The authors of this study also used a control 
dataset of 21 adult subjects, which produced artefacts on the output SPM maps 
highlighting the importance of using paediatric aged scans as the comparison group 
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rather than adults. The next largest study individually compared the FDG scans in 21 
children with temporal lobe epilepsy who underwent temporal lobe resection and good 
post-operative outcome, with 15 adult control subjects [69]. They reported successful 
SPM localisation to the surgical resection site in 18/21 (86%) of the patients. No patients 
with unsuccessful surgery were included in the analysis so the performance of SPM in 
patients that may not benefit from resective surgery (ie. the specificity of SPM analysis) 
cannot be determined. Another study individually compared FDG scans in 18 children 
with severe epilepsy associated with major cognitive impairment to 26 adults control 
subjects [92]. The authors found that there were variable patterns of hypo and hyper-
metabolism in this group of severe paediatric epilepsy and there was no attempt to test 
the utility of the SPM findings to guide management. The two other published studies 
each had small groups of eight children with “fever-induced refractory epileptic 
encephalopathy” and perisylvian dysgenesis. For their control groups these studies used a 
group of 21 “pseudo-control” epilepsy patients and a mixed group of 23 adult normal 
volunteers plus 19 “pseudo-control” paediatric epilepsy patients, respectively [59, 93]. 
Both of these studies were purely descriptive analyses with no correlation to patient 
outcomes and showed variable patterns of hypo and hyper-metabolism. All of these 
previous studies using SPM in evaluating paediatric patients with seizures have used 
various, empirically selected SPM pre-processing parameters and statistical thresholds. 
 
The large paediatric control dataset described in Chapters 3 and 4, in conjunction with 
the specificity optimised SPM parameters from Chapter 5, will be used to perform 
single-subject versus group SPM analyses in a large group of paediatric patients with 
medically intractable epilepsy. The underlying principle of the analysis presented in this 
chapter is that patients who have a good post-operative outcome (ie. improvement in 
seizure control) are defined as the reference standard positive patients for an 
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epileptogenic focus within the surgical resection zone (SRZ) and the ability for SPM to 
localise this hypo-metabolic, epileptogenic focus to the SRZ in these patients is 
examined (ie. true positive SPM findings). Patients with a poor post-operative outcome 
(ie. minimal or no improvement in seizure control) are defined as reference standard 
negative patients for an epileptogenic focus in within the SRZ, and SPM results 
localising a hypo-metabolic, epileptogenic focus to the SRZ in these patients constitute 
false positive SPM findings. 
 
6.3 Aims 
This chapter aims to use the normal control dataset and incorporating the SPM specificity 
optimised parameters to evaluate the performance of SPM in children with medically 
refractory epilepsy. The hypothesis is that SPM findings that localise a hypo-metabolic, 
epileptogenic focus to the SRZ will predict a good postoperative outcome, inferring that 
SPM is able to correctly identify the epileptogenic focus on inter-ictal FDG PET scans. 
The difference performance of voxel-level and cluster-level methods for correcting for 
multiple comparisons within SPM will be compared. 
 
6.4 Methods 
Approval for the study was obtained from the hospital ethics committee. The study 
period was a 7 year, 8 month period from the commencement of PET service in June 
2006 until February 2014. A retrospective SPM analysis of the preoperative cerebral 
FDG PET CT scan in patients undergoing resective neurosurgery for medically 
intractable epilepsy was performed. The SPM analysis was a single-subject versus group 
comparison to the normal control dataset targeting the identification of regional cerebral 
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hypo-metabolism. SPM results were compared to clinical factors and postoperative 
outcome in regard to improved seizure control. 
 
6.4.1 Control subjects 
Detailed description of the 28 subjects comprising the control dataset was provided in 
Chapters 3 and 4. 
 
6.4.2 Epilepsy patients 
The database of patients who underwent epilepsy surgery after the commencement of the 
study period was obtained from the Department of Neurology and crosschecked against 
the electronic database of FDG PET CT scans from the Department of Nuclear Medicine. 
Patients with a cerebral FDG PET scan prior to surgery and without previous 
neurosurgery were included. A proportion of the epilepsy patients had a scalp surface 
EEG undertaken during the FDG uptake phase (see Table XX). The acquisition of an 
EEG was dependent on service availability of neurophysiology technicians and was not 
able to be performed in every patient. 
 
6.4.3 PET CT imaging 
The technical details of the PET CT camera, imaging and reconstruction protocols used 
for all 28 subjects forming the control dataset and the included epilepsy patients have 
been described in Chapter 3. 
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6.4.4 SPM pre-processing 
A two-sample t-test was used to compare each eligible patient to the dataset of 28 normal 
FDG brain scans and including age as a covariate of interest, using the specificity 
optimised pre-processing parameters determined in Chapter 5. 
 
The “Normalise: Est and Wri” module was used to normalize the scan from every 
included patients to the specificity optimised (16mm smoothed) customised templates for 
SPM analyses using both voxel-level FWEp and cluster-level FWEc correction for 
multiple comparisons. Specificity optimised scan smoothing was 16mm for voxel-level 
FWEp correction for multiple comparisons and 24mm for cluster-level FWEc correction 
(see Chapter 5 for a full description of specificity optimised pre-processing parameters 
for these SMP analyses). In this module “Source Image Smoothing” was set to match the 
template smoothing for each normalisation procedure to maximise the accuracy of 
normalisation. The other SPM default parameters were unchanged and the resulting 
normalized images were written out using a bounding box dimension of -90:91 -126:91 -
72:109 with a voxel size of 2x2x2mm. In this way, each patient scan was normalised to 
the specificity optimised 16mm smoothed custom template and the normalised scans 
were then smoothed with either 16mm or 24mm depending on their use in either the 
FWEp or FWEc corrected SPM analysis. 
 
6.4.5 SPM analysis 
The “Basic models” module in SPM was used to create a 2-sample t-test looking for 
reduced FDG uptake comparing each patient scan to the normal control dataset and 
incorporating age as a covariate in the SPM statistical design matrix. As was done in the 
SPM analysis in Chapters 4 and 5, relative threshold masking of 0.8 was implemented to 
remove extra-cerebral tracer uptake. Recall that a relative threshold mask of 0.8 appeared 
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to perform optimally in the investigation of the effect of age in the normal dataset (see 
Chapter 4). Proportional normalisation was used as the global normalisation procedure to 
account for global differences in whole brain tracer uptake in part arising from variability 
in injected dose of FDG and uptake times. The variance was set to “Equal” and the 
remainder of the SPM8 default parameters in this module were unchanged. In this 
manner a 2-sample t-test was performed on each patient using the two different 
specificity optimised SPM pre-processing parameters, one set of parameters for the 
FWEp corrected analysis and another set of parameters for the FWEc corrected analysis. 
 
6.4.6 Application of statistical thresholds and multiple comparison 
correction  
The results for FWEp and FWEc corrected analyses were considered separately using the 
specificity optimised SPM pre-processing parameters and statistical thresholds for 
detecting hypo-metabolism determined in Chapter 5. In the case of voxel-level FWEp 
correction for multiple comparisons the specificity optimised threshold of p<0.094 was 
used and in the case of cluster-level FWEc correction for multiple comparisons, 
uncorrected p-value thresholds of p<0.00001 and 0.1 were used. These FWEc statistical 
thresholds correspond to the p-values at which there were no false positive results 
immediately outside the false positive “p-value window” (see Chapter 5). A cluster 
extent threshold was not applied for either the FWEp or FWEc corrected analyses 
consistent with the specificity optimized validation process implemented in Chapter 5. 
The results from these specificity optimised analyses were considered the most specific 
in identifying any regions of reduced FDG uptake (see “Categorisation of SPM results” 
below). 
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For SPM results not passing significance using the specificity optimised SPM parameters, 
the statistical threshold were liberalised and/or results uncorrected for multiple 
comparisons were examined. The SPM findings from these non-specificity optimised 
analyses were considered less specific in identifying hypo-metabolic regions (see 
“Categorisation of SPM results” below). 
 
6.4.7 Categorisation of SPM results 
The topology of an SPM refers to the spatial distribution of the statistical parameter 
represented in the SPM map. In the case of a 2-sample t-test, the statistical parameter is 
the t-statistic and a t-statistic value is assigned to each voxel according to a particular 
statistical model (viz. a particular “contrast” in SPM parlance). The t-statistic at each 
voxel has a corresponding p-value related to the strength of the statistical evidence for 
this value to have occurred beyond that expected by random chance. In SPM the chosen 
p-value threshold defines a statistical cut point and only those voxels with a p-value more 
significant than this chosen threshold (viz. a p-value less than the selected p-value 
threshold) are displayed on the output SPM map. According to random field theory and 
in the case of voxel level correction for multiple comparisons (FWEp), the statistical cut 
point is adjusted to correct for multiple comparisons and applied to each and every voxel. 
In the case of cluster level correction for multiple comparisons (FWEc) and based on the 
uncorrected voxel level results, the size of any surviving supra-threshold cluster is 
assessed for evidence of statistical significance. The statistical evidence relates to the 
likelihood that a cluster of this size or greater for the given uncorrected voxel level 
threshold would have occurred due to random chance. See Chapter 2 for a more complete 
discussion of the theory and application of these different methods to account for the 
multiple comparisons problem. 
 
 128
The output SPM map can show a variety of topological features. The SPM map topology 
was compared to each patient’s post-operative neuro-imaging to determine the ability of 
the SPM map to localise a hypo-metabolic focus to the SRZ. Topological patterns were 
categorised according to the strength of the findings to localise a hypo-metabolic focus to 
the SRZ. Localising findings when using the specificity optimised SPM parameters were 
considered the strongest evidence of localisation to the SRZ because these were less 
likely to represent false positive hypo-metabolic regions (see Chapter 5). Where required, 
the liberalised statistical thresholds and/or findings uncorrected for multiple comparisons 
were also examined and categorised according to the ability to localise a hypometabolic 
region to the SRZ, but these findings were considered less strongly localising because of 
the possibility of false positive results. 
 
The SPM map topological categories, descriptions, and the strength of localising a hypo-
metabolic region to the SRZ are shown in Tables 6.1 and 6.2, for FWEp and FWEc 
correction for multiple comparisons, respectively. Figures 6.1 and 6.2 graphically depict 
the different output SPM map topological patterns for FWEp and FWEc correction for 
multiple comparisons, respectively. In these figures each topological pattern has the 
spatial distribution of voxels represented on the horizontal axis and the corresponding 
voxel t-statistic values represented on the vertical axis. The location of the SRZ and the 
specificity optimised p-value threshold related to a particular t-statistic value are 
indicated on the graphs. 
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Table 6.1: FWEp corrected SPM topology categories. 
The voxel-level, FWEp correction for multiple comparisons SPM map topological categories, descriptions, 
and the strength of localising a hypo-metabolic region to the SRZ are shown. 
SPM 
map 
topology 
category 
SPM map topology description 
Strength of 
SRZ 
localisation 
1 
 Solitary SpO supra-threshold cluster localising to the 
SRZ 
 No other SpO supra-threshold clusters 
Strongly 
localising 
2 
 SpO supra-threshold cluster localising to the SRZ 
 Other, less significant SpO supra-threshold clusters 
non-localising to the SRZ 
Moderately 
localising 
3 
 No SpO supra-threshold clusters 
 The most significant SpO sub-threshold cluster 
localising to the SRZ 
Weakly 
localising 
4 
 SpO supra-threshold cluster localising to the SRZ 
 Other, more significant SpO supra-threshold clusters 
non-localising to the SRZ 
Non-localising 
5 
 No SpO suprathreshold clusters 
 The most significant SpO sub-threshold cluster non-
localising to the SRZ 
Non-localising 
6 
 Solitary SpO supra-threshold cluster non-localising to 
the SRZ 
 No other SpO supra-threshold clusters 
Strongly 
non-localising 
SRZ: surgical resection zone 
SpO: specificity optimised SPM parameters 
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Figure 6.1: FWEp SPM topological patterns and strength of localisation to the SRZ. 
The categories are grouped according to the strength of the result in localising a hypo-metabolic region to 
the SRZ. The FWEp corrected p-value threshold indicated on the vertical axis represents the specificity 
optimised threshold (see Chapter 5).(Figure continued on the following page) 
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(Figure 6.1 continued) 
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Table 6.2: FWEc corrected SPM topology categories. 
The cluster-level, FWEc correction for multiple comparisons SPM map topological categories, descriptions, 
and the strength of localising a hypo-metabolic region to the SRZ are shown. 
SPM 
map 
topology 
category 
SPM map topology description 
Strength of 
SRZ 
localisation 
1 
 Solitary SpO supra-threshold and FWEc significant 
cluster localising to the SRZ 
 No other SpO supra-threshold clusters 
Strongly 
localising 
2 
 SpO supra-threshold and FWEc significant cluster 
localising to the SRZ 
 Other SpO supra-threshold but non-FWEc significant, 
clusters non-localising to the SRZ 
Strongly 
localising 
3 
 SpO supra-threshold and FWEc significant cluster 
localising to the SRZ 
 Other, less significant SpO supra-threshold and FWEc 
significant clusters non-localising to the SRZ 
Moderately 
localising 
4 
 SpO supra-threshold but FWEc non-significant cluster 
localising to the SRZ 
 No other SpO supra-threshold clusters or if present, 
less significant SpO supra-threshold and FWEc non-
significant clusters non-localising to the SRZ 
Weakly 
localising 
5 
 No SpO supra-threshold clusters 
 The most significant SpO sub-threshold cluster 
localising to the SRZ 
Weakly 
localising 
6 
 SpO supra-threshold and FWEc significant cluster 
localising to the SRZ 
 Other, more significant SpO supra-threshold and FWEc 
significant clusters non-localising to the SRZ 
Non-localising 
7 
 SpO supra-threshold but FWEc non-significant cluster 
non-localising to the SRZ 
 Other, less significant SpO supra-threshold and FWEc 
non-significant clusters localising to the SRZ 
Non-localising 
8 
 No SpO supra-threshold clusters 
 The most significant SpO sub-threshold cluster non-
localising to the SRZ 
Non-localising 
9 
 SpO supra-threshold and FWEc significant cluster non-
localising to the SRZ 
 Other, less significant SpO supra-threshold but FWEc 
non-significant clusters localising to the SRZ 
Strongly 
non-localising 
10 
 Solitary SpO supra-threshold and FWEc significant 
cluster non-localising to the SRZ 
 No other SpO supra-threshold clusters 
Strongly 
non-localising 
SRZ: surgical resection zone 
SpO: specificity optimised SPM parameters 
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Figure 6.2: FWEc SPM topological patterns and strength of localisation to the SRZ. 
The categories are grouped according to the strength of the result in localising a hypo-metabolic region to 
the SRZ. The uncorrected p-value threshold indicated on the vertical axis represents the uncorrected p-
value threshold as determined by the specificity optimised validation process (see Chapter 5). 
(Figure continued on the following page)  
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(Figure 6.2 continued. Figure continued on the following page) 
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(Figure 6.2 continued. Figure continued on the following page) 
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(Figure 6.2 continued) 
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6.4.8 Assessment of post-operative outcome 
Post-operative outcome was assigned during review of the electronic medical record of 
each patient in a multidisciplinary setting including the Principle Complex Epilepsy 
Epileptologist and Clinical Nurse Consultant (see acknowledgements). Table 6.3 shows 
the Engel classification of postsurgical outcome in patients with epilepsy [94]. Engel 
classification was assigned after reviewing the last documented clinical contact with the 
patient incorporating clinical review in outpatient clinic, during a hospital admission or 
via telephone follow up with the patients family. The outcomes of all of the patients were 
classified during two multidisciplinary review sessions. For the analysis, Engel Class 1 
and 2 were categorised as “good” response” and Engel Class 3 and 4 were categorised as 
“poor” response. 
 
Table 6.3: Engel classification of post-operative outcome in patients following epilepsy surgery. 
Taken from Wieser et all [94]. 
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6.4.9 Subgroup analyses 
Other factors considered in the analysis were ictal status during the FDG uptake phase 
and patients undergoing temporal versus extra-temporal surgical resections. Subgroup 
analysis was undertaken to investigate the potential for these relevant clinical factors to 
confound the output SPM results. 
 
6.4.10 Statistical analysis 
The results for FWEp and FWEc correction for multiple comparisons were considered 
separately. 
 
Statistical analysis was aimed at determining the diagnostic test performance of SPM 
results that localise a hypo-metabolic focus to the SRZ in predicating a “good” post-
operative outcome (post-operative Engel classification of 1 or 2). The SPM topology 
categories (Tables 6.1 and 6.2, and Figures 6.1 and 6.2) represent ordinal categories 
ranging from 1 (the strongest evidence of a hypo-metabolic focus localising to the SRZ) 
to 6 (the weakest evidence of a hypo-metabolic focus localising to the SRZ) in the case 
of the FWEp results, and ranging from 1 (the strongest evidence of a hypo-metabolic 
focus localising to the SRZ) to 10 (the weakest evidence of a hypo-metabolic focus 
localising to the SRZ) in the case of the FWEc results.  
 
SPM results were cumulatively tabulated and diagnostic test performance was calculated 
using each ordinal SPM topology category sequentially from the strongest to the weakest 
localising, as the diagnostic test cut point to define a “positive” hypo-metabolic focus 
localising to the SRZ. 
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The diagnostic test metrics calculated at each cut point were: sensitivity (SN), specificity 
(SP), positive and negative likelihood ratios (PLR, NLR), and positive and negative 
predictive values (PPV, NPV); according to their standard definitions [95]. Receiver 
operator characteristic (ROC) curves and the area under the curve (AUC) were calculated 
and used to compare the diagnostic test performance of between different SPM analyses 
and between different subgroups [96]. 
 
6.5 Results 
6.5.1 Patient demographics and SPM topology category results 
There were 74 patients who had a cerebral FDG PET scan prior to undergoing epilepsy 
surgery during the study period. Six patients were excluded due to having non-resective 
surgery (corpus callosotomy), three patients were excluded due to previous surgery and 
four patients were lost to follow up after surgery. There remained 61 eligible patients 
included in the study. The age of the included patients at the time of the cerebral FDG 
scan ranged from six weeks to 15 years, seven months (mean seven years, three months). 
There were 33 boys and 28 girls. Twenty-two of the patients had scalp surface EEG 
performed during the FDG uptake phase and 13 of these showed focal epileptic 
discharges or more widespread abnormalities likely to perturb cerebral metabolism (see 
Table 6.4). Of the 13 patients with abnormal EEG findings four had clinical seizure 
activity. Two of the 39 patients that did not have EEG monitoring had clinical seizures 
during FDG uptake. 
 
Eighteen patients underwent isolated temporal lobe resections and 43 had extra-temporal 
resections, including three hemispherectomies. The histopathology results were: 23 with 
type 2 focal cortical dysplasia (FCD), 12 with neuronal heterotopia, 10 with type 1 FCD, 
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3 with dysembryoplastic neuroepithelial tumour (DNET), two with tuberous sclerosis 
tubers, two with WHO grade 1 ganglioglioma, and one each with type 3 FCD, WHO 
grade 2 oligodendroglioma, Rasmussen’s encephalitis, cortical scarring/gliosis and 
mesial temporal sclerosis. In addition there were four patients with mixed 
histopathological findings including schizencephaly, polymicrogyria and neuronal 
heterotopia; neuronal heterotopia and mesial temporal sclerosis; type 2 FCD, DNET and 
WHO grade 1 ganglioglioma; and type 2 FCD, neuronal heterotopia and WHO grade 2 
ganglioglioma. 
 
Follow up time ranged from two to 100 months (median follow up time 30 months) and 
post-operative outcome was Engel 1 in 41 patients, Engel 2 in 6 patients, Engel 3 in 11 
patients and Engel 4 in 3 patients. Table 6.4 includes the demographics, histopathology, 
post-operative outcome and SPM topology category results for the 61 included patients.
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Table 6.4: Demographics, histopathology, post-operative outcome and SPM results for the included patients. 
      SPM topology category results   
Age 
(years) Sex 
Location of surgical 
resection Histopathology 
Follow up 
(months) 
Post-operative 
Engel 
classification 
FWEp 
Corr. 
p<0.094 
FWEc 
Uncorr. 
p<0.00001 
FWEc 
Uncorr. 
p<0.1 
EEG during FDG uptake Clinical seizures during FDG uptake 
0.1 M Hemispherectomy Type 2A FCD 51 3a 6 10 7 Left hemisphere epileptic activity - 
0.2 M Fronto-parietal region Type 1 FCD 20 3a 6 6 7 
Right parietal epileptoform 
activity 
Focal seizures of left 
hand and leg 
0.4 M Temporo-parieto-occipital region Type 2A FCD 20 1a 6 10 4 
Right posterior quadrant 
epileptoform acitivity - 
0.7 M Frontal lobe Type 2B FCD 14 1a 5 8 7 - - 
0.9 M Fronto-temporal region Type 1 FCD 12 3a 3 8 7 
Right central-temporal 
discharges - 
0.9 F Frontal lobe Type 1 FCD 32 4c 5 8 7 - - 
1.2 M Frontal lobe Type 2B FCD 28 1b 1 1 4 - - 
1.4 M Temporal lobe Type 2B FCD 50 2b 5 8 7 - - 
1.6 M Temporal lobe Type 2A FCD 44 3a 1 1 4 - - 
1.8 F Temporal lobe Type 3 FCD 21 1a 5 5 4 Frequent generalised discharges - 
1.9 M Temporal lobe Neuronal heterotopia 18 1a 5 8 7 Generalised epileptic activity on EEG - 
1.9 M Frontal lobe Type 1 FCD 26 3a 5 8 7 - - 
2.1 F Frontal lobe Type 2B FCD 24 1a 3 8 7 Fronto-central and temporal discharges Tonic-clonic seizure 
2.1 F Temporo-parieto-occipital region Type 2A FCD 14 1a 6 10 7 
Bilateral focal and 
generalised discharges - 
2.5 M Frontal lobe Type 2B FCD 18 1a 2 6 4 - - 
3.0 M Frontal lobe Type 2B FCD 13 1a 3 8 7 Interictal - 
3.0 M Frontal lobe Type 1 FCD 50 3b 4 3 4 Interictal - 
3.2 M Frontal lobe Type 2A FCD 34 3a 4 3 4 - - 
3.2 F Frontal lobe Type 1 FCD 41 1a 5 8 7 Right frontal epileptoform activity Epileptic "spasms" 
3.5 F Temporal lobe Type 2B FCD 2 1a 2 1 4 - - 
3.7 F Frontal lobe Neuronal heterotopia 44 1a 5 8 7 - - 
4.5 F Frontal lobe Type 1 FCD 24 1b 6 10 7 Left frontal discharges - 
4.5 M Parietal lobe Tuberous sclerosis tuber 70 2c 4 6 4 Generalised epileptic activity Tonic-clonic seizure 
4.8 F Frontal lobe Type 2B FCD 38 1a 5 8 7 - - 
4.8 M Frontal lobe Type 2A FCD, DNET, WHO1 ganglioglioma 34 1a 2 1 4 - - 
5.1 F Frontal lobe Neuronal heterotopia 66 2d 3 8 7 - - 
6.2 M Frontal lobe Type 1 FCD 17 1a 6 10 4 - Generalised tonic seizure. 
6.4 M Parietal lobe DNET 34 1a 3 8 4 - - 
6.5 M Frontal lobe Type 2B FCD 37 1a 1 1 4 Right frontal discharges - 
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6.6 M Temporal lobe WHO1 ganglioglioma 17 1a 4 10 4 - - 
6.8 F Temporo-occipital region Type 2A FCD 33 3a 4 6 4 - - 
7.2 M Frontal lobe Tuberous sclerosis tuber 65 1b 1 5 4 Interictal - 
7.4 F Hemispherectomy Chronic (Rassmussen’s) encephalitis 100 1a 1 1 4 - 
Complex partial 
seizure 
7.4 M Occipital lobe DNET 51 1b 1 8 7 - - 
8.8 F Temporal lobe Neuronal heterotopia, mesial temporal sclerosis 11 1a 4 3 4 - - 
8.9 F Frontal lobe Type 2B FCD 16 1a 3 5 4 Interictal - 
9.2 F Frontal lobe Type 2B FCD 6 1a 5 8 7 - - 
9.7 F Frontal lobe DNET 21 1a 2 3 4 - - 
9.7 M Frontal lobe Cortical scarring and gliosis 22 2a 1 1 4 - - 
9.9 F Temporal lobe Neuronal heterotopia 22 1a 3 5 4 - - 
10.5 F Temporal lobe Neuronal heterotopia 24 1a 1 1 4 - - 
10.5 M Temporal lobe Neuronal heterotopia 49 2a 1 5 4 - - 
10.6 F Frontal lobe Type 1 FCD 30 4b 3 5 4 - - 
11.0 F Temporal lobe Type 2A FCD 36 1a 2 5 4 Interictal - 
11.5 F Frontal lobe Type 1 FCD 13 4 4 6 4 - - 
11.5 M Temporal lobe Neuronal heterotopia 32 1a 1 1 4 - - 
11.6 F Temporal lobe Type 2A FCD 38 3a 4 6 4 - - 
11.9 M Frontal lobe Neuronal heterotopia 37 1b 3 5 4 Left fronto-central discharges - 
12.0 M Parietal lobe Type 2B FCD 22 1a 4 10 7 Interictal - 
12.0 M Frontal lobe Type 2B FCD 41 1b 5 8 7 - - 
12.2 F Frontal lobe Neuronal heterotopia 64 1a 5 8 7 - - 
12.4 M Temporal lobe Neuronal heterotopia 34 1a 6 8 7 - - 
13.0 M Temporal and frontal lobe Neuronal heterotopia 27 3a 5 5 4 - - 
13.1 M Temporal lobe Neuronal heterotopia 25 3a 5 8 4 Interictal - 
14.2 M Hemispherectomy 
Schizencephaly, 
polymicrogyria, neuronal 
heterotopia 
35 1a 1 1 4 Interictal - 
14.8 M Occipital lobe WHO2 oligodendroglioma 36 1a 5 8 7 - - 
15.1 F Temporal lobe WHO1 ganglioglioma 30 1a 1 1 4 - - 
15.2 F Temporo-parietal region 
Type 2A FCD, neuronal 
heterotopia, WHO2 
ganglioglioma 
21 1b 3 8 7 - - 
15.3 F Parieto-occipital region Type 2B FCD 11 1a 6 10 7 - - 
15.6 F Frontal lobe Type 2B FCD 39 2a 2 1 4 -  
15.6 F Temporal lobe Mesial temporal sclerosis 18 1a 1 1 4 Interictal  
FCD: focal cortical dysplasia 
DNET: dysembryoplastic neuroepithelial tumor 
-: EEG not performed and/or no clinical seizures reported during FDG uptake 
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6.5.2 Diagnostic test performance of SPM analyses 
The cumulative SPM results and the corresponding diagnostic test performance at the 
sequential SPM topology category cut points for all of the included patients are presented 
in Table 6.5. There are the expected findings of increasing SN as the diagnostic test cut 
point is moved progressively from the most strongly localising through to the most 
strongly non-localising SPM topology categories. Progressively more SPM results are 
classified as positive resulting in the capturing of more patients with a good post-
operative Engel classification and therefore SN increases, ultimately to 100% when the 
most strongly non-localising SM result is used as the diagnostic test cut point and all of 
the SPM findings are classified as positive. Across all of the FWEp and FWEc results SN 
is poor at the more strongly localising SPM topology categories highlighting the 
significant number of false negative results of SPM localising the SRZ to predict good 
post-operative outcome. That is, there remained a significant number of patients with 
SPM topology poorly or non-localising to the SRZ that had a good post-operative 
outcome. In comparison, there were much fewer false positive results at the more 
strongly localising SPM topology categories. This low false positive rate translates to the 
high SP (and high PPV) at the SPM topology cut points categories that more strongly 
localise to the SRZ. 
 
There was a difference in performance between the FWEp analysis and the two FWEc 
analyses. The most apparent difference is the SPM topology categorisation falling into 
only 2/10 categories with FWEc at the uncorrected p<0.1 (categories 4 and 7), and 6/10 
categories with FWEc at the uncorrected p<0.00001 (categories 1, 3, 5, 6, 8 and 10), 
whereas the FWEp results involved all 6/6 categories. These differences are likely to be a 
result of the different smoothing and statistical thresholds used in each analysis (see 
Discussion). Also, the diagnostic test performance appears to be the best for the FEWp 
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analysis, followed by the FWEc analysis at uncorrected p<0.00001, then the FWEc 
analysis at uncorrected p<0.1 when broadly comparing the diagnostic test metrics across 
the various cut points for each analysis. The highest PLR was 5.4, which occurred in the 
FWEp analysis using SPM topology category 2 (moderately localising) as the cut point 
for a positive localisation to the SRZ (see Table 6.5). At this cut point there was the 
maximised combined performance of both SN (93%) and SP (38%). 
 
Table 6.5: Results for all 61 included epilepsy patients. 
Diagnostic test performance of the voxel-level FWEp corrected p<0.094 SPM analysis, and the cluster-
level FWEc corrected SPM analysis at the uncorrected voxel-level thresholds of p<0.00001 and p<0.1. The 
SPM map topology categories are listed in order from most strongly localising (category 1) to the most 
strongly non-localising (category 6 for FWEp results and category 10 for the FWEc results) of a hypo-
metabolic focus to the SRZ. As the diagnostic test cut point for defining positive SRZ localisation is 
progressively lowered (ie. classifying progressively less strong localisations SPM results as “positive” for 
localising the SRZ), the cumulative number of patients with positive localisations are indicated along with 
the corresponding number of true positive and false positive findings when compared against the reference 
standard of “good” post-operative outcome. The corresponding diagnostic test metrics for each given 
threshold are also listed. 
 SPM 
map 
topology 
category 
cut point 
Cumulative 
number of 
patients 
with +ve 
SRZ 
localisation 
Post-operative Engel 
classification Diagnostic test metric 
 
Cumulative 
1 or 2, “Good” 
(true positives) 
Cumulative 
3 or 4, “Poor” 
(false positives) 
SN 
(%) 
SP 
(%) PLR NLR 
PPV 
(%) 
NPV 
(%) 
FW
Ep
 c
or
r. 
re
su
lts
 a
t 
co
rr.
 p
<0
.0
94
 
1 13 12 1 26 93 3.6 0.8 92 27 
2 19 18 1 38 93 5.4 0.7 95 31 
3 29 26 3 55 79 2.6 0.6 90 34 
4 38 30 8 64 43 1.1 0.8 79 26 
5 53 41 12 87 14 1.0 0.9 77 25 
6 61 47 14 100 0 1.0 - 77 - 
Total 61 47 14       
FW
Ec
 c
or
re
ct
ed
 re
su
lts
 
at
 u
nc
or
r. 
p<
0.
00
00
1 
1 13 12 1 26 93 3.6 0.8 92 27 
2 13 12 1 26 93 3.6 0.8 92 27 
3 17 14 3 30 79 1.4 0.9 82 25 
4 17 14 3 30 79 1.4 0.9 82 25 
5 26 21 5 45 64 1.3 0.9 81 26 
6 32 23 9 49 36 0.8 1.4 72 17 
7 32 23 9 49 36 0.8 1.4 72 17 
8 53 40 13 85 7 0.9 2.1 75 13 
9 53 40 13 85 7 0.9 2.1 75 13 
10 61 47 14 100 0 1.0 - 77 - 
Total 61 47 14       
FW
Ec
 c
or
re
ct
ed
 re
su
lts
 
at
 u
nc
or
r. 
p<
0.
1 
1 0 0 0 0 100 - 1.0 - 23 
2 0 0 0 0 100 - 1.0 - 23 
3 0 0 0 0 100 - 1.0 - 23 
4 36 27 9 57 36 0.9 1.2 75 20 
5 36 27 9 57 36 0.9 1.2 75 20 
6 36 27 9 57 36 0.9 1.2 75 20 
7 61 47 14 100 0 1.0 - 77 - 
8 61 47 14 100 0 1.0 - 77 - 
9 61 47 14 100 0 1.0 - 77 - 
10 61 47 14 100 0 1.0 - 77 - 
Total 61 47 14       
SN: sensitivity 
SP: specificity 
PLR: positive likelihood ratio 
NLR: negative likelihood ratio 
PPV: positive predictive value 
NPV: negative predictive value 
- : unable to be calculated due to a denominator of zero 
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The cumulative SPM results after excluding the 15 patients who had clinical seizures 
and/or EEG abnormalities likely to perturb cerebral metabolism during FDG uptake are 
shown in Table 6.6. The diagnostic test performance is similar to that when including all 
patients, with high SP at the more stringent categories of localisation to the SRZ and 
generally poor SN reflecting the persisting high number of false negative results. The 
highest PLR again occurred at in the FWEp analysis using SPM topology category 2 
(moderately localising) as the cut point. 
 
Table 6.6: Results for the remaining 46 patients after excluding 15 patients with clinical seizures 
and/or EEG findings likely to perturb cerebral metabolism during FDG uptake. 
Diagnostic test performance of the voxel-level FWEp corrected p<0.094 SPM analysis, and the cluster-
level FWEc corrected SPM analysis at the uncorrected voxel-level thresholds of p<0.00001 and p<0.1. The 
SPM map topology categories are listed in order from most strongly localising (category 1) to the most 
strongly non-localising (category 6 for FWEp results and category 10 for the FWEc results) of a hypo-
metabolic focus to the SRZ. As the diagnostic test cut point for defining positive SRZ localisation is 
progressively lowered (ie. classifying progressively less strong localisations SPM results as “positive” for 
localising the SRZ), the cumulative number of patients with positive localisations are indicated along with 
the corresponding number of true positive and false positive findings when compared against the reference 
standard of “good” post-operative outcome. The corresponding diagnostic test metrics for each given 
threshold are also listed. 
 SPM 
map 
topology 
category 
cut point 
Cumulative 
number of 
patients 
with +ve 
SRZ 
localisation 
Post-operative Engel 
classification Diagnostic test metric 
 
Cumulative 
1 or 2, “Good” 
(true positives) 
Cumulative 
3 or 4, “Poor” 
(false positives) 
SN 
(%) 
SP 
(%) PLR NLR 
PPV 
(%) 
NPV 
(%) 
FW
Ep
 c
or
r. 
re
su
lts
 a
t 
co
rr.
 p
<0
.0
94
 
1 11 10 1 29 91 3.1 0.8 91 29 
2 17 16 1 46 91 5.0 0.6 94 34 
3 24 22 2 63 82 3.5 0.5 92 41 
4 32 25 7 71 36 1.1 0.8 78 29 
5 44 33 11 94 0 0.9 - 75 0 
6 46 35 11 100 0 1.0 - 76 - 
Total 46 35 11       
FW
Ec
 c
or
re
ct
ed
 re
su
lts
 
at
 u
nc
or
r. 
p<
0.
00
00
1 
1 11 10 1 29 91 3.1 0.8 91 29 
2 11 10 1 29 91 3.1 0.8 91 29 
3 15 12 3 34 73 1.3 0.9 80 26 
4 15 12 3 34 73 1.3 0.9 80 26 
5 22 17 5 49 55 1.1 0.9 77 25 
6 26 18 8 51 27 0.7 1.8 69 15 
7 26 18 8 51 27 0.7 1.8 69 15 
8 43 32 11 91 0 0.9 - 74 0 
9 43 32 11 91 0 0.9 - 74 0 
10 46 35 11 100 0 1.0 - 76 - 
Total 46 35 11       
FW
Ec
 c
or
re
ct
ed
 re
su
lts
 
at
 u
nc
or
r. 
p<
0.
1 
1 0 0 0 0 100 - 1.0 - 24 
2 0 0 0 0 100 - 1.0 - 24 
3 0 0 0 0 100 - 1.0 - 24 
4 29 20 9 57 18 0.7 2.4 69 12 
5 29 20 9 57 18 0.7 2.4 69 12 
6 29 20 9 57 18 0.7 2.4 69 12 
7 46 35 11 100 0 1.0 - 76 - 
8 46 35 11 100 0 1.0 - 76 - 
9 46 35 11 100 0 1.0 - 76 - 
10 46 35 11 100 0 1.0 - 76 - 
Total 46 35 11       
SN: sensitivity  PLR: positive likelihood ratio  PPV: positive predictive value 
SP: specificity  NLR: negative likelihood ratio  NPV: negative predictive value 
- : unable to be calculated due to a denominator of zero 
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Continuing to exclude patients with clinical seizures and/or abnormal EEG findings 
during FDG uptake, the results when sub-grouping according to either temporal or extra-
temporal lobe resections are presented in Tables 6.7 and 6.8, respectively. There are no 
false positive results for the FWEp analysis at the more stringent categories of 
localisation to the SRZ (categories 1 and 2) in the extra-temporal lobe resection patients 
resulting in the very high SP at this cut point.  SN remains poor due to persisting false 
negative results in both resection subgroups. 
 
Table 6.7: Results for the 16 patients with temporal lobe surgical resections after excluding those 
with clinical seizures and/or EEG findings likely to perturb cerebral metabolism during FDG uptake. 
Diagnostic test performance of the voxel-level FWEp corrected p<0.094 SPM analysis, and the cluster-
level FWEc corrected SPM analysis at the uncorrected voxel-level thresholds of p<0.00001 and p<0.1. The 
SPM map topology categories are listed in order from most strongly localising (category 1) to the most 
strongly non-localising (category 6 for FWEp results and category 10 for the FWEc results) of a hypo-
metabolic focus to the SRZ. As the diagnostic test cut point for defining positive SRZ localisation is 
progressively lowered (ie. classifying progressively less strong localisations SPM results as “positive” for 
localising the SRZ), the cumulative number of patients with positive localisations are indicated along with 
the corresponding number of true positive and false positive findings when compared against the reference 
standard of “good” post-operative outcome. The corresponding diagnostic test metrics for each given 
threshold are also listed. 
 SPM 
map 
topology 
category 
cut point 
Cumulative 
number of 
patients 
with +ve 
SRZ 
localisation 
Post-operative Engel 
classification Diagnostic test metric 
 
Cumulative 
1 or 2, “Good” 
(true positives) 
Cumulative 
3 or 4, “Poor” 
(false positives) 
SN 
(%) 
SP 
(%) PLR NLR 
PPV 
(%) 
NPV 
(%) 
FW
Ep
 c
or
r. 
re
su
lts
 a
t 
co
rr.
 p
<0
.0
94
 
1 6 5 1 42 75 1.7 0.8 83 30 
2 8 7 1 58 75 2.3 0.6 88 38 
3 9 8 1 67 75 2.7 0.4 89 43 
4 13 10 3 83 25 1.1 0.7 77 33 
5 15 11 4 92 0 0.9 - 73 0 
6 16 12 4 100 0 1.0 - 75 - 
Total 16 12 4       
FW
Ec
 c
or
re
ct
ed
 re
su
lts
 
at
 u
nc
or
r. 
p<
0.
00
00
1 
1 6 5 1 42 75 1.7 0.8 83 30 
2 6 5 1 42 75 1.7 0.8 83 30 
3 7 6 1 50 75 2.0 0.7 86 33 
4 7 6 1 50 75 2.0 0.7 86 33 
5 10 9 1 75 75 3.0 0.3 90 50 
6 12 9 3 75 25 1.0 1.0 75 25 
7 12 9 3 75 25 1.0 1.0 75 25 
8 15 11 4 92 0 0.9 - 73 0 
9 15 11 4 92 0 0.9 - 73 0 
10 16 12 4 100 0 1.0 - 75 - 
Total 16 12 4       
FW
Ec
 c
or
re
ct
ed
 re
su
lts
 
at
 u
nc
or
r. 
p<
0.
1 
1 0 0 0 0 100 - 1.0 - 25 
2 0 0 0 0 100 - 1.0 - 25 
3 0 0 0 0 100 - 1.0 - 25 
4 14 10 4 83 0 0.8 - 71 0 
5 14 10 4 83 0 0.8 - 71 0 
6 14 10 4 83 0 0.8 - 71 0 
7 16 12 4 100 0 1.0 - 75 - 
8 16 12 4 100 0 1.0 - 75 - 
9 16 12 4 100 0 1.0 - 75 - 
10 16 12 4 100 0 1.0 - 75 - 
Total 16 12 4       
SN: sensitivity  PLR: positive likelihood ratio  PPV: positive predictive value 
SP: specificity  NLR: negative likelihood ratio  NPV: negative predictive value 
- : unable to be calculated due to a denominator of zero  
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Overall, the optimal analysis occurs with voxel-level FWEp correction for multiple 
comparisons and using the cut point SPM topology category of 2 (ie. a cut point that 
includes the strongly and moderately localising localisation groups). SPM performed best 
in the sub-group of extra-temporal resections after excluding patients with clinical 
seizures and/or EEG abnormalities likely to perturb cerebral metabolism during FDG 
uptake. 
 
Table 6.8: Results for the 30 patients with extra-temporal surgical resections after excluding those 
with clinical seizures and/or EEG findings likely to perturb cerebral metabolism during FDG uptake. 
Diagnostic test performance of the voxel-level FWEp corrected p<0.094 SPM analysis, and the cluster-
level FWEc corrected SPM analysis at the uncorrected voxel-level thresholds of p<0.00001 and p<0.1. The 
SPM map topology categories are listed in order from most strongly localising (category 1) to the most 
strongly non-localising (category 6 for FWEp results and category 10 for the FWEc results) of a hypo-
metabolic focus to the SRZ. As the diagnostic test cut point for defining positive SRZ localisation is 
progressively lowered (ie. classifying progressively less strong localisations SPM results as “positive” for 
localising the SRZ), the cumulative number of patients with positive localisations are indicated along with 
the corresponding number of true positive and false positive findings when compared against the reference 
standard of “good” post-operative outcome. The corresponding diagnostic test metrics for each given 
threshold are also listed. 
 SPM 
map 
topology 
category 
cut point 
Cumulative 
number of 
patients 
with +ve 
SRZ 
localisation 
Post-operative Engel 
classification Diagnostic test metric 
 
Cumulative 
1 or 2, “Good” 
(true positives) 
Cumulative 
3 or 4, “Poor” 
(false positives) 
SN 
(%) 
SP 
(%) PLR NLR 
PPV 
(%) 
NPV 
(%) 
FW
Ep
 c
or
r. 
re
su
lts
 a
t 
co
rr.
 p
<0
.0
94
 
1 5 5 0 22 100 - 0.8 100 28 
2 9 9 0 39 100 - 0.6 100 33 
3 15 14 1 61 86 4.3 0.5 93 40 
4 19 15 4 65 43 1.1 0.8 79 27 
5 29 22 7 96 0 1.0 - 76 0 
6 30 23 7 100 0 1.0 - 77 - 
Total 30 23 7       
FW
Ec
 c
or
re
ct
ed
 re
su
lts
 
at
 u
nc
or
r. 
p<
0.
00
00
1 
1 5 5 0 22 100 - 0.8 100 28 
2 5 5 0 22 100 - 0.8 100 28 
3 8 6 2 26 71 0.9 1.0 75 23 
4 8 6 2 26 71 0.9 1.0 75 23 
5 12 8 4 35 43 0.6 1.5 67 17 
6 14 9 5 39 29 0.5 2.1 64 13 
7 14 9 5 39 29 0.5 2.1 64 13 
8 28 21 7 91 0 0.9 - 75 0 
9 28 21 7 91 0 0.9 - 75 0 
10 30 23 7 100 0 1.0 - 77 - 
Total 30 23 7       
FW
Ec
 c
or
re
ct
ed
 re
su
lts
 
at
 u
nc
or
r. 
p<
0.
1 
1 0 0 0 0 100 - 1.0 - 23 
2 0 0 0 0 100 - 1.0 - 23 
3 0 0 0 0 100 - 1.0 - 23 
4 15 10 5 43 29 0.6 2.0 67 13 
5 15 10 5 43 29 0.6 2.0 67 13 
6 15 10 5 43 29 0.6 2.0 67 13 
7 30 23 7 100 0 1.0 - 77 - 
8 30 23 7 100 0 1.0 - 77 - 
9 30 23 7 100 0 1.0 - 77 - 
10 30 23 7 100 0 1.0 - 77 - 
Total 30 23 7       
SN: sensitivity  PLR: positive likelihood ratio  PPV: positive predictive value 
SP: specificity  NLR: negative likelihood ratio  NPV: negative predictive value 
- : unable to be calculated due to a denominator of zero 
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The ROC curves for the FWEp and both FWEc analyses, when applied to all of the 
patients and each subgroup are displayed in Figure 6.3. The AUC is indicated in each 
ROC curve plot. The profile of the ROC curves support the findings on the diagnostic 
test metric comparisons at various cut points. The FWEc uncorrected p<0.1 analyses 
performs very poorly with the ROC curves very close to the diagonal line of non-
discrimination and in fact the ROC curve falls below the diagonal line for the subgroup 
analyses. The ROC curve for the FWEc uncorrected p<0.00001 analyses performs better 
with the AUC becoming greater than 0.5 in the patients with temporal lobe resections 
(0.635). The FWEp analysis clearly outperforms both FWEc analyses with the AUC 
being greater than 0.5 in all groups. The SPM FWEp analysis performed best in the 
subgroup of extra-temporal resections after exclusion of patients with clinical seizures 
and/or abnormal EEG findings during FDG uptake, where the ROC AUC was 0.686. 
 
 
 
 
 
 
 
 
Figure 6.3 (following page): ROC curves for SPM analysis. 
Receiver operator characteristic (ROC) curves for FWEp corrected analysis (left panel), FWEc corrected 
analysis at uncorrected p<0.00001 (middle panel) and FWEc corrected analysis at uncorrected p<0.1 (right 
panel) for all included patients (top row), excluding patients with EEG abnormalities or clinical seizures 
during FDG uptake (second row), and further sub-grouped by temporal lobe resections (third row) and 
extra-temporal lobe resections (forth row). The area under the curve (AUC) is indicated on each ROC 
curve. The FWEc corrected SPM analysis with uncorrected p<0.1 performed very poorly for the whole 
group and for each subgroup with AUC ranging from 0.360 to 0.466. The FWEc corrected SPM analysis 
with uncorrected p<0.00001 performed very poorly for the whole group and for each subgroup except the 
temporal lobe resection patients where AUC was 0.635. The FWEp corrected SPM analysis performed the 
best with AUC ranging from 0.638 to 0.686. The SPM analysis performed the best when using the FWEp 
corrected analysis in the extra-temporal lobe resection patients after excluding those with EEG 
abnormalities or clinical seizures during the FDG uptake phase.
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Figure 6.3: ROC curves for SPM analysis. (see figure legend on previous page)
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6.5.3 Examples of SPM analyses in selected patients 
Examples of the output SPM maps in patients with various SPM topology categories for 
the FWEp and FWEc analyses are presented in Figures 6.3 to 6.10. The patient’s 
demographics, and post-operative outcome are indicated on each figure, and the post-
operative imaging is displayed to clarify the localisation of any supra-threshold clusters 
to the SRZ. For each patient the differences in SPM localisation to the SRZ can be 
appreciated between the three different SPM analyses. The results in the displayed 
patients demonstrate the more accurate localisation to the SRZ in patients with good 
post-operative outcome when using the FWEp analysis compared to the FWEc analyses 
(Figures 6.3, 6.4, 6.5, 6.6 and 6.7), the non-localising SPM result in patients with poor 
post-operative outcome (Figures 6.8 and 6.9), and the strongly non-localising SPM result 
in a patient with good post-operative outcome but seizure activity on EEG during FDG 
uptake (Figure 6.10). It can also be seen the expanded supra-threshold cluster size when 
using the increased smoothing and lower statistical thresholds implicit in the FWEc 
analyses, particularly the FWEc uncorrected p<0.1 analysis. This reduces the spatial 
precision of any successful localisation to the SRZ. 
 
 
 
Figure 6.4 (following page): FWEp and FWEc strongly localising SPM with good outcome. 
Example of a category 1, strongly localising FWEp corrected SPM analysis and weakly localising FWEc 
uncorrected p<0.00001 analysis in a patient with good post-operative outcome. 
Post-operative CT scan demonstrating the location and extent of the right temporal lobe surgical resection 
(a). The SPM results are shown for the specificity optimised SPM parameters using FWEp analysis 
(column b), and the FWEc corrected analyses at uncorrected p<0.00001 (column c) and uncorrected p<0.1 
(column d). In each column the SPM results are shown as a glass brain display, then overlayed on the T1 
MRI template provided within SPM8 with the cross-hairs triangulated on the peak voxel in the supra-
threshold cluster localising to the SRZ, and lastly overlayed on the “SPM96” single subject surface 
rendered brain within SPM8. Where no supra-threshold voxels survive at the specificity optimised SPM 
parameters (in the case of this patient this occurs at the FWEc corrected analysis at uncorrected p<0.1 
(column d)), the glass brain display is shown with no surviving supra-threshold voxels followed by the 
SPM results when not applying FWEc correction for multiple comparisons as indicated. The patient’s 
eventual SPM topology classification for each SPM analysis is indicated at the foot of each column. 
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Figure 6.4: FWEp and FWEc strongly localising SPM with good outcome. 
(see figure legend on previous page) 
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Figure 6.5: FWEp strongly localising, FWEc weakly localising SPM with good outcome. 
Example of a category 1, strongly localising FWEp corrected SPM analysis and weakly localising FWEc 
analyses in a patient with good post-operative outcome. 
Post-operative MRI scan demonstrating the location and extent of the right temporal lobe surgical resection 
(a). The SPM results are shown for the specificity optimised SPM parameters using FWEp analysis 
(column b), and the FWEc corrected analyses at uncorrected p<0.00001 (column c) and uncorrected p<0.1 
(column d). In each column the SPM results are shown as a glass brain display, then overlayed on the T1 
MRI template provided within SPM8 with the cross-hairs triangulated on the peak voxel in the supra-
threshold cluster localising to the SRZ, and lastly overlayed on the “SPM96” single subject surface 
rendered brain within SPM8. Where no supra-threshold voxels survive at the specificity optimised SPM 
parameters (in the case of this patient this occurs at both FWEc corrected analyses (column c and d)), the 
glass brain display is shown with no surviving supra-threshold voxels followed by the SPM results when 
liberalising the statistical p-value threshold and/or when not applying FWEc correction for multiple 
comparisons, as indicated. The patient’s eventual SPM topology classification for each SPM analysis is 
indicated at the foot of each column. 
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Figure 6.5: FWEp strongly localising, FWEc weakly localising SPM with good outcome. 
(see figure legend on previous page) 
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Figure 6.6 (following page): FWEp strongly localising, FWEc non-localising SPM with good outcome. 
Example of a category 1, strongly localising FWEp corrected SPM analysis and non-localising FWEc 
analyses in a patient with good post-operative outcome. 
Post-operative MRI scan demonstrating the location and extent of the left occipital lobe surgical resection 
(a). The SPM results are shown for the specificity optimised SPM parameters using FWEp analysis 
(column b), and the FWEc corrected analyses at uncorrected p<0.00001 (column c) and uncorrected p<0.1 
(column d). In each column the SPM results are shown as a glass brain display, then overlayed on the T1 
MRI template provided within SPM8 with the cross-hairs triangulated on the peak voxel in the supra-
threshold cluster localising to the SRZ, and lastly overlayed on the “SPM96” single subject surface 
rendered brain within SPM8. Where no supra-threshold voxels survive at the specificity optimised SPM 
parameters (in the case of this patient this occurs at both FWEc corrected analyses (column c and d)), the 
glass brain display is shown with no surviving supra-threshold voxels followed by the SPM results when 
liberalising the statistical p-value threshold and/or when not applying FWEc correction for multiple 
comparisons, as indicated. The patient’s eventual SPM topology classification for each SPM analysis is 
indicated at the foot of each column. 
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Figure 6.6: FWEp strongly localising, FWEc non-localising SPM with good outcome. 
(see figure legend on previous page) 
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Figure 6.7 (following page): FWEp moderately localising, FWEc weakly localising SPM with good 
outcome. 
Example of a category 2, moderately localising FWEp corrected SPM analysis and weakly localising 
FWEc analyses in a patient with good post-operative outcome. 
Post-operative CT scan demonstrating the location and extent of the left temporal lobe surgical resection 
(a). The SPM results are shown for the specificity optimised SPM parameters using FWEp analysis 
(column b), and the FWEc corrected analyses at uncorrected p<0.00001 (column c) and uncorrected p<0.1 
(column d). In each column the SPM results are shown as a glass brain display, then overlayed on the T1 
MRI template provided within SPM8 with the cross-hairs triangulated on the peak voxel in the supra-
threshold cluster localising to the SRZ, and lastly overlayed on the “SPM96” single subject surface 
rendered brain within SPM8. Where no supra-threshold voxels survive at the specificity optimised SPM 
parameters (in the case of this patient this occurs at both FWEc corrected analyses (column c and d)), the 
glass brain display is shown with no surviving supra-threshold voxels followed by the SPM results when 
liberalising the statistical p-value threshold and/or when not applying FWEc correction for multiple 
comparisons, as indicated. The patient’s eventual SPM topology classification for each SPM analysis is 
indicated at the foot of each column. 
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Figure 6.7: FWEp moderately localising, FWEc weakly localising SPM with good outcome. 
(see figure legend on previous page)  
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Figure 6.8 (following page): FWEp weakly localising, FWEc non-localising SPM with good outcome. 
Example of a category 3, weakly localising FWEp corrected SPM analysis and non-localising FWEc 
analyses in a patient with good post-operative outcome. 
Post-operative MRI scan demonstrating the location and extent of the right frontal lobe surgical resection 
(a). The SPM results are shown for the specificity optimised SPM parameters using FWEp analysis 
(column b), and the FWEc corrected analyses at uncorrected p<0.00001 (column c) and uncorrected p<0.1 
(column d). In each column the SPM results are shown as a glass brain display, then overlayed on the T1 
MRI template provided within SPM8 with the cross-hairs triangulated on the peak voxel in the supra-
threshold cluster localising to the SRZ, and lastly overlayed on the “SPM96” single subject surface 
rendered brain within SPM8. Where no supra-threshold voxels survive at the specificity optimised SPM 
parameters (in the case of this patient this occurs at the FWEp analysis and at both FWEc corrected 
analyses), the glass brain display is shown with no surviving supra-threshold voxels followed by the SPM 
results when liberalising the statistical p-value threshold and/or when not applying FWEc correction for 
multiple comparisons, as indicated. The patient’s eventual SPM topology classification for each SPM 
analysis is indicated at the foot of each column. 
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Figure 6.8: FWEp weakly localising, FWEc non-localising SPM with good outcome. 
(see figure legend on previous page)  
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Figure 6.9 (following page): FWEp non-localising and FWEc weakly localising SPM with poor 
outcome. 
Example of a category 4, non-localising FWEp corrected SPM analysis and non and weakly localising 
FWEc analyses in a patient with poor post-operative outcome. The patient subsequently underwent a 
second, more extensive temporo-occipital resection with histopathology showing type 2A FCD outside of 
the original SRZ. Post-operative outcome following this second surgery was good (Engel class 2). Note 
that the SPM analysis of the original pre-operative FDG scan shown in this figure demonstrates a hypo-
metabolic cluster on the FWEp analysis extending beyond the original SRZ. Note also a more highly 
significant hypo-metabolic cluster in the right anterior temporal pole outside of the SRZ producing a 
category 4, non-localising interpretation. 
Post-operative MRI scan demonstrating the location and extent of the right temporo-occipital surgical 
resection (a). The SPM results are shown for the specificity optimised SPM parameters using FWEp 
analysis (column b), and the FWEc corrected analyses at uncorrected p<0.00001 (column c) and 
uncorrected p<0.1 (column d). In each column the SPM results are shown as a glass brain display, then 
overlayed on the T1 MRI template provided within SPM8 with the cross-hairs triangulated on the peak 
voxel in the supra-threshold cluster localising to the SRZ, and lastly overlayed on the “SPM96” single 
subject surface rendered brain within SPM8. Where no supra-threshold voxels survive at the specificity 
optimised SPM parameters (in the case of this patient this occurs at the FWEc corrected analysis at 
uncorrected p<0.1 (column d)), the glass brain display is shown with no surviving supra-threshold voxels 
followed by the SPM results when not applying FWEc correction for multiple comparisons. The patient’s 
eventual SPM topology classification for each SPM analysis is indicated at the foot of each column. 
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Figure 6.9: FWEp non-localising and FWEc weakly localising SPM with poor outcome. 
(see figure legend on previous page)  
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Figure 6.10 (following page): FWEp non-localising and FWEc weakly localising SPM with poor 
outcome. 
Example of a category 5, non-localising FWEp corrected SPM analysis and non and weakly localising 
FWEc analyses in a patient with poor post-operative outcome. 
Post-operative MRI scan demonstrating the location and extent of the left temporal lobe surgical resection 
(a). The SPM results are shown for the specificity optimised SPM parameters using FWEp analysis 
(column b), and the FWEc corrected analyses at uncorrected p<0.00001 (column c) and uncorrected p<0.1 
(column d). In each column the SPM results are shown as a glass brain display, then overlayed on the T1 
MRI template provided within SPM8 with the cross-hairs triangulated on the peak voxel in the supra-
threshold cluster localising to the SRZ, and lastly overlayed on the “SPM96” single subject surface 
rendered brain within SPM8. Where no supra-threshold voxels survive at the specificity optimised SPM 
parameters (in the case of this patient this occurs at the FWEp analysis and at both FWEc corrected 
analyses), the glass brain display is shown with no surviving supra-threshold voxels followed by the SPM 
results when liberalising the statistical p-value threshold and/or when not applying FWEc correction for 
multiple comparisons, as indicated. The patient’s eventual SPM topology classification for each SPM 
analysis is indicated at the foot of each column. 
 163
 
Figure 6.10: FWEp non-localising and FWEc weakly localising SPM with poor outcome. 
(see figure legend on previous page) 
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Figure 6.10 (following page): FWEp strongly non-localising, FWEc weakly-localising SPM due to 
seizure activity during FDG uptake and poor outcome. 
Example of a category 6, strongly non-localising FWEp corrected SPM analysis and weakly localising 
FWEc uncorrected p<0.1 analysis in a patient with good post-operative outcome. The patient demonstrated 
continuous epileptiform activity over the right posterior quadrant on the scalp surface EEG performed 
during the FDG uptake phase. It is suspected that in this patient the electrical seizure activity during the 
FDG uptake impaired the ability to localise the subsequent successful SRZ. 
Post-operative CT scan demonstrating the location and extent of the right temporo-parietal surgical 
resection (a). The SPM results are shown for the specificity optimised SPM parameters using FWEp 
analysis (column b), and the FWEc corrected analyses at uncorrected p<0.00001 (column c) and 
uncorrected p<0.1 (column d). In each column the SPM results are shown as a glass brain display, then 
overlayed on the T1 MRI template provided within SPM8 with the cross-hairs triangulated on the peak 
voxel in the supra-threshold cluster localising to the SRZ, and lastly overlayed on the “SPM96” single 
subject surface rendered brain within SPM8. Where no supra-threshold voxels survive at the specificity 
optimised SPM parameters (in the case of this patient this occurs at the FWEc corrected analysis at 
uncorrected p<0.1 (column d)), the glass brain display is shown with no surviving supra-threshold voxels 
followed by the SPM results when not applying FWEc correction for multiple comparisons. The patient’s 
eventual SPM topology classification for each SPM analysis is indicated at the foot of each column. 
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Figure 6.11: FWEp strongly non-localising, FWEc weakly-localising SPM due to seizure activity 
during FDG uptake and poor outcome. (see figure legend on previous page) 
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6.6 Discussion 
This chapter has demonstrated the utility of SPM in predicating that an intended SRZ 
will result in improved post-operative seizure control. The analysis has utilised the 
largest reported control dataset of dedicated FDG scans in neurologically normal children 
in conjunction with rigorous specificity optimised SPM parameters to reduce the chance 
of false positive hypo-metabolic SPM findings. Voxel-level FWEp correction for 
multiple comparison was superior to cluster-level FWEc correction and the results 
indicate the very high specificity of SPM when used in this context. Due to a relatively 
high false negative rate, only modest positive likelihood ratios and modest overall test 
performance based on ROC analysis were obtained. 
 
The differences in the pre-processing parameters and the statistical thresholds as 
determined by the specificity validation methods in Chapter 5 are the likely cause for the 
improved performance of the FEWp corrected analysis compared to the FWEc corrected 
analyses. Specificity optimised FWEc correction required increased scan smoothing 
(24mm) compared to FWEp correction (16mm). As was discussed in Chapter 5, 
increased scan smoothing may reduce the detection of small clusters of hypo-metabolism 
if the magnitude of the signal is not larger than the associated variability due to noise in 
the underlying image. Also, the reduction in of spatial precision associated with cluster-
level FWEc correction for multiple comparisons contribute to the reduced diagnostic 
performance relative to FEWp correction (see Chapter 5).  
 
The very high specificity for localising a hypo-metabolic foci to the SRZ in patients with 
a good post-operative outcome infers that pre-operative SPM analysis will be useful in 
confirming the suitability of a planned surgical resection site. A positive SPM localising 
finding would predict a very high chance of achieving a good post-operative outcome. 
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For intervention that are associated with a high cost or a carry a high risk of unwanted 
complications such as epilepsy surgery, a test with a high specificity is likely to be 
worthwhile to confirm the high likelihood of benefit. Positive localisation of the 
epileptogenic focus by SPM does not obviate the need for other neuroimaging modalities 
but may reduce the requirement for invasive intra-operative cortical mapping. Intra-
operative cortical grid assessment could be reserved for patient with FDG PET findings 
that are discordant with other imaging modalities [97]. 
 
The patient dataset had a high prevalence of good post-operative outcome, with 47/61 
(77%) of the included patients achieving Engel class 1 or 2 outcomes. Evaluating a 
diagnostic test in a cohort with a high pre-test probability of a positive reference standard 
outcome would be expected to elevate the calculated PPV [95], however the cohort of 
patients use in the analysis is likely to be representative of patients being considered for 
epilepsy surgery and therefore the predictive values of SPM are likely to be applicable to 
similar patient groups. PLR is a metric that is independent of the reference standard 
outcome prevalence in the underlying study population [95]. When applied across the 
whole paediatric epilepsy dataset a PLR of 5.4 was achieved at the optimal FWEp cut 
point (see Table 6.5). This conveys a moderate improvement in post-test probability of 
having a good post-operative outcome when localising to the SRZ [95]. Hence, SPM 
analysis following the same methodology as described in this chapter would be expected 
to perform moderately well in other groups of patients with variable prevalence of good 
post-operative outcome. An extension of this reasoning is that if there is no previous 
imaging, EEG or clinical data available to guide surgical planning in a child with 
epilepsy or if it is the first imagine modality to be performed in a child being considered 
for epilepsy surgery, then SPM analysis will perform moderately well in localising the 
epileptogentic focus. In clinical practice epilepsy surgical planning is a multi-modality 
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process and analysis of cerebral FDG scan would rarely, if ever, be the sole imaging 
modality to guide surgery [81, 82].  
 
The SN using SPM to localise the SRZ in patients with a good post-operative outcome 
was relative poor across all of the cut points. In the only other paediatric analysis 
correlating SPM findings to successful epilepsy surgery, a SN of 86% was reported in a 
cohort of 21 children with temporal lobe epilepsy when compared in a single-subject 
versus group design to 15 adult control subjects. Notably, this previous study use an 
uncorrected voxel threshold of p<0.005 with a cluster extent threshold of 100 voxels. 
These are very liberal thresholds, particularly when comparing against an adult control 
dataset where false positive findings are at high risk [60]. Also, only patients with a good 
post-operative outcome were included in the study and it is probable that the SPM 
method used by these authors would result in significant false localisation if applied to a 
group of patients that include those that may not benefit from temporal lobe resection. 
This is a realistic scenario in a clinical group of patient in whom FDG PET would be 
used. In the sub-group analysis presented in this chapter, and consisting of 16 patients 
with temporal lobe resections, the SPM analysis approached this level of SN when a cut 
point of SPM topology category 4 (non-localising) was use with the FEWp corrected 
analysis. At this cut point the improved SN (83%) came at a cost of significantly 
impaired SP (25%, ie. a high false positive rate) resulting in a non-useful PLR of 1.1 (see 
Table 6.7). Therefore, studies such as that reported by Lee et al [69] may be misleading 
in the reported performance of SPM in children with epilepsy and the analysis presented 
in this chapter has a significantly more rigorous SPM method, uses a more appropriate 
control dataset and is tested in a more similar set of patients that would undergo FDG 
PET in the clinical setting. 
 
 169
All of the other published studies in children that use a single-subject versus group SPM 
design were purely descriptive studies or compared SPM to visual assessment of FDG 
scans with no correlation to post-operative outcome [59, 60, 92, 93]. 
 
The SPM methodology employed in this chapter was a whole brain analysis assuming no 
a priori knowledge or assumptions for a predetermined epileptogenic focus. In children 
where there is a known structural cortical abnormality the SPM analysis could be limited 
to a smaller brain region. This would change the associated calculations required for 
correction for multiple comparisons within SPM (small volume correction) and may 
improve the diagnostic test performance. Similarly, normalising the voxel intensities to a 
particular brain region such as the basal ganglia or cerebellum, rather than whole brain 
mean uptake may improve the results. These analyses require more technical expansion 
of the SPM technique and are beyond the scope of this report, but provide possible 
extensions of the SPM technique using the same data in the future. 
 
A limitation of the analysis presented in this chapter is the high proportion of patients 
that did not have scalp surface EEG monitoring during the FDG uptake phase. The 
presence of sub-clinical electrical seizures or other EEG abnormalities could impair the 
ability of SPM to localise a hypo-metabolic, epileptogenic focus to guide successful 
resection surgery. In the dataset, 39/61 (64%) patients did not have an EEG performed 
during the FDG uptake phase. Of the 22 patients that did have an uptake EEG, 13/22 
(60%) had abnormal or epileptogenic activity during FDG uptake, only 4 of which had 
clinically apparent seizures. Using the most accurate FWEp analysis, the SPM 
localisation results in these 13 patients with abnormal uptake EEG findings produced 
three true positive, one false positive, seven false negative and two true negative results, 
respectively. This produces a false negative rate (ie. 1-SN) of 70%. Contamination by 
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these unidentified “ictal” patients is a plausible explanation for the high false negative 
rate (ie. low SN) that was found with SPM analysis. This conclusion is supported by the 
results when excluding patients with abnormal EEG or clinical seizures during FDG 
uptake compared to the entire dataset to show a trend for higher SN at all cut points (see 
the FWEp results in Figures 6.5 and 6.6) and the trend for a larger AUC on the ROC 
curves (see Figure 6.11). 
 
Inter-ictal cerebral FDG PET has previously been shown in children to have poor 
concordance to epileptogenic foci successfully mapped by invasive intracranial 
electrophysiological techniques and excised [98], and it has been advocated that children 
with epilepsy should not forgo surgery on the basis of a normal inter-ictal FDG PET scan 
[97]. Our findings using SPM analysis support this view based on the significant number 
of false negative SRZ localisations in patients with good post-operative outcomes (ie. 
poor sensitivity). We propose that subclinical epileptoform activity may confound the 
interpretation of the presumed inter-ictal FDG scan and reduce the sensitivity for 
identifying the hypo-metabolic epileptogenic focus. Scalp surface EEG recording during 
the FDG uptake phase is recommended in all patients to assist in interpretation of the 
scan, either by qualitative or SPM analysis methods. This notion has been opposed by 
studies that did not show significant influence of scalp surface EEG findings during FDG 
uptake on the interpretation of the FDG scan [99]. Ictal and peri-ictal status during FDG 
uptake also alter cerebral metabolic patterns and are further complicating factors [100]. 
The value of EEG monitoring during FDG uptake will vary depending on the clinical 
spectrum of the epilepsy patients under investigation and EEG monitoring may be more 
relevant in children than in adults, but this has yet to be comprehensively examined. 
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Medical conditions that have central nervous system pathologies in addition to seizures, 
such as tuberous sclerosis (TS), Sturge-Weber Syndrome and Landau-Kleffner Syndrome 
have altered patterns of cerebral metabolism as seen on FDG PET [101-104] and 
therefore mapping a hypo-metabolic focus to identify the epileptogenic zone in patients 
such as these may be less accurate. There were two patients with TS in the patient group 
investigated in this chapter, both of whom had resection of tubers suspected to be the 
epileptogenic focus. One patient had true positive localisation to the SRZ with good post-
operative outcome and the other had a false negative mislocalisation to a region remote 
to the SRZ but with good post-operative outcome. Both patients had surface EEG 
monitoring during FDG uptake. Only the false negative patient had epileptoform activity 
and a clinical seizure during uptake (see Table 6.4), which is suspected cause for the 
false negative result. The cohort analysed in this chapter also contained a child with 
Rasmussen’s Encephalitis who underwent a hemispherectomy with good post-operative 
outcome and had a strongly localising pre-operative SPM result despite having a clinical 
seizure during FDG uptake (see Table 6.4). Rasmussen’s Encephalitis has been reported 
showing increased metabolism in the affected cortex and emphasises the importance of 
determining the ictal state during FDG uptake in cases where this aetiology is suspected 
[105]. Prioritisation of surface EEG monitoring in these patients who have a higher 
likelihood of more extensively abnormal cerebral metabolic activity during FDG uptake 
is probably a useful strategy when resources for EEG monitoring are limited. 
 
Various types of cortical malformations may potentially be epileptogenic foci driving 
seizure generation in medically intractable epilepsy. FDG PET evaluation has been 
reported in small case series to show increased metabolism in cortical malformations in 
the inter-ictal state although this findings may be more apparent in neuronal heterotopias 
rather than FCD [106, 107]. Therefore there may be mechanisms other than ictal status 
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that determine the metabolic characteristics of epileptogenic foci related to cortical 
malformations. Concurrent drug therapy in epilepsy can alter cerebral FDG uptake and 
these effects are also a potential cause for determining the performance of inter-ictal 
FDG PET in identifying the epileptogenic focus [64, 108]. These effect of these potential 
confounders on inter-ictal FDG PET requires further clarification in paediatric epilepsy 
and will not be overcome by statistical analysis methods such as SPM. 
 
Hypo-metabolism on FDG PET distant to the epileptogenic focus in medically 
intractable paediatric epilepsy has been previously described [90]. So-called “remote” 
hypo-metabolism could relate to cortical or sub-cortical networks linked to the 
epileptogenic zone, particularly involving the thalami and basal ganglia and may relate to 
the chronicity of the epilepsy or the frequency of secondary generalisation [109, 110]. 
These factors therefore could impact on the ability of inter-ictal FDG PET to strongly 
localise a hypo-metabolic epileptogenic focus, particularly when using the categorisation 
of the output SPM maps described in this chapter. 
 
6.7 Conclusion 
This chapter described the SPM analysis of the largest cohort of paediatric patients with 
medically intractable epilepsy and uses as the comparison group the largest group of 
reported dedicated cerebral FDG PET scans in neurologically normal children. The study 
is the only SPM analysis in children to determine the diagnostic test accuracy to predict 
post-operative outcome and found that voxel-level FWEp correction for multiple 
comparisons is the most accurate SPM technique. At optimum SPM settings there is a 
high specificity for predicting if the proposed SRZ will result in a good post-operative 
outcome but a low sensitivity may be attributed to unknown ictal status during FDG 
uptake, the diverse mix of histopathology results and concurrent medication. 
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7 CHAPTER SEVEN: SUVMAX AND QUALITATIVE 
ANALYSIS OF CEREBRAL FDG UPTAKE IN 
CHILDREN WITH NEUROFIBROMATOSIS 
TYPE 1 
7.1 Abstract 
Aims: The four published studies investigating cerebral FDG uptake in patients with 
Neurofibromatosis Type 1 (NF1) have all suggested thalamic hypo-metabolism. This has 
not been comprehensively determined in children with NF1. The aim of this chapter is to 
use semi-quantitative (SUV) and qualitative methods to determine differences in cerebral 
FDG distribution between children with NF1 compared to unaffected children. 
 
Methods: The cerebral FDG scans in 41 children with NF1 were compared to the 30 
scans in normal control dataset (see Chapters 3 and 4). FDG uptake was analysed by 
SUVmav measurement in five regions and qualitatively by relative uptake (RU) 
compared to maximal cortical uptake in eight regions. Linear regression modelling was 
used to determine if there was a significant independent effect of patient group (normal 
control or NF1) independent of patient age on regional FDG uptake in each region. 
 
Results: After allowing for the effect of age on FDG uptake, the SUVmax analysis 
revealed that children with NF1 have reduced FDG uptake in the thalami, bilaterally 
compared to unaffected children. The qualitative analysis showed reduced FDG RU in 
the thalami, medial temporal lobes and occipital lobes bilaterally; and in the left 
cerebellum. 
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Conclusions: This chapter reports the findings of the analysis of the largest cohort of 
cerebral FDG scans in children compared to a large dataset of FDG scans in unaffected, 
neurologically normal children. The findings confirm the presence of thalamic hypo-
metabolism shown in smaller previous publications, and reveal new findings of hypo-
metabolism in the medial temporal and occipital lobes, and the left cerebellum. It 
remains unclear if the hypo-metabolic regions relate to cognitive dysfunction and/or the 
presence of T2H on MRI scans. Further research is required to correlate metabolic 
derangements such as those seen on the FDG scans presented in this chapter to MRI 
abnormalities and measures of neurocognitive function in children with this common 
genetic disorder. 
 
7.2 Introduction 
7.2.1 Neurofibromatosis Type 1 and Neuro-Cognitive Impairment 
Neurofibromatosis type 1 (NF1) is a common genetic disorder with a prevalence of 
approximately 1 in 3500. Cognitive defects are the most common neurological 
manifestation of NF1 [111, 112] occurring in up to 81% of patients typically affecting 
the domains of perceptual skills, executive functioning and attention as well as overall 
intellectual ability [113]. NF1 is associated with a shift to the left in full scale IQ (FSIQ) 
with a mean in the low 90s (compared to mean of 100 in the general population). 
Consequently there is a slightly higher frequency of intellectual impairment (FSIQ <70) 
in patients with NF1 (6-8% compared to 3% in the general population)[113]. Cognitive 
deficits result in academic learning difficulties in over half of patients with NF1 [114] 
and contribute to the significant morbidity associated with this condition. As such, the 
pathogenesis and biological correlates of these neurocognitive deficits in patients with 
NF1 is an area of active research. 
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7.2.2 Central nervous system abnormalities in NF1 
NF1 is associated with several structural central nervous system abnormalities including 
macrocephaly, increased cross-sectional area of the corpus callosum, optic pathway 
tumours and a predisposition to develop other primary brain tumours. There are other 
radiologic abnormalities commonly seen on cerebral MRIs in patients with NF1 which 
are well characterised and typically involve T2 hyper-intense lesions (T2H) located in the 
deep white matter and in various subcortical grey matter locations.  The pathogenesis and 
biological nature of T2H are largely unknown. Their natural history appears to be 
variable and may be related to their location [115, 116]. T2H in the basal ganglia, 
brainstem and cerebellum appear to resolve by early adulthood although lesions in the 
cerebral cortex and deep white matter tend to remain, and infrequently progress [116]. 
There have been a number of studies exploring the association between T2H and 
cognitive function in patients with NF1 and although results have been mixed and at 
times conflicting, more recent studies have agreed that there is an association between 
T2H lesions in the thalamus and neurocognitive deficits [117-120]. 
 
7.2.3 Cerebral FDG PET studies in patients with NF1 
Studies using cerebral FDG PET to investigate cerebral metabolism in patients with NF1 
are sparse. To date four published studies exist, three of which included pediatric patients, 
and although limited by small study samples and methodological issues primarily 
associated with an inaccurate comparative group, all raise the possibility of thalamic 
hypo-metabolism as a consistent finding with variable cortical hypo-metabolism in 
patients with NF1 [67, 121-123]. 
 
 177
Balestri and coworkers described cerebral FDG PET appearance in four patients with 
NF1 and attempted to correlate PET findings with MRI, cognitive function and seizures 
[121]. The patients with NF1 were aged 9, 11, 15 and 20 years of age. Their IQ ranged 
from 49-89, and all had language delay and learning disability ranging from mild to 
severe and some had seizures. Three of the NF1 patients had the presence of MRI T2H 
lesions in the splenium of the corpus callosum, internal capsule, globus pallidus, striatum, 
pons and cerebellar white matter. FDG PET abnormalities were determined by 
comparison to a control group of nine patients aged between 10-20 years who underwent 
whole body FDG PET CT for “mild forms of various neurological disturbances”: five  
patients had epilepsy, two had “mild cognitive developmental disability”, one had 
headache and one had spinal amyotrophy. The authors describe these “normal” patients 
as all having cerebral MRI scans that were either normal or with “aspecific 
abnormalities…such as mild enlargement of the subarachnoid spaces or ventricles.” The 
FDG PET CT scans were performed with an arterial sampling catheter placed in the 
radial artery allowing timed arterial blood sampling at intervals throughout the scanning 
procedure. Invasive arterial sampling for plasma glucose and FDG concentration in 
combination with the imaging findings allowed the derivation of an input function and 
subsequent quantification of regional FDG uptake. The regional cerebral metabolic rate 
of glucose (rCMRglc) utilisation, measured in mg/100/min, was used to compare NF1 
patients to the control subjects. Two-dimensional 9.6mm circular regions of interest were 
manually drawn through the slices of 13 cortical, sub-cortical and cerebellar structures 
identified on the PET scan in reference to a cerebral PET imaging atlas [124]. The mean 
rCMRglc in each structure was determined by averaging the values obtained from the 
multiple 2D regions of interest included in each anatomical region. To overcome the 
difference in age between the 2 groups of patients and with a-priori assumption of a 
normal decline in whole brain rCMRglc that occurs with age [16], the authors fitted a 
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straight line to the values of rCMRglc obtained from each region in the control group. 
This extrapolated linear relationship between regional rCMRglc and age was used to 
visually compare the regional glucose metabolism in the NF1 group. While this linear 
decrease in rCMRglc has been previously reported it was in the context of overall brain 
rCMRglc and the assumption that this relationship applies to specific regions of the brain 
is questionable. 
 
The study showed inconsistent patterns of cortical hypo-metabolism in all of the NF1 
patients that did not appear related to the severity of cognitive impairment or presence of 
T2H lesions on MRI. Three out of the four NF1 patients had thalamic rCMRglc lower 
than was predicted for their age by the control group. Due to the very small number of 
subjects no statistical measures of significance were possible. 
 
Kalpan examined FDG PET in 10 children with NF1 aged 4-15 years, and compared 
them to a control group consisting of five normal adult volunteers and four children 
without NF1 [123]. The four children in the control group were scanned to evaluate a 
brain tumour in three cases and intracranial hypertension in one case. The authors justify 
combining adults and children in their analysis by stating that there was no statistical 
difference between these groups, but the small sample size would likely have made this 
analysis significantly underpowered. The primary objectives of this study were to 
evaluate metabolic activity in T2H lesions and to look for abnormalities on FDG PET 
specific for children with NF1. In this study there was no blood sampling undertaken 
during the scan to allow quantification of tracer uptake. Instead, the authors created 
relative measures of tracer uptake to investigate the metabolic activity in T2H lesions, 
thalamus and striatum. Mean pixel values in focal areas of T2H, the thalamus and 
striatum were calculated by manually placing two-dimensional regions of interest drawn 
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“well within the boundaries” of each structure seen on the MRI images. This was 
performed on each image slice for those structures seen over several contiguous slices. 
These regions were then transferred to the patient’s co-registered PET images. The mean 
pixel value on the PET scan in each defined region was compared to both the whole brain 
(after thresholding the image to 33% of whole brain maximal uptake) and the striatum to 
create a “regional cerebral metabolic rate for glucose index”. None of the patients had 
T2H within the thalamus.The tracer uptake index in the largest focal areas of T2H in 
each subject were also compared to the uptake index in adjacent normal tissue within the 
same structure, for example, the brain stem, pallidum or white matter. Metabolic activity 
in the thalami relative to both the striatum and whole brain was calculated in a similar 
fashion.  
 
Regional cortical metabolism was also assessed for inhomogeneity. A qualitative 
assessment was performed by each scan being interpreted by two people independently 
who rated regional cortical tracer distribution on a four point Likert scale (0 = normal, 1 
= mild, 2 = moderate, 3 = marked inhomogeneity). No assessment of the inter-rater 
reliability of this method of analysis was presented and the authors did not state that the 
readers were blinded to the patient group (NF1 or control) when assessing the scans. 
Cortical inhomogeneity was quantified for each patient and control subject by calculating 
an index “utilising a spatial standard deviation of FDG-PET counts over the whole 
brain…and transformed to the stereotactic coordinate space.” No further technical 
information is given by the authors in regards to the computer program or the 
transformation parameters used in this calculation. All subjects also had brain MRI 
imaging and 9/10 NF1 patients had formal neuropsychological testing. 
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The authors found that in the children with NF1, T2H had a lower cerebral metabolic rate 
for glucose than adjacent normal tissue and when compared to their control group, 
children with NF1 had lower regional cerebral metabolic rate for glucose indices in the 
thalami (reduced by approximately 35%), both when indexed against the striatum or the 
whole brain metabolic rate for glucose. 
 
Statistical comparison of the qualitative measures of cortical inhomogeneity between 
NF1 and controls was not presented. Quantified cortical inhomogeneity between the two 
groups showed a significant difference with p=0.04 using an un-paired t-test with pooled 
variances, but only when adjusted for total counts. Parametric tests of statistical inference, 
as were used in this study, may be considered inappropriate for the small sample size of 
10 subjects and nine controls. When adjusted for total counts there was no statistical 
difference in homogeneity between the two groups. The authors suggest that this 
apparent count dependent inhomogeneity may reflect lower counts in the scans of 
children with NF1, but they did nothing to compare overall counts between the 2 groups 
or adjust for possible confounding variables such as age, sex, neurocognitive function or 
presence of T2H which they had already established as having reduced tracer uptake 
compared to normal brain structures. 
 
Overall, this study by Kaplan and coworkers suggests the thalamus may be hypo-
metabolic in children with NF1 but they lacked a suitable control group for comparison. 
Their analysis of cortical inhomogeneity has methological issues although suggests that 
children with NF1 have reduced uptake and increased heterogeneity in cortical FDG 
uptake. 
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There are also technical details of the PET scan acquisition described in previous reports 
and relate to improvements in scanner instrumentation and software that have occurred 
since these previous publications. Notably, the reports described above used methods of 
attenuation correction utilising a Ge68/Ga68 transmission source [121] and a fixed 
attenuation coefficient [123]. Modern systems use hybrid PET CT machines and make 
use of a concurrently acquired low dose or diagnostic quality CT scan to provide 
measured attenuation from which to apply in reconstruction of the FDG PET scan. Both 
of these studies also used filtered back projection reconstruction as opposed to iterative 
reconstruction methods that is now standard in modern PET CT systems. 
 
The major criticism of the above studies that attempt to describe abnormalities in 
cerebral FDG uptake in paediatric patients with NF1 are the validity of their comparative 
group, allowing for age related changes in cerebral FDG uptake and the small sample 
sizes. Both studies used as their control group children that underwent cerebral FDG PET 
CT imaging to evaluate neurological disturbance, the majority having a seizure disorder. 
In Chapter 3 it was shown that there are changes in regional cerebral FDG uptake that 
occur throughout childhood that warrant either using age matched data or applying a 
method to adjust for different age distributions between the groups of patients being 
compared. To accurately define abnormalities in cerebral FDG scans, adjusting for the 
effect of age and the use of controls subject without a neurological condition should be 
employed. No comparative studies in children with NF1 have been published which fulfil 
these two criteria. 
 
Despite their limitations, these two previous studies suggest that children with NF1 may 
have reduced thalamic glucose metabolism compared to children without NF1 and 
variable degrees of cortical hypo-metabolism elsewhere. In addition to these studies by 
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Balestri and Kaplan, two further papers have been more recently published and attempt 
to use statistical parametric mapping (SPM) techniques to analysis adult [122] and 
paediatric [67] patients with NF1, compared with locally accrued normal control datasets. 
Both of these SPM reports suggest thalamic hypo-metabolism in NF1 compared to the 
non-NF1 control datasets. A detailed description and critique of these papers are 
presented in the next chapter (Chapter 8) where SPM methodology is applied to the 
current dataset of NF1 patients and normal control subjects. 
 
7.3 Aims 
The aim of this chapter was to evaluate cerebral FDG uptake in paediatric patients with 
NF1. The hypothesis was that there is reduced FDG uptake in the thalami compared to 
unaffected children. 
 
7.4 Methods 
Approval for this retrospective study was obtained from the hospital human research 
ethics committee. 
 
7.4.1 Control subjects 
The control subjects forming the comparative group was the same group as that 
described in Chapter 3. Briefly, the normal control dataset was recruited from the 
dedicated cerebral FDG scan performed as part of a whole body scan in children being 
staged for suspected or proven extra-cranial solid tumours, with no evidence of cerebral 
metastasis, no neurological disorders, not on anti-epileptic medications and without a 
general anaesthetic within 24 hours prior to the FDG PET CT scan. The dedicated 
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cerebral scan was considered to represent a normal cerebral FDG PET scan for a child of 
their age. 
 
7.4.2 NF1 patients 
A retrospective review of cerebral FDG PET CT scans performed in children with NF1 
was undertaken. A search was conducted of the electronic database of all PET CT scans 
performed at The Children’s Hospital at Westmead during the four year review period 
starting from the commencement of the FDG PET CT service in June 2006 until July 
2010. All dedicated cerebral FDG PET CT scans were extracted and crosschecking 
clinical information contained within each patient’s electronic medical record identified 
children with NF1. 
 
7.4.3 PET CT imaging 
Children fasted for 4–6 hours and had blood glucose levels confirmed to be within the 
normal range before injection of 370 MBq of FDG scaled to body surface area using a 
weight based nomogram. During an approximate 30-minute uptake period, the children 
rested in a dimly lit room, supine and with minimal stimulation. A 15 minute dedicated 
brain acquisition was performed followed by a whole body scan acquisition from the 
base of brain to toes. 
 
PET CT acquisition was performed on a Siemens Biograph16 HiRez PET-CT scanner 
(Siemens Medical Solutions, Erlangen, Germany) with field of view of 500mm in width 
and 160mm in axial length. CT attenuation correction was used with a source rotation 
speed of 0.5 sec/rotation at 80 kV. Siemens proprietary CT dose modulation protocol 
(“Caredose”) was used to modulate the CT tube current from a maximum of 100 mA. 
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All PET CT scans were decay corrected and reconstructed using an iterative 
reconstruction algorithm based on ordered-subset expectation maximization (OSEM; 8 
iterations, 16 subsets) with scatter correction and measured attenuation correction. 
OSEM images underwent a 4.1 mm full-width-at-half-maximum Gaussian post 
smoothing. The reconstructed cerebral FDG PET CT scans were reviewed on a Siemens 
e.soft workstation (Siemens Medical Solutions, Erlangen, Germany). 
 
7.4.4 Semi-Quantitative, SUVmax analysis 
Maximal standardized uptake values (SUVmax) were extracted from the PET CT scans 
using a three-dimensional ellipsoid volume of interest (VOI) with an isocontour 
threshold set at SUV 2.5. the VOI was manually placed individually around the caudate 
head, putamen and thalamus, bilaterally. The location of the resulting thresholded 
volume was confirmed by visual assessment in all three planes (transaxial, coronal and 
sagittal) to accurately outline the structure being analysed. In a similar manner, white 
matter SUVmax was sampled from the centrum semiovale taking care to avoid the grey 
matter of the adjacent cerebral cortex and subcortical nuclei. White matter VOIs were 
situated more anterior or posterior allowing for the different sulcal patterns of the 
adjacent parietal cortex in different patients. The cerebellum was analysed by manually 
moving the ellipsoid VOI through the cerebellar grey matter to obtain the SUVmax in 
each cerebellar hemisphere. A total of five different regions were analysed bilaterally in 
the regional SUVmax analysis: the caudate head, putamen, thalamus, white matter and 
cerebellum (see Figure 7.1). 
 
  
  
Figure 7.1: The five regions used in the regional SUVmax analysis. 
 
Due to the large and irregular spatial profile encompassed by the cerebral cortex, using 
an ellipsoid VOI tool to sample regional cortical SUV data was not able to reliably 
represent tracer uptake in each lobe. Therefore, regional SUVmax analysis of the cerebral 
cortex was not performed, but the cerebral cortex was considered in the regional relative 
uptake (RU) analysis described below. 
 
7.4.5 Qualitative, relative uptake analysis 
Each scan was de-identified and coded with a randomly generated patient identification 
number. Three readers who were all qualified paediatric nuclear medicine physicians 
assessed each scan independently. The readers were blinded to patient details including 
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age, group (either NF1 or normal control group), indication for the scan and the results of 
the other readers. 
 
The readers were instructed to view each scan using a ten-step colour scale thresholded 
to maximum cerebral cortical uptake.  Each reader was then required to assess and record 
the intensity of tracer uptake in 8 specified anatomical regions. The eight regions 
assessed bilaterally were: the frontal lobe, medial temporal lobe, lateral temporal lobe, 
parietal lobe, occipital lobe, cerebellum, thalamus and basal ganglia (caudate head and 
putamen; the striatum). These particular regions were selected for analysis because they 
can be well defined visually on cerebral FDG PET CT scans (see Figure 7.2). The 
intensity of tracer uptake was recorded that best represented of the overall degree of FDG 
uptake within each region and expressed as a percentage relative to the maximal cortical 
uptake in 10% increments (ie. 0%, 10%, 20%...80%, 90%, 100%). 
 
It was shown in Chapter 3 that using this method there is good inter-reader agreement in 
the assignment of regional relative uptake (RU). As was done in Chapter 3, the mean 
regional RU of the three readers was used in the statistical analysis. 
 
Figure 7.2: The eight regions used in the RU analysis. 
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7.4.6 Statistical analysis 
All statistical analysis was carried out using SPSS v22 (IBM). Scatterplots were 
produced using Microsoft Excel (Microsoft Office 2010). 
 
It was shown in Chapter 3 that in normal subjects there is a positive linear association 
between age and SUVmax in all regions analysed; a negative linear association between 
age and RU in the parietal, lateral temporal, medial temporal and occipital lobes; and no 
relationship between age and RU in the other regions. Scatterplots of the data were also 
produced and inspected. Hypothesis testing for the evidence of a significant effect of the 
variable “Group” (ie. normal control subjects or NF1 patients) while adjusting for the 
effect of age was undertaken using multiple linear regression modelling. t-tests on the 
regression coefficients were performed to determine the evidence of independent linear 
associations between FDG uptake (SUVmax or RU) and age, and FDG uptake and group 
with p<0.05 as the cut point for statistical significance. In the linear regression models, 
the predictor variable “Group” was coded as 1 for NF1 patients and 2 for normal control 
subjects. Therefore the resulting coefficient for the variable “Group” relates to the 
change in the outcome variable (either SUVmax or RU) associated with the normal 
control group compared to the NF1 group. The adjusted R2 values for the multiple 
regression of FDG uptake (measured by both SUVmax and RU) on age and group were 
compared to the adjusted R2 values using a univariate linear model with age as the only 
predictor variable, as another measure of the benefit of adding group to the model.  
7.5 Results 
7.5.1 Control subjects 
As mentioned in the Methods section, the normal controls subjects used as the 
comparative group for the SUVmax analysis and RU analysis were the same as described 
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in Chapter 3. The age of the normal control subjects ranged from 11 months to 16 years 
(mean age10.4 years). 
 
7.5.2 NF1 patients 
There were 65 dedicated cerebral FDG scans performed in 49 children with NF1 during 
the study period. Thirty-eight patients had only one scan, seven patients had two scans, 
three patients had three scans and one patient had four scans. For the patients with 
multiple scans during the study period, only the first scan was included leaving 49 scans 
in 49 patients. From these 49 patients, eight were excluded because they were beyond of 
the age range of the normal controls subjects. These eight excluded NF1 patients were 
aged 18.7, 18.7, 19.3, 19.5, 19.6, 20.7, 22.6 and 37.2 years old. There remained 41 scans 
in 41 NF1 patients included in the SUVmax and RU analysis. The clinical indications for 
the scans are shown in Table 7.1. The patients undergoing assessment of MRI T2 
hyperintense lesions had various locations involved with T2 hyperintensities commonly 
found in patients with NF1. None of the patients had received prior chemotherapy or 
previous neurosurgery. The age distribution of the included NF1 patients and normal 
control subjects are displayed in Figures 7.3 and 7.4, respectively. 
 
Table 7.1: Indication for the FDG PET CT scan of the 41 included cerebral FDG PET scans in the 
NF1 patient group. 
No of scans Clinical Indication 
16 Assessment of optic pathway gliomas 
13 Assessment of extra-cranial plexiform neurofibromas 
  6 Assessment of MRI T2 hyperintense cerebral lesions 
  3 Assessment of optic pathway gliomas and extra-cranial plexiform neurofibromas 
  1 Assessment following excision and regional radiotherapy of an extracranial 
MPNST* 
  1 Staging of an abdominal extra-adrenal adrenocortical carcinoma (no metastases) 
  1 Assessment of a cranio-facial plexiform neurofibroma 
* MPNST: malignant peripheral nerve sheath tumor 
 
  
 
 
Figure 7.3: Age histogram of the included NF1 patients. 
 
 
 
 
Figure 7.4: Age histogram of the normal control subjects. 
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7.5.3 Regional SUVmax analysis 
Scatterplots of regional SUVmax against age for the normal control subjects and the NF1 
patients in each region are shown in Figure 7.5. The corresponding statistical output of 
the univariate linear regression of SUVmax on age for each group in each region is 
presented in Table 7.2.  From the scatterplots there appears to be a positive linear 
association between age and SUVmax in all of the subcortical grey matter regions and 
the cerebellum for both the normal control and NF1 groups. The linear regression lines 
are closely overlapping in all regions except for the thalamus where although the slope of 
the regression line is similar, the NF1 patients appear to have lower SUVmax than the 
normal control subjects across the age range. These findings are supported by the linear 
regression output results where both the NF1 and control groups showed evidence of 
increasing SUVmax with age (p<0.001) in all grey matter regions. In the white matter, 
SUVmax was less than the other regions, as expected, although there remained evidence 
of increasing SUVmax with age in the left white matter for both groups (p=0.021 in the 
control group and p=0.016 in the NF1 group) and in the right white matter in the control 
group (p=0.013) but not in the NF1 group (p=0.059). 
 
 
 
 
 
Figure 7.5 (following page): Scatterplots of SUVmax against age in the NF1 group and control 
group, in all the regions analysed. 
The linear regression line is included in each graph, except for the right white matter data for the NF1 
group where there was no evidence of a linear association of SUVmax to age (in this case the mean 
SUVmax for the NF1 group was plotted across the age range). Increasing SUVmax with age is seen in all 
of the subcortical grey matter regions and the cerebellum. The regression lines closely overlap in all 
regions except the left and right thalamus where there apeared to be lower SUVmax in the NF1 groups 
across the age range. 
* indicates the regions where there was statistical evidence of an independent effect of group on SUVmax 
based on the multiple linear regression based hypothesis testing (see Table 7.3). 
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Figure 7.5: Scatterplots of SUVmax against age in the NF1 group and control group in all the regions 
analysed. (see figure legend on previous page)  
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Table 7.2: Statistical output of the univariate linear regression of SUVmax on age in the five regions 
analysed. 
The results for the normal control subjects and the NF1 patients are separated and shown for each region. 
There is evidence of a positive linear relationship between SUVmax and age in all regions except in the 
right white matter for the NF1 group where p=0.059. 
Dependent 
Variable Group 
Age 
Coefficient 
Std 
Error 
Age Standardized 
Coefficient T statistic P value R R
2 
Right WM Control 0.072 0.027 0.448 2.653 0.013* 0.448 0.201 NF1 0.061 0.031 0.297 1.944 0.059 0.297 0.088 
Left WM Control 0.057 0.023 0.418 2.436 0.021* 0.418 0.175 NF1 0.079 0.031 0.373 2.512 0.016* 0.373 0.139 
Right 
Thalamus 
Control 0.371 0.072 0.696 5.126 <0.001* 0.696 0.484 
NF1 0.320 0.062 0.638 5.173 <0.001* 0.638 0.407 
Left 
Thalamus 
Control 0.364 0.070 0.703 5.232 <0.001* 0.703 0.494 
NF1 0.314 0.062 0.632 5.090 <0.001* 0.632 0.399 
Right 
Caudate 
Control 0.389 0.083 0.664 4.699 <0.001* 0.664 0.441 
NF1 0.383 0.086 0.582 4.467 <0.001* 0.582 0.338 
Left 
Caudate 
Control 0.400 0.091 0.639 4.398 <0.001* 0.639 0.409 
NF1 0.413 0.086 0.612 4.829 <0.001* 0.612 0.374 
Right 
Putamen 
Control 0.371 0.088 0.624 4.221 <0.001* 0.624 0.389 
NF1 0.373 0.087 0.564 4.267 <0.001* 0.564 0.318 
Left 
Putamen 
Control 0.400 0.088 0.650 4.530 <0.001* 0.650 0.423 
NF1 0.402 0.084 0.607 4.775 <0.001* 0.607 0.369 
Right 
Cerebellum 
Control 0.305 0.056 0.720 5.484 <0.001* 0.720 0.518 
NF1 0.281 0.063 0.580 4.442 <0.001* 0.580 0.336 
Left 
Cerebellum 
Control 0.333 0.058 0.737 5.768 <0.001* 0.737 0.543 
NF1 0.295 0.058 0.630 5.069 <0.001* 0.630 0.397 
* Group (NF1 or Control) where there is evidence of a linear relationship between regional 
SUVmax and age at p<0.05. 
 
The scatterplots show generally more variability around the linear regression lines in the 
NF1 patients compared to the normal control subjects. The univariate regression 
correlation coefficients (R in Table 7.2, equivalent to the Pearson’s correlation 
coefficient) and the R2 values are consistently lower for the NF1 group compared to the 
control group in all regions also indicating that the data for NF1 have more variability 
about the linear regression line and the univariate linear models explain less of the 
relationship between SUVmax and age, than the control group. 
 
Table 7.3 shows the statistical output of the multiple linear regression of SUVmax on age 
and group for each region. There is evidence of an independent effect of group (higher 
SUVmax in the normal controls compared to NF1), after adjusting for the effect of age in 
the thalamus bilaterally (p=0.009 in the right thalamus and p=0.004 in the left thalamus). 
There was no evidence of an independent effect of group on SUVmax in the other 
regions analysed. 
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Table 7.3: Statistical output of the multiple linear regression of SUVmax on age and group in the five 
regions analysed. 
In the multivariate modelling there is evidence of an independent positive linear association between 
SUVmax and age in all regions; and an independent effect of group on SUVmax in the right and left 
thalamus (right thalamus p=0.009, left thalamus p=0.004). In the model, the predictor variable group was 
coded as NF1 = 1 and Control = 2, therefore the group coefficient indicates the change in predicted 
SUVmax in the control group compared to the NF1 group after adjusting for the effect of age. Linear 
modelling suggested the increase in SUVmax in the control group compared to the NF1 group was 1.100 in 
the right thalamus and 1.190 in the left thalamus, after adjusting for the effect of age. 
Dependent 
Variable 
Predictor 
Variables 
Variable 
Coefficient 
Std 
Error 
Standardized 
Coefficient T statistic P value R R
2 
Right WM Age 0.066 0.021 0.358 3.154 0.002 0.374 0.140 Group 0.116 0.184 0.072 0.632 0.529 
Left WM Age 0.069 0.020 0.384 3.402 0.001 0.388 0.151 Group 0.044 0.177 0.028 0.251 0.803 
Right 
Thalamus 
Age 0.344 0.047 0.637 7.357 <0.001 0.706 0.499 Group 1.100 # 0.409 0.233 2.687 0.009 * 
Left 
Thalamus 
Age 0.338 0.046 0.632 7.362 <0.001 0.712 0.507 Group 1.190 ^ 0.402 0.254 2.963 0.004 * 
Right 
Caudate 
Age 0.386 0.060 0.621 6.468 <0.001 0.619 0.383 Group -0.125 0.523 -0.023 -0.240 0.811 
Left 
Caudate 
Age 0.407 0.062 0.628 6.580 <0.001 0.626 0.392 Group -0.068 0.542 -0.012 -0.125 0.901 
Right 
Putamen 
Age 0.372 0.062 0.594 6.023 <0.001 0.591 0.349 Group -0.185 0.541 -0.034 -0.341 0.734 
Left Putamen Age 0.401 0.060 0.631 6.627 <0.001 0.627 0.394 Group -0.197 0.530 -0.035 -0.372 0.711 
Right 
Cerebellum 
Age 0.292 0.043 0.644 6.859 <0.001 0.641 0.411 Group -0.075 0.373 -0.019 -0.201 0.842 
Left 
Cerebellum 
Age 0.313 0.041 0.679 7.638 <0.001 0.686 0.471 Group 0.176 0.359 0.044 0.491 0.625 
* Regions where there is evidence of an independent effect of group (ie. increased in the control 
group compared to the NF1 group) at p<0.05. 
# The group coefficient predicting a right thalamic SUVmax increase of 1.100 in the Control group 
compared to the NF1 group after adjusting for the effect of age. 
^ The group coefficient predicting a left thalamic SUVmax increase of 1.190 in the Control group 
compared to the NF1 group after adjusting for the effect of age 
 
Table 7.4 shows the statistical output for the univariate linear regression of age on 
regional SUVmax (including all data from both groups) and there is evidence of a 
positive linear association between age and SUVmax in all regions. Table 7.5 shows the 
comparison of the adjusted R2 values for the univariate regression models including only 
age and the adjusted R2 values for the multivariate regression models that include both 
age and group as predictor variables. It is apparent that in both the right and left thalamus 
there is evidence of an improved model when group is added to age as another predictor 
variable. With group in the model the adjusted R2 value increased in the linear regression 
models for the right and left thalamus (by 0.046 and 0.057, respectively), but did not 
increase in any other region. 
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Table 7.4: Statistical output of the univariate linear regression of SUVmax on age in the five regions 
analysed, including all data from both the normal control subjects and NF1 patients. 
In all regions there is evidence of a positive linear relationship between age and SUVmax. Comparison is 
made to the multivariate linear models that included group as a predictor variable; to test the hypothesis 
that group has an independent effect on SUVmax after adjusting for age (see Table 7.3). 
Dependent 
Variable 
Predictor 
Variables Coefficient 
Std 
Error 
Standardized 
Coefficient T statistic P value R R
2 
Right WM Age 0.068 0.021 0.367 3.279 0.002 * 0.367 0.135 
Left WM Age 0.069 0.020 0.387 3.488 0.001 * 0.387 0.150 
Right 
Thalamus Age 0.360 0.048 0.668 7.447 <0.001 * 0.668 0.446 
Left 
Thalamus Age 0.356 0.048 0.666 7.410 <0.001 * 0.666 0.443 
Right 
Caudate Age 0.384 0.059 0.618 6.537 <0.001 * 0.618 0.382 
Left 
Caudate Age 0.406 0.061 0.626 6.668 <0.001 * 0.626 0.392 
Right 
Putamen Age 0.370 0.061 0.590 6.070 <0.001 * 0.590 0.348 
Left 
Putamen Age 0.398 0.060 0.626 6.677 <0.001 * 0.626 0.392 
Right 
Cerebellum Age 0.291 0.042 0.641 6.940 <0.001 * 0.641 0.411 
Left 
Cerebellum 
Age 0.315 0.040 0.685 7.812 <0.001 * 0.685 0.469  
* Regions where there is evidence of a linear relationship between regional SUVmax and age at 
p<0.05. 
 
 
Table 7.5: Comparison of the adjusted R2 values from the linear regression models with and without 
group as a covariate. 
The adjusted R2 value from the multivariate model (with age and group as covariates) was greater than the 
univariate model (with age as the only predictor variable) in the right and left thalamus, but not in any 
other region. This provides evidence that patient group (normal control subject or NF1 patient) is a 
significant independent variable in predicting SUVmax in the thalamus in addition to patient age. There 
was no evidence that patient group was an independent predictor of SUVmax in any other region. 
Dependent Variable 
Univariate Adjusted R2 
(age as the only predictor 
variable) 
Multivariate Adjusted R2 
(age and group included 
as predictor variables) 
Change in 
Adjusted R2 
Right WM 0.122 0.115 -0.007 
Left WM 0.138 0.126 -0.012 
Right Thalamus * 0.438 0.484 0.046 
Left Thalamus * 0.435 0.492 0.057 
Right Caudate 0.373 0.365 -0.008 
Left Caudate 0.383 0.374 -0.009 
Right Putamen 0.339 0.330 -0.009 
Left Putamen 0.384 0.376 -0.008 
Right Cerebellum 0.403 0.394 -0.009 
Left Cerebellum 0.462 0.456 -0.006 
* Regions where there is evidence of an independent effect of group (ie. increased in the normal 
control group compared to the NF1 group) at p<0.05, on the multivariate linear regression model. 
 
 
Both the visual inspection of the scatterplots and the results of the linear regression based 
hypothesis testing indicate that there is an effect of group on thalamic SUVmax, 
independent of age. Patients with NF1 have lower thalamic SUVmax than the normal 
control subjects across the age range studied. 
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7.5.4 Regional RU 
Figure 7.6 shows the scatterplots of RU against age for the normal control subjects and 
the NF1 patients in each region. The statistical output of the univariate linear regression 
of RU on age for each group in each region is presented in Table 7.6. Where there was 
evidence of a linear association between age and RU the linear regression line has been 
plotted on the scatterplot. If no evidence of an association exists then the mean RU has 
been plotted on the scatterplot.  
 
The scatterplots show that in most regions the NF1 group and the normal control group 
share similar patterns of RU between different regions and share a similar relationship of 
RU to age. These relationships between regional RU in each group can be summarised as 
follows and correlate to the findings from Chapter 3, which more comprehensively 
discuss the results in the normal control group: 
1. The most intense RU occurs in the basal ganglia and frontal lobes with no change 
with age. 
2. Less intense RU in the thalamus but also no change with age. 
3. A negative linear association between RU and age in the parietal and occipital 
lobes (albeit not evident in the left parietal lobe in the NF1 group where there was 
more scatter in the RU data (see Discussion)). 
4. No change with age or a small negative linear association with age in the lateral 
and medial temporal lobes. 
5. No change with age in the cerebellum (with a small positive linear association 
between RU and age in the left cerebellum in the NF1 group where the was more 
scatter in the RU data in the younger patients (see Discussion)). 
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Figure 7.6 (following page): Scatterplots of RU against age in the NF1 group and control group, in 
all the regions analysed. 
Where there is evidence of a linear association between age and RU the linear regression line has been 
plotted on the scatterplot and if no evidence of an association exists then the mean RU have been plotted 
on the scatterplot (see results in Table 7.6). Visually there is reduced RU in the left and right thalamus in 
the NF1 group compared to the normal control group across the age range. Less markedly reduced RU in 
the NF1 group (but still significant based on multiple linear regression hypothesis testing; see Table 7.7) is 
seen in the left and right medial temporal lobes, left and right occipital lobes and left cerebellum. 
* indicates the regions where there was statistical evidence of an independed effect of group on RU based 
on the multiple linear regression based hypothesis testing (see Table 7.7). 
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Figure 7.6: Scatterplots of RU against age in the NF1 group and control group, in all the regions 
analysed. (see figure legend on previous page)  
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(Figure 7.6 continued)  
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Table 7.6: Statistical output of the univariate linear regression of RU on age in the eight regions 
analysed. 
The results for the normal control subjects and the NF1 patients are separated and shown for each region. 
In the normal control subjects there is evidence of a negative linear relationship between RU and age in the 
right lateral temporal, right medial temporal, right and left parietal, and the right and left occipital lobes. In 
the NF1 patients there is evidence of a negative linear relationship between RU and age in the right parietal, 
and the right and left occipital lobes; and a positive linear relationship in the left cerebellum. 
Dependent 
Variable Group 
Age 
Coefficient 
Std 
Error 
Age Standardized 
Coefficient T statistic P value R R
2 
Right 
Frontal 
Control 0.112 0.394 0.056 0.284 0.778 0.056 0.003 
NF1 0.447 0.342 0.205 1.308 0.199 0.205 0.042 
Left 
Frontal 
Control -0.005 0.487 -0.002 -0.011 0.991 0.002 <0.001 
NF1 0.301 0.289 0.164 1.040 0.305 0.164 0.027 
Right Lat 
Temporal 
Control -0.570 0.231 -0.436 -2.470 0.020 * 0.436 0.190 
NF1 -0.292 0.186 -0.244 -1.571 0.124 0.244 0.060 
Left Lat 
Temporal 
Control -0.427 0.223 -0.352 -1.917 0.066 0.352 0.124 
NF1 -0.230 0.248 -0.147 -0.929 0.358 0.147 0.022 
Right Med 
Temporal 
Control -0.500 0.238 -0.381 -2.102 0.045 * 0.381 0.145 
NF1 -0.261 0.238 -0.173 -1.099 0.279 0.173 0.030 
Left Med 
Temporal 
Control -0.439 0.217 -0.369 -2.025 0.053 0.369 0.136 
NF1 -0.136 0.232 -0.093 -0.585 0.562 0.093 0.009 
Right 
Parietal 
Control -1.505 0.278 -0.728 -5.412 <0.001 * 0.728 0.530 
NF1 -1.368 0.304 -0.585 -4.508 <0.001 * 0.585 0.343 
Left 
Parietal 
Control -1.198 0.344 -0.563 -3.478 0.002 * 0.563 0.318 
NF1 -0.085 0.399 -0.034 -0.212 0.833 0.034 0.001 
Right 
Occipital 
Control -1.587 0.461 -0.560 -3.445 0.002 * 0.560 0.313 
NF1 -1.669 0.340 -0.618 -4.912 <0.001 * 0.618 0.382 
Left 
Occipital 
Control -1.367 0.455 -0.508 -3.006 0.006 * 0.508 0.258 
NF1 -0.974 0.418 -0.350 -2.332 0.025 * 0.350 0.122 
Right 
Cerebellum 
Control 0.203 0.315 0.126 0.645 0.524 0.126 0.016 
NF1 0.355 0.246 0.225 1.445 0.156 0.225 0.051 
Left 
Cerebellum 
Control 0.210 0.317 0.129 0.663 0.513 0.129 0.017 
NF1 0.644 0.236 0.400 2.728 0.010 * 0.400 0.160 
Right 
Thalamus 
Control 0.225 0.491 0.089 0.458 0.651 0.089 0.008 
NF1 0.468 0.337 0.217 1.389 0.173 0.217 0.047 
Left 
Thalamus 
Control 0.118 0.492 0.047 0.240 0.813 0.047 0.002 
NF1 0.496 0.335 0.230 1.478 0.148 0.230 0.053 
Right Basal 
Ganglia 
Control 0.001 0.236 0.001 0.003 0.998 0.001 <0.001 
NF1 -0.333 0.231 -0.225 -1.444 0.157 0.225 0.051 
Left Basal 
Ganglia 
Control 0.349 0.380 0.177 0.919 0.366 0.177 0.031 
NF1 -0.316 0.235 -0.211 -1.348 0.185 0.211 0.045 
* Group (NF1 or Control) where there is evidence of a linear relationship between regional RU 
and age at p<0.05. 
 
The scatterplots also show a pronounced difference in RU in the thalamus between the 
normal control subjects and the NF1 patients (reduced in the NF1 group) across the age 
range. Visually, there is similar but less markedly reduced RU in the NF1 group across 
the age range in the medial temporal lobes, occipital lobes and left cerebellum. The 
statistical output of the multiple linear regression of regional RU on age and group is 
shown Table 7.7. These results support a significant independent effect of group after 
adjusting for the effect of age (all reduced in the NF1 group compared to the control 
group) in the right and left medial temporal lobes (p=0.003 and p=0.003, respectively), 
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the right and left occipital lobes (p=0.031 and p=0.001, respectively), the left cerebellum 
(p=0.010), and most strongly in the right and left thalamus (p<0.001 and p<0.001, 
respectively). 
 
Table 7.7: Statistical output of the multiple linear regression of RU on age and group in the eight 
regions analysed. 
In the multivariate modelling there is evidence of an independent effect of group on RU (lower in the NF1 
group) in the right and left medial temporal lobes (p=0.003 and p=0.003, respectively), the right and left 
occipital lobes (p=0.031 and p=0.001, respectively), the left cerebellum (p=0.010), and in the right and left 
thalamus (p<0.001 and p<0.001, respectively). 
Dependent 
Variable 
Predictor 
Variables 
Variable 
Coefficient 
Std 
Error 
Standardized 
Coefficient T statistic P value R R
2 
Right 
Frontal 
Age 0.295 0.257 0.138 1.149 0.255 0.248 0.062 Group 3.635 2.249 0.194 1.616 0.111 
Left 
Frontal 
Age 0.162 0.264 0.075 0.613 0.542 0.144 0.021 Group 2.199 2.310 0.116 0.952 0.345 
Right Lat 
Temporal 
Age -0.418 0.145 -0.336 -2.888 0.005 0.338 0.114 Group -0.164 1.267 -0.015 -0.130 0.897 
Left Lat 
Temporal 
Age -0.320 0.170 -0.226 -1.882 0.064 0.233 0.054 Group 0.985 1.487 0.080 0.662 0.510 
Right Med 
Temporal 
Age -0.370 0.169 -0.247 -2.187 0.032 0.408 0.167 Group 4.583 1.480 0.350 3.097 0.003 * 
Left Med 
Temporal 
Age -0.273 0.162 -0.193 -1.690 0.096 0.388 0.151 Group 4.421 1.415 0.356 3.124 0.003 * 
Right 
Parietal 
Age -1.430 0.209 -0.645 -6.847 <0.001 0.648 0.420 Group -0.622 1.829 -0.032 -0.340 0.735 
Left 
Parietal 
Age -0.589 0.278 -0.252 -2.122 0.038 0.284 0.081 Group 3.260 2.432 0.159 1.341 0.185 
Right 
Occipital 
Age -1.632 0.274 -0.586 -5.949 <0.001 0.605 0.366 Group 5.299 2.401 0.217 2.207 0.031 * 
Left 
Occipital 
Age -1.152 0.306 -0.399 -3.761 <0.001 0.513 0.263 Group 9.169 2.682 0.363 3.418 0.001 * 
Right 
Cerebellum 
Age 0.286 0.193 0.176 1.482 0.143 0.287 0.083 Group 3.016 1.691 0.211 1.784 0.079 
Left 
Cerebellum 
Age 0.447 0.191 0.263 2.336 0.023 0.417 0.174 Group 4.469 1.676 0.300 2.667 0.010 * 
Right 
Thalamus 
Age 0.358 0.283 0.110 1.265 0.210 0.708 0.502 Group 19.533 2.475 0.689 7.893 <0.001 * 
Left 
Thalamus 
Age 0.324 0.283 0.101 1.146 0.256 0.699 0.488 Group 19.090 2.478 0.682 7.703 <0.001 * 
Right Basal 
Ganglia 
Age -0.182 0.166 -0.133 -1.094 0.278 0.167 0.028 Group -1.065 1.454 -0.089 -0.732 0.467 
Left Basal 
Ganglia 
Age -0.015 0.213 -0.008 -0.068 0.946 0.195 0.038 Group -2.984 1.860 -0.195 -1.604 0.113 
* Regions where there is evidence of an independent effect of Group (ie. increased in the Control 
group compared to the NF1 group) at p<0.05. 
 
 
Table 7.8 shows the statistical output for the univariate linear regression of age on 
regional RU (including all data from both groups). Table 7.9 shows the comparison of 
the adjusted R2 values for the univariate regression models including only age a predictor 
variable, and the R2 values for the multivariate regression models that include both age 
and group as predictor variables. The largest improvement in adjusted R2 with the 
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multiple linear models occurred in the right and left thalamus (increased by 0.469 and 
0.460, respectively), supporting the relevance of group as an independent predictor of 
RU in the thalamus. The next largest increases in adjusted R2 were seen in the left 
occipital, left medial temporal, right medial temporal, left cerebellum and right occipital 
lobes (adjusted R2 increased by 0.121, 0.114, 0.110, 0.078 and 0.038, respectively), also 
supporting group to be an independent predictor of RU in these regions. 
 
Table 7.8: Statistical output of the univariate linear regression of RU on age in the eight regions 
analysed, including all data from both the normal control subjects and NF1 patients. 
There is evidence of a negative linear relationship between age and RU in the right lateral temporal, right 
parietal, and the right and left occipital lobes; and a positive linear relationship between age and RU in the 
left cerebellum. Comparison is made to the multivariate linear models that included group as a predictor 
variable; to test the hypothesis that group is an independent variable after adjusting for the effect of age 
(see Table 7.7). 
Dependent 
Variable 
Predictor 
Variables Coefficient 
Std 
Error 
Standardized 
Coefficient T statistic P value R R
2 
Right 
Frontal Age 0.335 0.259 0.156 1.294 0.200 0.156 0.024 
Left 
Frontal Age 0.186 0.263 0.086 0.707 0.482 0.086 0.007 
Right Lat 
Temporal Age -0.420 0.143 -0.338 -2.935 0.005 * 0.338 0.114 
Left Lat 
Temporal Age -0.309 0.168 -0.219 -1.835 0.071 0.219 0.048 
Right Med 
Temporal Age -0.320 0.179 -0.213 -1.788 0.078 0.213 0.046 
Left Med 
Temporal Age -0.225 0.171 -0.159 -1.314 0.193 0.159 0.025 
Right 
Parietal Age -1.437 0.207 -0.648 -6.957 <0.001 * 0.648 0.419 
Left 
Parietal Age -0.554 0.278 -0.236 -1.991 0.051 0.236 0.056 
Right 
Occipital Age -1.574 0.281 -0.565 -5.605 <0.001 * 0.565 0.319 
Left 
Occipital Age -1.052 0.328 -0.364 -3.204 0.002 * 0.364 0.133 
Right 
Cerebellum Age 0.319 0.195 0.196 1.634 0.107 0.196 0.038 
Left 
Cerebellum Age 0.496 0.199 0.291 2.492 0.015 * 0.291 0.085 
Right 
Thalamus Age 0.571 0.389 0.176 1.465 0.147 0.176 0.031 
Left 
Thalamus Age 0.533 0.385 0.166 1.382 0.172 0.166 0.028 
Right Basal 
Ganglia Age -0.193 0.165 -0.142 -1.173 0.245 0.142 0.020 
Left Basal 
Ganglia Age -0.047 0.214 -0.027 -0.220 0.826 0.027 0.001 
* Regions where there is evidence of a linear relationship between regional RU and age at p<0.05. 
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Both the visual inspection of the scatterplots and the results of the linear regression based 
hypothesis testing suggest that there is an effect of group on regional RU (in all cases 
lower in the NF1 group compared to the normal control subjects) that is independent of 
age in the thalami, medial temporal lobes, occipital lobes and the left cerebellum. 
 
Table 7.9: Comparison of the adjusted R2 values from the linear regression models with and without 
group as a covariate. 
The largest improvement in adjusted R2 with the multiple linear models occurred in the right and left 
thalamus (increased by 0.469 and 0.460, respectively) and the next largest increases were in the left 
occipital, left medial temporal, right medial temporal, left cerebellum and right occipital lobes (increased 
by 0.121, 0.114, 0.110, 0.078 and 0.038, respectively). These findings provide evidence that patient group 
(either normal control subjects or NF1 patients) is a significant independent variable in predicting RU in 
these regions after allowing for patient age. 
 
Univariate Adj R2 
(only Age as a 
dependent variable) 
Multivariate Adj R2 
(Age and Patient Group included as 
dependent variables) 
Change in Adj R2 
Right Frontal 0.010 0.033 0.023 
Left Frontal -0.007 -0.009 -0.002 
Right Lat Temporal 0.101 0.087 -0.014 
Left Lat Temporal 0.034 0.025 -0.009 
Right Med Temporal * 0.031 0.141 0.110 
Left Med Temporal * 0.011 0.125 0.114 
Right Parietal 0.411 0.403 -0.008 
Left Parietal 0.042 0.053 0.011 
Right Occipital * 0.309 0.347 0.038 
Left Occipital * 0.120 0.241 0.121 
Right Cerebellum 0.024 0.055 0.031 
Left Cerebellum * 0.071 0.149 0.078 
Right Thalamus * 0.017 0.486 0.469 
Left Thalamus * 0.013 0.473 0.460 
Right Basal Ganglia 0.006 -0.001 -0.007 
Left Basal Ganglia -0.014 0.009 0.023 
* Regions where there is evidence of an independent effect of Group (ie. increased in the Control 
group compared to the NF1 group) at p<0.05, on the multivariate linear regression model. 
 
 
Figure 7.7 shows the FDG PET CT scans of three patients with NF1 of different ages and 
three approximately age-matched normal control subjects. The images show the thalamic 
hypo-metabolism in all of the NF1 patients and variable cortical hypo-metabolism 
elsewhere. 
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Figure 7.7: Cerebral FDG scans in 3 children with NF1 and age matched control subjects. 
Examples of cerebral FDG PET CT scans from three patients with NF1 (upper row) compared against 
approximately age-matched subjects from the normal control dataset (lower row).  Reduced thalamic FDG 
uptake is clearly apparent in the NF1 patients compared to the controls (arrows). In these patients there are 
also more variable cortical regions of reduced FDG uptake (arrow heads). 
 
7.6 Discussion 
The current analysis has shown that after allowing for the effect of age on regional 
cerebral FDG uptake, children with NF1 have reduced FDG uptake in the thalamus 
bilaterally as assessed by SUVmax; and reduced FDG uptake in the thalamus, occipital 
and medial temporal lobes bilaterally, and the left cerebellum as measured by qualitative 
uptake relative to maximal cortical activity. These results come from the largest reported 
cohort of cerebral FDG scans in paediatric NF1 patients (41 patients compared to 4 [121], 
6 [67] and 10 [123], in previous studies) and uses a large, robust control group of 
paediatric age subjects with no known underlying neurological abnormalities. 
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Thalamic hypo-metabolism in children with NF1 is a finding consistent with the very 
limited available literature and correlates to the main findings in two of the three 
previous studies in children with NF1 [67, 123]. 
 
The cortical hypo-metabolism in the medial temporal and occipital lobes, and the left 
cerebellum are intriguing findings not previously reported. In their assessment of 
regional cortical FDG uptake, Balestri et al showed reduced FDG uptake in the “occipital 
lateral” and “calcarine” cortices in three; and in the “temporal medial-inferior cortex” in 
two out of the four children they studied with NF1, compared to the trend line predicted 
by their nine control subjects. The very small number of patients in this study severely 
limits the strength of these findings. The results from this chapter come from a much 
larger cohort with a more valid control group and thus provide more compelling evidence 
for hypo-metabolism in the occipital and mesial temporal lobes in children with NF1. 
 
The medial temporal lobe has functions involving memory [125, 126] and also visual 
processing and possibly in visual perception itself [127-129]. The hypo-metabolism in 
the medial temporal lobes in children with NF1 could relate to the visual-spatial deficits 
and learning disabilities, a common symptomatology in NF1. Similarly, the occipital 
lobe hypo-metabolism in our group of children with NF1 may signify a functional 
problem with the primary visual cortex, however the method of qualitative assessment 
was not able to more accurately localise regions smaller that a rather coarse assessment 
of overall lobar FDG uptake. 
 
Another possible aetiology for the regional hypo-metabolism seen in the study is the 
disruption of white matter connectivity causing resting state regional hypo-metabolism in 
patients with NF1. White matter morphometry and tractography is abnormal is NF1. 
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White matter volume is increased in NF1 patients with macrocephaly [130] and occurs 
disproportionately in the frontal lobes, parietal lobes and the more anterior regions of the 
brain [131, 132]. Diffusion tensor imaging studies in children and adults with NF1 have 
revealed increased volume and abnormal white matter tractography in the corpus 
callosum [133, 134]. Although these white matter abnormalities in NF1 do not provide a 
direct correlation to the pattern of hypo-metabolism described in this chapter, these 
reports do underline abnormal white matter in patients with NF1 which via disrupted 
connectivity could produce grey matter hypo-metabolism. A more thorough 
consideration of the results within the context of aberrant resting state connectivity in 
NF1 is provided in the Discussion section of Chapter 8. 
 
Kaplan et al showed that T2H in the brains of children with NF1 demonstrate lower FDG 
uptake than surrounding tissue [123]. It therefore remains a possibility that although the 
pathogenesis of T2H are not known, the changes observed in cerebral FDG scans could 
reflect hypo-metabolism related to the distribution of T2H. T2H in children with NF1 are 
most commonly in the basal ganglia, brainstem, cerebellum and sub-cortical white matter 
[115, 135-137]; and hence the hypo-metabolism in the medial temporal and occipital 
cortices are probably less likely to be due to this phenomena. Further analysis of the 
current cohort of children with NF1 to correlate the location of T2H with the pattern of 
cortical and subcortical hypo-metabolism would be of interest. 
 
Overall, the NF1 group and the normal control group show similar relative patterns of 
regional RU (extensively described and discussed in Chapter 3) and broadly speaking 
both groups showed a clear reducing trajectory of RU in the parietal and occipital lobes 
when normalised to maximal cortical uptake. In the NF1 patients this pattern is likely to 
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be due to the different rates of increasing FDG uptake with age in different regions of the 
brain as is the case with the normal control subject and fully explained in Chapter 3. 
 
The normal control dataset used in the current analysis is the largest control group of 
pediatric aged subjects in a published comparative analysis of cerebral FDG PET scans. 
Although none of the normal control subjects had apparent neurological conditions they 
all has suspected or proven extra-cranial malignancies which has the possibility to 
perturb cerebral FDG uptake. Due to the ionising radiation burden associated with FDG 
PET CT scanning, a truly normal pediatric dataset is unlikely to ever be ethically 
recruited for a similar study. Also, formalised assessment of the children forming the 
normal control dataset in the current study to exclude the presence of sub-clinical 
neurocognitive deficits was not performed.  
 
Another limitation is the semi-quantification of FDG uptake using SUVs, which has well 
described limitations [41, 138]. However, SUVs remain a common metric used in 
publications where absolute quantification of FDG uptake using blood sampling methods 
from the patient during scanning is not feasible, particularly from clinical cohorts such as 
those used in the current study and especially in children. 
 
7.7 Conclusion 
It has been shown that in children with NF1 there is reduced FDG uptake in the thalamus, 
the medial temporal lobes, the occipital lobes, and the left cerebellum, compared to a 
normal control dataset. 
 
Neuro-cognitive impairment and MRI cerebral abnormalities (T2H) are common in 
children with NF1 and although there are recent reports showing an association with 
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discrete T2H located in the thalamus and the degree of neuro-cognitive deficit [117-120], 
a firm relationship remains elusive. The thalamic hypo-metabolism shown in the current 
report is finding consistent with the very limited published literature in children [67, 121, 
123]. The question remains if thalamic hypo-metabolism can function as a biomarker for 
the presence of severity of neurocognitive deficit, independent of any relationship with 
thalamic T2H. If so then this imaging modality may play an important role in the long 
term follow up, stratification for future therapeutic interventions and response assessment 
directed towards improving cognitive ability in children with NF1 [139-141]. 
 
Medial temporal lobe, occipital lobe and left cerebellar hypo-metabolism are new 
findings in children with NF1 and although the unilateral cerebellar hypo-metabolism 
may reflect T2H in this location, the other cortical regions of hypo-metabolism could 
relate to underlying visual-spatial processing deficits and/or learning problems common 
in these patients. Further analysis of the cerebral MRI findings and neuro-cognitive 
assessments in the included cohort of children with NF1 is required to address these 
issues. 
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8 CHAPTER EIGHT: APPLICATION OF 
STATISTICAL PARAMETRIC MAPPING IN 
CHILDREN WITH NEUROFIBROMATOSIS 
TYPE 1 
8.1 Abstract 
Aims: Group versus group SPM analysis of cerebral FDG PET scans in children with 
NF1 has been previously reported in a single study with only six patients in the NF1 
group and using the head portion of a whole body scan acquisition protocol. This chapter 
aims to use SPM to perform a group versus group analysis comparing a large group of 
dedicated cerebral FDG scans in children with NF1 to a normal control dataset of 
unaffected, neurologically normal children. 
 
Methods: The dedicated cerebral FDG scans of 41 paediatric patients with NF1 were 
analysed using SPM and compared to a normal control dataset of cerebral FDG scans in 
unaffected children with no neurological abnormalities. A custom FDG normalisation 
template was created from a balanced combination of both NF1 and normal control 
subjects and used as the normalisation template for the analysis, to reduce the chance of 
normalisation bias affecting the SPM results. Strict voxel-level FWEp correction for 
multiple comparisons was used. A descriptive SPM analysis of the NF1 patients was also 
performed to investigate the effect of age on cerebral FDG uptake and the results were 
contrasted against the results from the same analysis of the normal control subjects, 
which were presented in Chapter 4. 
 
Results: The results of the group versus group SPM analysis showed reduced FDG 
uptake in the NF1 group affecting the thalami and medial temporal lobes, bilaterally. 
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The descriptive analysis of the NF1 group showed a similar but less extensive pattern of 
regional increasing FDG uptake with age than was seen with the same analysis of the 
normal control dataset (see Chapter 4)  
Conclusions: The thalamic hypo-metabolism in NF1 is in agreement with the few 
previous studies, but the medial temporal lobe hypo-metabolism is a new finding and 
correlates to the results from Chapter 7. Further studies are required to determine the 
significance of medial temporal lobe hypo-metabolism in children with NF1. This 
appearance may provide an important biomarker for underlying neurocognitive deficits 
in children with NF1 or may relate to the presence of cortical T2H. 
The regional pattern of increasing FDG uptake with age has not previously been reported 
in children with NF1. This differences compared to the normal control dataset appeared 
to be due to more variability in cortical FDG uptake in the NF1 group. Further studies 
correlating the metabolic derangements seen with FDG PET to  MRI abnormalities and 
neurocognitive function are required. 
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8.2 Introduction 
Neurofibromatosis Type 1 (NF1) has a prevalence of approximately 1 in 3500 and 
cognitive defects are the most common neurological manifestation of this genetic 
disorder [111, 112]. If patterns of cerebral metabolism in NF1 are related to the nature 
and severity of underlying neuro-cognitive deficits, FDG PET could serve as an 
important imaging biomarker for the surveillance or selection of children with NF1 who 
may benefit from available future therapies [139, 140]. Cerebral metabolism in NF1 as 
seen on FDG PET CT imaging has been studied in an extremely limited number of 
published reports [67, 121-123] of which only two have applied statistical parametric 
mapping (SPM) to compare scans in patients to a control dataset: one involving adults 
[122] and one involving children [67]. 
 
Buchert et al used SPM to compare FDG PET scans of a group of 29 adult patients with 
NF1 (age range 15 – 56 years) to a control group of 29 age and sex matched patients 
without NF1 [122]. The control group underwent whole body FDG PET CT scanning for 
evaluation of an oncological condition and did not have neurological or psychiatric 
disease. The included control subjects came from a larger group but the authors excluded 
an unspecified number of subjects if they found clusters of either increased or decreased 
FDG uptake when compared against the remaining potential normal control subjects 
using SPM and default statistical thresholds. This method of excluding normal subjects 
potentially could exclude those with outlying but still normal physiologic levelsl of FDG 
uptake thereby falsely reducing the normal variability in voxel-wise FDG uptake 
predisposing the analysis to false positive results when comparing to the NF1 patients. 
The NF1 patients were scanned either to evaluate the malignant potential of plexiform 
neurofibromas (eight patients) or to assess clinical stage of disease in patients with 
proven malignant peripheral nerve sheath tumours (21 patients). In both the NF1 and 
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control groups the brain region of a whole body scanning protocol was used for the 
analysis. A dedicated cerebral FDG emission scan was not acquired. PET CT scanning 
was performed on an ECAT EXACT 921/47 PET system (Siemens/CTI, Knoxville, 
Tennessee, USA) in two-dimensional mode. Each scan was acquired in two or three 
separate acquisitions depending on the indication for the scan. Separate “upper thorax 
plus head”, “abdomen” and/or “feet” scans were acquired in various sequences 
depending on the indication and sometimes with a time delay between acquisitions to 
allow patients to rest or to void their bladder. This disrupted scan sequence during 
acquisition resulted in a longer tracer uptake period in relation to the “upper thorax plus 
head” acquisition in the NF1patients and therefore uptake time was included as a 
covariate in the SPM model. 
 
In their study, two types of analysis were undertaken. The first used a voxel-based 
comparison of scaled FDG retention to identify regions of significantly different FDG 
accumulation. Images were spatially normalised to the (non-FDG) PET template 
provided within SPM2, then smoothed with a 15mm FWHM Gaussian kernel and scaled 
to a constant predefined grey/white matter mask using SPM2 software. A voxel-based 
comparison was then performed using the ANCOVA model in SPM2 using an FWEp 
corrected threshold of p<0.05. The second type of analysis used a regional volume of 
interest (VOI) comparison (also using SPM) to quantify the difference in mean FDG 
retention. An automated anatomic labelling toolbox for SPM was used to interrogate 
brain structures within predefined VOIs for significant differences. FDG uptake was 
characterised by the mean FDG retention over all of the voxels within each VOI. 
 
The voxel-based SPM analysis showed significant reduction in scaled FDG retention in 
the thalamus in the NF1 group. On the VOI analysis the reduction was calculated as 8% 
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in NF1 compared to the control group. No other regions of increased or decreased FDG 
retention were seen. The VOI SPM analysis showed no correlation between mean 
thalamic FDG retention and age, or between mean FDG retention and gender, when 
controlling for uptake time. In patients with NF1, there was no relationship between 
thalamic mean FDG retention and the presence of T2H, plexiform neurofibromas, 
malignant peripheral nerve sheath tumors, balance disorders, motor deficits during 
childhood, muscle hypotonia, pervasive developmental disorders or attention deficits. 
 
The authors also performed the voxel based SPM analysis at a less stringent and 
explorative significance level (p<0.001 uncorrected for multiple comparisons) to search 
for potential regional differences in FDG retention. In addition to the reduced retention in 
the thalamus, this analysis showed a trend for reduced FDG retention in the cerebellum 
and increased retention in the peri-sylvian regions. 
 
In the only published report of an SPM analysis of cerebral FDG PET in children with 
NF1, Nguyen et al analysed a very small dataset comprising six children with NF1 
ranging in age from six to 18 years, compared against a control group of 21 patients 
undergoing FDG PET scanning to stage extra-cranial neoplasm not related to NF1. The 
six NF1 patients underwent whole-body FDG PET CT scanning to evaluate extra-cranial 
soft tissue or bone lesions in four patients (the results of which were not reported and one 
patient had had previous stereotactic radiosurgery of an optic chiasm tumor), re-staging 
of a malignant peripheral nerve sheath tumor following chemotherapy in one, and the 
reason was not specified in the other patient. The controls subjects ranged in age from 
three to 18 years and “did not have a history of brain tumor, neuropsychological disease, 
or chemotherapy prior to PET/CT” [67]. In this study neither the NF1 patients nor the 
control subjects had dedicated brain PET acquisition, but the brain region from a whole 
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body scan acquisition protocol was used in the analysis. CT attenuation correction was 
used with a Gemini TF PET CT scanner (Philips Healthcare). The normalisation template 
employed in image pre-processing was not specified, but presumably the non-FDG, adult 
template provided within SPM8 was used. Proportional scaling of the images was 
performed and the normalised scans were smoothing with a 6mm Gaussian kernel. 
 
A voxel-wise comparison was performed using SPM8 to detect hypo-metabolism in the 
NF1 group compared to the control subjects, and implemented with both a strict (voxel 
level FWEp p<0.05) and liberal (p<0.001, uncorrected for multiple comparisons) 
statistical threshold. It is notable that patient age was not adjusted for and was not 
included as a covariate in the SPM model. Computer software was used to convert the 
MNI coordinates of the resulting SPM map to Talairach coordinates prior to automated 
atlas-based localisation of any supra-threshold clusters. Using the strict FWEp p<0.05 
threshold, four supra-threshold clusters were found. The largest and most statistically 
significant involved the thalamus bilaterally, with smaller clusters involving the right 
cingulate gyrus/medial frontal gyrus, the left occipital cortex and the left fronto-parietal 
cortex. 
It is worth noting that the figures presented in this publication were confusing and 
appeared to display the cortical supra-threshold clusters on the opposite side of the brain 
to that described in the text. 
 
This study also has several major methodological limitations. Firstly, the sample size is 
very small with only 6 patients forming their NF1 group. With such a small dataset there 
would be a risk of producing false positive hypo-metabolic clusters; particularly in the 
absence of an assessment of the patients cerebral MRI scans to correlate the apparent 
cortical hypo-metabolic areas to the possible presence of structural lesions and/or T2 
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hyper-intense lesions (T2H). The authors justify the larger sample size of their control 
group (21 subjects) by citing a study looking at the accuracy of statistical analysis of 
adult FDG PET CT scans. The publication they cited suggested that a control group 
sample size of at least 20 may be adequate [142] but this study used adult patients with 
Alzheimer’s disease and used statistical analysis software different to SPM 
(Neurostat/3D-SSP [143]). 
 
Secondly, they analysed the relatively low count scans acquired as part of a whole body 
imaging procedure rather than a dedicated brain acquisition protocol. This would 
exacerbate the effect of serendipitous cortical regions of hypo-metabolism, not necessary 
reflecting the situation across the wider pediatric NF1 population. The authors cite a 
solitary conference poster abstract suggesting minimal effect with the use of low count 
brain PET images compared to dedicated brain acquisition however very little detail is 
available from the abstract alone, the study used adult patients with Alzheimer’s disease, 
used different statistical analysis software (Neurostat/3D-SSP), and did not appear to be 
eventually published other than in abstract form [144]. 
Thirdly, 33% of the NF1 group (two out of six) were reported to have had an intervention 
prior to the FDG scan likely to effect cerebral FDG distribution (ie. stereotactic 
radiosurgery and chemotherapy). This is a large proportion of their small cohort. 
 
For these reasons, the authors technical interpretation of “adequate” sample size and scan 
acquisition protocol is questionable and these important methodological factors may not 
be directly translatable to an analysis using SPM in a pediatric population with NF1. 
 
Both of the two previous SPM studies in patients with NF1 did not use an FDG template 
for spatial normalisation nor did they evaluate the effect of different template or scan 
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smoothing parameters. Normalisation errors and normalisation bias therefore remain a 
potential issue in both studies. Despite their limitations both of the previously published 
adult and pediatric studies in NF1 using SPM have suggested thalamic hypo-metabolism 
and less pronounced cortical regions of altered FDG uptake elsewhere. 
 
This chapter uses the largest reported cohort of cerebral FDG scans in NF1 and a highly 
unique dataset of control pediatric cerebral FDG scans to perform SPM analysis to detect 
hypo-metabolism in children with NF1, adjusting for the effect of age. 
 
8.3 Aims 
The aim of this chapter is to implement SPM to perform a voxel-by-voxel whole brain 
analysis to detect areas of reduced FDG uptake in children with NF1. The analysis will 
compare the cerebral FDG PET CT scans of a cohort of children with NF1 to a normal 
control dataset of unaffected children. The analysis is treated as an exploratory analysis 
of the whole brain volume and will implement stringent voxel-level correction for 
multiple comparisons across the entire brain. The analysis will serve as an example of the 
use of SPM to compare groups of FDG PET scans using the unique dataset of control 
subjects previously described and analysed in Chapters 3 and 4. 
 
8.4 Methods 
Approval for this retrospective study was obtained from the hospital human research 
ethics committee. 
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8.4.1 Control subjects 
The control subjects forming the comparative group was the same group as that 
described in Chapter 3. Briefly, the normal control dataset was recruited from the 
dedicated cerebral FDG scan performed as part of a whole body scan in children being 
staged for suspected or proven extra-cranial solid tumours, with no evidence of cerebral 
metastasis, no neurological disorders, not on anti-epileptic medications and without a 
general anaesthetic within 24 hours prior to the FDG PET CT scan. The dedicated 
cerebral scan was considered to represent a normal cerebral FDG PET scan for a child of 
their age. 
 
8.4.2 NF1 patients 
A retrospective review of cerebral FDG PET CT scans performed in children with NF1 
was undertaken. A search was conducted of the electronic database of all PET CT scans 
performed at The Children’s Hospital at Westmead during the four year review period 
starting from the commencement of the FDG PET CT service in June 2006 until July 
2010. All dedicated cerebral FDG PET CT scans were extracted and crosschecking 
clinical information contained within each patient’s electronic medical record identified 
children with NF1. 
 
8.4.3 PET CT imaging 
Children fasted for 4–6 hours and had blood glucose levels confirmed to be within the 
normal range before injection of 370 MBq of FDG scaled to body surface area using a 
weight based nomogram. During an approximate 30-minute uptake period, the children 
rested in a dimly lit room, supine and with minimal stimulation. A 15 minute dedicated 
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brain acquisition was performed followed by a whole body scan acquisition from the 
base of brain to toes. 
 
PET CT acquisition was performed on a Siemens Biograph16 HiRez PET-CT scanner 
(Siemens Medical Solutions, Erlangen, Germany) with field of view of 500mm in width 
and 160mm in axial length. CT attenuation correction was used with a source rotation 
speed of 0.5 sec/rotation at 80 kV. Siemens proprietary CT dose modulation protocol 
(“Caredose”) was used to modulate the CT tube current from a maximum of 100 mA. 
 
All PET CT scans were decay corrected and reconstructed using an iterative 
reconstruction algorithm based on ordered-subset expectation maximization (OSEM; 8 
iterations, 16 subsets) with scatter correction and measured attenuation correction. 
OSEM images underwent a 4.1 mm full-width-at-half-maximum Gaussian post 
smoothing. 
 
8.4.4 SPM pre-processing parameters: Determination of an 
appropriate normalisation template and scan smoothing 
parameters 
Spatial pre-processing and statistical analyses were performed using the “PET & VBM” 
module of SPM8 (Wellcome Trust Centre for Neuroimaging, Institute of Neurology, 
London, UK), which was implemented using Matlab 7.12.0 (R2011a, MathWorks Inc., 
Sherborn, MA). 
8.4.4.1 Assessment of normalisation bias 
The potential problems when using inappropriate normalisation templates generated from 
adults or using a different tracer to that being studied have been discussed in Chapter 4 
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and the same principles warrant the creation of a custom template for the comparison of 
patients with NF1 to the normal control dataset. Normalisation bias is a term that 
describes the biasing of the normalisation process towards a particular group of scans in 
the analysis. This comes about if there is a systematic difference in the normalisation of 
the FDG scans and could lead to spurious group related results on the SPM map. 
 
NF1 patients are known to have structural differences in brain morphometry compared to 
unaffected children including larger brain volumes, white matter differences including a 
structurally larger corpus callosum [130-133]. Therefore consideration was given for 
normalisation bias to occur if the custom template comprising only the children in the 
normal dataset developed and described in Chapter 4 was also used to spatially normalise 
the FDG scans of the patients with NF1. The resulting normalisation routines applied to 
the native FDG scans might systematically warp the scans of the normal control subject 
differently from the NF1 patients and cause spurious findings on the resulting SPM maps. 
Such normalisation bias can be minimised by the use of a template created from an equal 
number of scans from each group being compared [145, 146].The potential for this type 
of spatial normalisation bias in the study was addressed in two ways. Firstly, by 
assessing differences between the templates created from the normal controls subjects 
(the normal control template) and a template created from the NF1 patients (the NF1 
template). To achieve this, the “ImCalc” module of SPM8 was used to subtract the NF1 
template from the normal control template to produce a “subtraction” image for each 
level of template smoothing (see Figure 8.3 in Results section). Secondly, the resulting 
SPM maps assessing the evidence of hypo-metabolism in the NF1 patients compared to 
the normal control subjects were compared with the use of the normal control template 
and the NF1 template. For this comparison 8mm template smoothing was applied with 
both 8mm and 16mm scan smoothing. 
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8.4.4.2 Creation and assessment of templates to minimise normalisation bias 
To mitigate potential normalisation bias, custom templates were developed that 
comprised of both the normal control subjects plus the NF1 patients. The resulting 
template would be less likely to favour one group over the other than either of the normal 
control or the NF1 templates. SPM analyses were compared between using a “combined” 
normalisation template (generated from the entire dataset of all 28 normal control 
subjects plus all of the NF1 patients) and an age matched, “balanced” template 
(comprising of all 28 normal control subjects plus 28 of the most closely age matched 
NF1 patients, see Table 8.2). In Chapter 5 it was found that for the assessment of hypo-
metabolism in patients with epilepsy that a 16mm smoothed normalisation template was 
optimal to reduce false positive results. Hence, the 16mm smoothed templates were used 
to assess the resulting SPM maps resulting from the use of the “combined” and 
“balanced” custom templates, across the range of scan smoothing parameters. The 
optimal custom template was determined from these SPM results and this template was 
then used to assess the optimal smoothing parameters (with respect to both template 
smoothing and scan smoothing). 
 
8.4.4.3 Determination of optimal template smoothing and scan smoothing 
parameters 
After spatial normalisation to the optimal custom template at 0mm (no further 
smoothing), 8mm, 16mm, and 24mm template smoothing kernels, every normalised scan 
was then smoothed with the same four different Gaussian smoothing kernels. In this way 
and using the identified optimum normalisation template, there were 16 different 
template and scan smoothing combinations (see Table 8.1). The resulting SPM maps 
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from all of these 16 combinations were examined to determine the most appropriate 
degree of template and scan smoothing to apply. 
 
 
Table 8.1: The 16 different template smoothing and scan smoothing combinations used to test the 
optimum normalisation template. 
  Template smoothing 
  0x0x0mm 8x8x8mm 16x16x16mm 24x24x24mm 
Scan 
smoothing 
0x0x0mm Temp0.Scan0 Temp8.Scan0 Temp16.Scan0 Temp24.Scan0 
8x8x8mm Temp0.Scan8 Temp8.Scan8 Temp16.Scan8 Temp24.Scan8 
16x16x16mm Temp0.Scan16 Temp8.Scan16 Temp16.Scan16 Temp24.Scan16 
24x24x24mm Temp0.Scan24 Temp8.Scan24 Temp16.Scan24 Temp24.Scan24 
For each combination, “Temp#” denotes the normalization template smoothing kernel and 
“Scan#” demotes the scan smoothing kernel. 
 
 
The optimal normalisation template, along with the optimal template smoothing and scan 
smoothing was used in the scan pre-processing of an SPM two-sample t-test procedure to 
asses on a voxel-by-voxel basis the evidence of cerebral hypometabolism in the NF1 
group compared to the normal control dataset.  
 
8.4.4.4 SPM workflow for producing custom normalisation templates 
Using the “Normalise: Est and Wri” module in SPM8, the reconstructed scans of all the 
control subjects and the NF1 patients were spatially normalized to the SPM8 “PET” 
template and written out using a bounding box dimension of -90:91 -126:91 -72:109. The 
remainder of the default parameters in this module were unchanged. The “Smooth” 
module of SPM8 was used to smooth the warped images with 0mm (no further 
smoothing), 8mm, 16mm and 24mm Gaussian kernels. The “ImCalc” module of SPM8 
was then used to calculate the mean image of chosen subsets of these normalised and 
smoothed scans to create the various custom templates (see Table 8.2). Each custom 
template was created with four different levels of smoothing based on the smoothing 
applied to the warped scans prior to calculation of the mean image. 
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Table 8.2: Composition of the different custom templates. 
The name and composition of the various custom templates are shown. These templates were created and 
applied in the process of evaluating normalisation bias and the optimal template for use in the SPM 
comparative analysis between NF1 patients and normal control subjects. 
Custom template name Scan composition of the template 
Normal control template All 28 normal control subjects 
NF1 template All 39 NF1 patients 
Combined template All 28 normal control subjects plus all 39 NF1 patients 
Balanced template All 28 normal control subjects plus the 28 closest age matched NF1 patients 
 
8.4.4.5 SPM workflow for pre-processing of the native scans 
The “Normalise: Est and Wri” module, was then used to spatially normalize each native 
reconstructed FDG PET scan to the custom templates and then written out using a 
bounding box dimension of -90:91 -126:91 -72:109 with voxel sixe of 2x2x2mm. The 
remainder of the SPM8 default parameters were unchanged. Finally, after normalisation, 
each scan was then smoothed with 0mm (no further smoothing), 8mm, 16mm and 24mm 
Gaussian kernels to produce sets of scans all normalised to the same template but with 
different degrees of smoothing. In this way all of the native reconstructed FDG PET 
scans for both the control dataset and the NF1 patients were normalized to the MNI 
standard space (Montreal Neurological Institute, McGill University, Montreal, Canada) 
with a voxel size of 2x2x2mm, using the various custom templates and with four 
different levels of individual scan smoothing. These normalized and smoothed images 
were used as the input scans for model specification and estimation within SPM8. 
 
8.4.5 SPM analysis: The workflow for detecting hypo-metabolism in 
NF1 patients compared to the normal control dataset 
The “Basic models” module in SPM8 was used to create a two-sample t-test comparing 
the group of cerebral FDG scans in the NF1 group to the normal control dataset 
incorporating age as a covariate in the SPM statistical design matrix. Relative threshold 
masking of 0.8 was implemented to remove extra-cerebral tracer activity from the images. 
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Recall that a relative threshold mask of 0.8 performed optimally in the investigation of 
the effect of age in the normal dataset (see Chapter 4). Proportional normalisation was 
used as the global normalisation procedure to account for global differences in whole 
brain tracer uptake in part arising from variability in injected dose of FDG and uptake 
times. The remainder of the SPM8 default parameters in this module were unchanged. A 
contrast was constructed to test for evidence of reduced FDG uptake across the whole 
brain adjusting for age. Correction for multiple comparisons was performed at the voxel 
level using a family-wise error (FWEp) corrected peak threshold of p<0.05. A cluster 
extent threshold of k = 20 was used to exclude single voxel effects and very small 
clusters that might not be biologically credible. A 20-voxel cluster equates to 0.16 cm3 of 
neural tissue in the scan after normalisation to the standard MNI space. 
 
In this manner the cerebral FDG scans in children with NF1 were compared against the 
normal control dataset to detect areas of hypo-metabolism while adjusting for the effect 
of age on voxel-wise FDG uptake and correcting for multiple comparisons with a strict 
statistical threshold. The hypothesis was that there is reduced metabolism in the thalami 
in children with NF1 compared to normal controls. 
 
As a secondary comparison, a one-sample t-test was performed on the NF1 group to 
evaluate the effect of age on FDG uptake and the results were compared to the same 
analysis performed in the normal control dataset (reported in Chapter 4). As has been 
explained in Chapter 4 this analysis highlights those voxels with statistical evidence of an 
increasing linear relationship between age and FDG uptake. For this analysis the NF1 
custom template was used (see Table 8.2 for a description of the scans included in this 
template) with 8mm template smoothing and 8mm scan smoothing, and a FWEp 
threshold of p<0.05 with a cluster extent threshold of k = 50. These are the same SPM 
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parameters as were used in the analysis of the normal control dataset and therefore 
provides for a more valid comparison. 
 
8.5 Results 
8.5.1 Control subjects 
As mentioned in the Methods section, the normal controls subjects used as the 
comparative group for the SPM analysis were the same as described in Chapter 3. The 
age of the normal control subjects ranged from 11 months to 16 years (mean age10.4 
years). 
 
8.5.2 NF1 patients 
There were 65 dedicated cerebral FDG scans performed in 49 children with NF1 during 
the study period. Thirty eight patients had only one scan, seven patients who had two 
scans, three patients had three scans and one patient had four scans. For the patients with 
multiple scans during the study period, only the first scan was included leaving 49 scans 
in 49 patients. From these 49 patients, eight were excluded because they were beyond of 
the age range of the normal controls subjects. These eight excluded patients were aged 
18.7, 18.7, 19.3, 19.5, 19.6, 20.7, 22.6 and 37.2 years old. Two further patients were 
excluded due to significant cerebral abnormalities including a 10.6 year old girl with 
marked left ventricular dilatation requiring a ventriculo-peritoneal shunt and a 15.3 year 
old boy with an extensive right cranio-facial plexiform neurofibroma with associated 
right cerebral hemisphere atrophy and ventricular dilatation. After exclusion of these 10 
patients there remained 39 scans in 39 patients with NF1 included in the SPM analysis. 
The clinical indications for the FDG PET CT scans of the included 39 patients are shown 
in Table 8.3. The patients undergoing assessment of MRI T2H lesions had various 
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locations involved with T2H commonly found in patients with NF1 but none had 
clinically significant ventriculomegaly or mass effect demonstrated by the lesions under 
assessment. None of the patients had received prior chemotherapy or neurosurgery. The 
age distribution of the included NF1 patients are displayed in Figure 8.1 and the normal 
control subject are displayed in Figure 8.2. 
 
 
Table 8.3: Indication for the FDG PET CT scan of the 39 included cerebral FDG PET scans in 
patients with NF1. 
No of scans Clinical indication 
15 Assessment of optic pathway gliomas 
13 Assessment of extra-cranial plexiform neurofibromas 
6 Assessment of MRI T2 hyperintense cerebral lesions 
3 Assessment of optic pathway gliomas and extra-cranial plexiform neurofibromas 
1 Assessment following excision and regional radiotherapy of an extracranial 
MPNST* 
1 Staging of an abdominal extra-adrenal adrenocortical carcinoma (no metastases) 
* MPNST: malignant peripheral nerve sheath tumour 
 
 
 
Figure 8.1: Age histogram of the 39 included NF1 patients. 
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Figure 8.2: Age histogram of the 28 included normal control subjects. 
 
8.5.3 SPM pre-processing parameters: Normalisation template and 
scan smoothing 
8.5.3.1 Normalisation bias: Differences between the normal control template and 
the NF1 template 
Figure 8.3 is a display showing the normal control template (left column), the NF1 
template (centre column), and the resulting image after subtracting the NF1 template 
from the normal control template (right column); for each level of smoothing. Although 
the normal control and NF1 look similar for each level of smoothing, the subtraction 
images highlight some differences in voxel intensity that have the potential to create 
normalisation bias. Note that the different voxel intensities between the normal control 
and NF1 templates are apparent in the region of the thalamus. This is depicted by the 
highly positive (light grey/white) voxels in the region of the thalamus on the subtraction 
images and can also be appreciated visually on the templates with lower intensity voxels 
apparent in the NF1 template in the region of the thalamus than in the normal control 
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template (best seen on the coronal slices). Another feature on the subtraction images is a 
higher proportion of light grey/white voxels centrally in the periventricular/corpus 
callosum/brainstem/4th ventricle regions and dark grey/black voxels in the right parietal 
region on the subtraction images. The thalamic differences probably reflect hypo-
metabolism on the underlying NF1 scans but the periventricular differences may be 
related to larger ventricles in the NF1 patients and different degrees of warping when 
normalised to the SPM PET template. Note that on all of the NF1 templates the region of 
low level or absent tracer activity corresponding to the lateral ventricles/deep 
hemispheric white matter/centrum semiovale areas appear relatively more expanded than 
on the corresponding normal control template for each particular level of smoothing. It is 
not readily apparent if the relatively more intense FDG activity in the right parietal 
region in the NF1 template is due to relative increased uptake in this region on the 
underlying scans in the NF1 group or from errors in normalization. Overall, these results 
show pronounced regional differences in voxel intensities between the normal control 
template and the NF1 template regardless of the degree of template smoothing and 
support the creation of a custom template using scans from both the normal control 
subjects plus the NF1 patients to minimise normalisation bias during SPM pre-processing. 
 
Figure 8.3 (following page): Comparison between the normal control template and the NF1 template 
at different levels of smoothing. 
Brain images are shown in 3 orthogonal planes with the cross hairs set at the centre of the volume. The 
columns from left to right represent the normal control template, NF1 template and the subtraction image 
(normal control template minus the NF1 template). The rows from top to bottom represent the different 
levels of template smoothing (no smoothing on the top row, 8mm smoothing on the second row, 16mm 
smoothing on the third row, and 24mm smoothing on the bottom row). The template images have all been 
manually scaled to the same voxel intensity window (0, 20000) and displayed in grey-scale. The 
subtraction images have all been manually scaled to the same voxel intensity window (-7000, 7000) and 
displayed in grey-scale with the darker grey/black voxels representing negative values and lighter 
grey/white voxels representing positive values. Images are displayed in neurological convention with the 
left side of the image representing the left side of the brain. There are three main features in the subtraction 
images that highlight differences between the normal control and NF1 templates: 
1. Positive voxels in the region of the thalamus (arrow). 
2. Higher proportion of positive voxels centrally in the periventricular/corpus callosum/brainstem/4th 
ventricle regions (arrow heads). 
3. Negative voxels in the right parietal region (parenthesis). 
These differences in the normal control and NF1 templates indicate the potential for normalisation bias. 
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Figure 8.3: Comparison between the normal control template and the NF1 template at different 
levels of smoothing. 
(see figure legend on previous page) 
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8.5.3.2 Normalisation bias: Discrepant SPM results when using the normal control 
template and the NF1 template 
 
Figure 8.4 shows the SPM results of a two-sample t-test looking for reduced FDG uptake 
in the NF1 patients compared to the normal controls dataset, when using the normal 
control template and the NF1 template. Results for 8mm and 16mm scan smoothing are 
displayed. These results are the first look at possible regions of hypo-metabolism in the 
NF1 group and show a very strong signal of thalamic hypo-metabolism with possible 
smaller less significant regions of hypo-metabolism elsewhere. The glass brain displays 
shows larger supra-threshold clusters in the SPM maps when using the normal controls 
template compared to the NF1 template. The sum total of the supra-threshold voxels in 
each analysis confirm that with 8mm scan smoothing there are 17% more supra-threshold 
voxels in the resulting SPM maps using the normal control template compared to the 
NF1 template (7,875 voxels and 6,744 voxel, respectively), and 14% more with 16mm 
scan smoothing (20,453 voxels and 17,924 voxels, respectively). The choice of either the 
normal control or NF1 template has a clear effect on the resulting SMP maps and 
therefore the use of one or the other template may be biasing the results. Hence a custom 
template comprising of a combination of the normal control subjects plus NF1 subject is 
likely to perform more uniformly across the entire dataset. 
 
When the SPM maps are overlayed on the T1 MRI template provided with SPM8 it 
appears that there are suprathreshold voxels near the edge of the brain in the left parietal 
region, in a periventricular distribution, and inferior to the cerebellar hemispheres (see 
Figure 8.5). These areas are possibly due to artefacts related to normalisation errors or 
over-smoothing of the scans and will be further discussed in the next sub-section. 
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Figure 8.4: SPM results for hypo-metabolism in the NF1 group compared to the normal control 
dataset using two different normalisation templates: the normal control template and the NF1 
template. 
The SPM glass brain displays using the normal control template are on the left column and the using the 
NF1 template are on the right column. Scan smoothing of 8mm is on the top row and scan smoothing of 
16m is on the bottom row. The total number of supra-threshold voxels in each SPM map is indicated. 
There are 17% more supra-threshold voxels when using the normal control template than when using the 
NF1 template at 8mm scan smoothing, and 14% more at 16mm scan smoothing. These differences in SPM 
results are suspicious for a systematic differences in normalisation between the normal controls scans and 
NF1 scans, particularly given the differences in these two template shown in the previous Figure (Figure 
8.3). 
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Figure 8.5: The same SPM results as figure 8.4 but now overlayed on the single subject T1 MRI 
template provided with SPM8. 
Clusters are larger in the 16mm scan smoothing compared to 8mm, and larger when using the normal 
control template compared to the NF1 template. Supra-threshold clusters are seen in the region of the 
thalamus with the cluster extending to a periventricular pattern in the region of the corpus callosum (open 
arrows) and 4th ventricle (closed arrows). Supra-threshold clusters are also seen at the edge of the brain 
volume in the left parietal region (closed arrow head) and inferior to the cerebellum (open arrow heads). 
These patterns of supra-threshold voxels are suggestive of artefacts related to inadequate normalisation 
across both groups of scans and could relate to the structural difference in the brains of children with NF1 
compared to unaffected children particularly in relation to the corpus callosum [133]. 
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8.5.3.3 Templates to minimise normalisation bias: Assessment of a combined 
template and a balanced template 
 
Figure 8.6 shows the SPM results for assessing hypo-metabolism in the NF1 group 
compared to the normal control dataset, using the combined and balanced templates both 
smoothed by 16mm and across the various levels of scan smoothing. The glass brain 
displays of the SPM results are shown when using the combined template and the 
balanced template, at all four levels of scan smoothing. Visual comparison shows 
patterns of supra-threshold voxels emerging related to degree of scan smoothing and the 
normalisation template used. The (presumably normalisation related) artefacts in the left 
parietal region and inferior to the cerebellum are both more prominent on the combined 
template than on the balanced template, and are also more prominent at higher levels of 
scan smoothing. At moderate levels of scan smoothing there were supra-threshold 
clusters seen bilaterally in the mesial frontal lobe regions that were very much more 
apparent when using the combined template. Given the artefacts seen elsewhere with the 
use of the combined template, these clusters are suspicious for further normalisation 
artefacts. These results support the selection of the balanced template as the optimal 
template rather than the combined template, to reduce possible artefacts on the SPM map. 
 
Figure 8.6 (following page): SPM results for hypo-metabolism in the NF1 group compared to the 
normal control dataset using two different normalisation templates: the combined template and the 
balanced template. 
Results are shown at different levels of scan smoothing. The glass brain displays are shown with the results 
using the combined template in the left column and the balanced template in the right column. The degree 
of scan smoothing is indicated on the four rows. The main features are: 
Artefacts at the edge of the brain in the left parietal region (closed arrow head) and inferior to the 
cerebellum (open arrow head) that are more apparent with the combined template and with higher degrees 
of scan smoothing. 
The clusters in the mesial frontal lobe regions (arrows) are most prominent in the combined template with 
8mm scan smoothing suggesting further artefacts. 
Overall the results indicate the improved performance of the balanced template and this was chosen as the 
optimal template for SPM analysis. 
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Figure 8.6: SPM results for hypo-metabolism in the NF1 group compared to the normal control 
dataset using two different normalisation templates: the combined template and the balanced 
template. (see figure legend on previous page) 
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8.5.3.4 Optimal template smoothing and scan smoothing parameters 
 
Figure 8.7 shows the SPM results for hypo-metabolism in the NF1 group compared to 
the normal control dataset using the optimal normalisation template, ie. the balanced 
template. The glass brain displays for each of the 16 different combinations of template 
smoothing and scan smoothing are shown. Several patterns emerge from which the most 
suitable template and scan smoothing combination can be chosen. All SPM maps show 
strong evidence of hypo-metabolism in the thalami across all levels of template and scan 
smoothing. This highly consistent finding strongly supports that this is a true result and 
not related to aberrant normalisation or inappropriate scan smoothing. There are 
differences elsewhere in the brain with various smaller supra-threshold clusters scattered 
around the cerebral cortex with a noticeable clusters becoming more apparent at the edge 
of the brain volume in the left parietal region and inferior to the cerebellum. These 
appearances appear similar to those seen in the previous sub-section with the less optimal 
templates and have a configuration suspicious for statistical artefacts related to low 
variability in voxel intensities in masked areas outside of the brain volume that are close 
to the surface of the non-masked brain volume. Such artefacts are known to occur in 
voxel-wise statistical analysis of brain images, particularly near the interface of different 
tissues such as near the outer surface of the brain or near the cerebral ventricles [7]. The 
supra-threshold clusters in the region of the mesial frontal lobes when using the 
combined template are seen in the balanced template with 24mm template smoothing and 
8mm scan smoothing. This is not a consistent finding and remains suspicious for an 
artefact most likely related to over-smoothing of the template because the left parietal 
and inferior cerebellum edge artefacts were most apparent with 24mm template 
smoothing. 
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Overall these results indicate that higher levels of template smoothing are probably 
exacerbating edge related artefacts, most noticeably in the left parietal region and inferior 
to the cerebellum. These effects are less apparent and in fact, disappear with the lower 
levels of template smoothing. The non-scan smoothed results in addition to the large 
supra-threshold clusters in the region of the thalami, appear to have more very small 
clusters (some comprising of only 1 or 2 voxels) elsewhere in the brain which can be 
explained by statistical noise in the absence of applied smoothing to increase the signal 
to noise ratio. Based on these appearances the non-smoothed template appears to be the 
most appropriate to avoid artefacts at the edge of the brain, and when applied with a 
small amount of scan smoothing (8mm) to increased signal to noise ratio. The optimal 
normalisation template, template smoothing and scan smoothing was therefore 
considered to be the balanced template with no further applied template smoothing and 
8mm scan smoothing. This template and smoothing parameters was used in the pre-
processing of the SPM two-sample t-test procedure to test for evidence of cerebral hypo-
metabolism in the NF1 group compared to the normal control dataset. 
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Figure 8.7: SPM results using the optimal, balanced template with all 16 different combinations of 
template smoothing and scan smoothing. 
The degrees of template smoothing are indicated across the top of the columns and the degrees of scan 
smoothing are indicated at the left of the rows. The glass brain displays of the SPM maps are shown for 
each combination of template and scan smoothing. The patterns that emerge are: 
1. Hypo-metabolism in the region of the thalami is a consistent findings across all template and scan 
smoothing combinations 
2. Edge artefacts are present in the left parietal region (closed arrow head) and inferior cerebellum (open 
arrow head); both more prominent with the higher levels of template and scan smoothing. 
3. Supra-threshold cluster is seen in the mesial frontal lobe regions with 24mm template smoothing; an 
inconsistent finding and probably also an artefact related to inaccurate normalisation. 
4. Scattered, very small supra-threshold clusters seen with no scan smoothing suggesting statistical noise 
related to inadequate smoothing to improve the signal to noise ratio of the voxel-wise intensities. 
These findings support the use of a template with no added smoothing, and a low level of scan smoothing 
for optimal results. The balanced template with no added smoothing and 8mm scan smoothing was chosen 
as the optimal combination for use in subsequent SPM analysis. 
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8.5.4 SPM analysis: Regions of hypo-metabolism in NF1 patients 
compared to the normal control dataset 
 
In the previous section the optimal normalisation template and the optimal template and 
scan smoothing parameters were determined. In this section these optimal pre-processing 
parameters have been applied in a SPM comparison of the NF1 patients with the normal 
control subjects to detect regions of hypo-metabolism in the NF1 group. The statistical 
thresholds and family-wise voxel level correction for multiple comparisons were used as 
described in the Methods section. 
 
Figure 8.8 shows the SPM results including the glass brain display of the SPM map, the 
statistical model and contrast matricies, and the statistical output. The results show a 
supra-threshold cluster of 3,715 voxels in the region of the thalami bilaterally providing 
very strong evidence for hypo-metabolism in this region in the NF1 patients compared to 
the normal control subjects. When the SPM results are shown overlayed on the T1 MRI 
template provided within SPM8 the cluster appears to involve both thalami and extend 
postero-laterally to involve the cortex of the medial temporal lobes, bilaterally (Figure 
8.9). 
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Figure 8.8: SPM output results for hypo-metabolism in the NF1 group compared to normal controls. 
The glass brain display, statistical model and contrast matricies, and SPM8 statistical output table for the 
analysis of reduced FDG uptake in the NF1 patients compared to the normal control subjects are shown. 
Statistical thresholding consisted of a FWEp corrected voxel level threshold of p<0.05 and a cluster extent 
threshold of 20 voxels. There is a 3,715 voxel supra-threshold cluster in the region of the thalami 
bilaterally. 
 
 
 
 
 
 
Figure 8.9 (following page): SPM output results for hypo-metabolism in the NF1 group compared to 
normal controls overlayed on T1 MRI template. 
The SPM results showing voxels with evidence of reduced FDG uptake in the NF1 group compared to the 
normal control subjects, overlayed on the T1 MRI template provided with SPM8 in the coronal plane from 
posterior to anterior (upper images, MNI coordinate of each slice in the y-axis is indicated) and in the 
transaxial plane from inferior to superior (lower images, MNI coordinate of each slice in the z-axis is 
indicated). The distance between slices is 2mm in both planes. The t-score colour scale is shown in the 
bottom right of the figure (images created using xjView SPM toolbox (http://www.alivelearn.net/xjview)). 
The hypo-metabolic region appears to encompass the thalami bilaterally (closed arrow heads) and extends 
postero-laterally on both sides to involve the cortex of both medial temporal lobes (open arrow heads). 
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Figure 8.9: SPM output results for hypo-metabolism in the NF1 group compared to normal controls 
overlayed on T1 MRI template. 
(see figure legend on previous page) 
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The SPM results were thresholded with an extremely strict FWEp voxel-wise threshold 
of p<0.000 001 which filtered out some of the lower level significant voxels and split the 
single FWEp p<0.05 cluster into two clusters. Using this extremely strict statistical 
thresholding the SPM output identified four distinct statistical peaks (local maxima) at 
MNI coordinates [-22, -34, -8], [-14, -28, 0], [16, -28, -2] and [22, -34, -4] (see Figure 
8.10). Figure 8.11 shows the SPM results using this stricter threshold overlayed on the 
T1 MRI template provided with SPM8 and more clearly shows the most highly 
significant voxels within the cluster to visually, involve the thalami and medial temporal 
cortex, bilaterally. Figure 8.12 shows the results of the SPM analysis thresholded at 
FWEp p<0.05 and p<0.000 001 overlayed on the T1 MRI SPM template with the cross 
hairs placed on the four local maxima. These four voxel local maxima localise to the 
thalami and medial temporal cortex, bilaterally. Figure 8.13 shows the same SPM results, 
but this time overlayed on the balanced custom FDG template. The balanced template is 
made up of the pediatric cerebral FDG dataset being interrogated by SPM and 
notwithstanding the spatial resolution of FDG PET, may provided a better estimate of 
voxel localisation than the adult T1 MRI template provided with SPM8. The voxel 
response at these four local maxima are plotted for the NF1 patients and the normal 
control dataset (see Figure 8.14) and graphically depict the lower age adjusted voxel 
response in the NF1 patients compared to the normal control subjects across all ages. 
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Figure 8.10: SPM output results for hypo-metabolism in the NF1 group compared to normal 
controls with more strict statistical thresholds. 
The glass brain display, statistical model and contrast matricies, and SPM8 statistical output table for the 
analysis of reduced FDG uptake in the NF1 patients compared to the normal control subject sare shown, 
using an extremely strict FWEp voxel level statistical threshold of p<0.000 001. Using this threshold 
separates out the four peaks contained within the single 3,715 voxel supra-threshold cluster that occurred at 
the FWEp p<0.05 threshold. The MNI coordinates of these four peaks are listed in the SPM statistics 
output table. 
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Figure 8.11: SPM results with a more strict FWEp threshold overlayed on T1 MRI template. 
The SPM results thresholded at FEWp p<0.000 001, overlayed on the T1 MRI template provided within 
SPM8, presented in the coronal plane from posterior to anterior (upper images, the MNI coordinate of each 
slice in the y-axis is indicated) and in the transaxial plane from inferior to superior (lower images, the MNI 
coordinate of each slice in the z-axis is indicated). The distance between slices is 1mm in both planes. The 
t-score colour scale is shown in the bottom right of the figure (images created using xjView SPM toolbox 
(http://www.alivelearn.net/xjview)). Using this more strict statistical threshold, the most highly significant 
clusters containing the four local maxima can more clearly been seen to involve the thalami bilaterally 
(closed arrow heads) and the cortex of both medial temporal lobes (open arrow heads). 
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Figure 8.12: SPM results at two different statistical overlaid on the T1 MRI template provided 
within SPM8. 
SPM results thresholded at FWEp p<0.05 (top panel) and p<0.000 001 (bottom panel), overlaid on the T1 
MRI template provided within SPM8 and displayed in multi-planar format. Cross hairs are placed on the 
four local maxima at the following MNI coordinates: left thalamus [-14, -28, 0], right thalamus [16, -28, -
2], left medial temporal cortex [-22, -34, -8] and right medial temporal cortex [22, -34, -4]. The local 
maxima are able to be more clearly localised on the more highly thresholded SPM map. 
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Figure 8.13: SPM results at two different statistical overlaid on the custom “balanced” FDG 
template. 
SPM results thresholded at FWEp p<0.05 (top panel) and p<0.000 001 (bottom panel), overlayed on the 
custom “balanced” FDG template used in the SPM pre-processing and displayed in multi-planar format. 
Cross hairs are placed on the four local maxima at the following MNI coordinates: left thalamus [-14, -28, 
0], right thalamus [16, -28, -2], left medial temporal cortex [-22, -34, -8] and right medial temporal cortex 
[22, -34, -4]. The local maxima are able to be more clearly localised on the more highly thresholded SPM 
map. The balanced template is made up of the pediatric cerebral FDG dataset being interrogated by SPM 
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and notwithstanding the limited spatial resolution of FDG PET, may provided a better visual judgement of 
voxel localisation than the adult T1 MRI template provided with SPM8. 
 
Figure 8.14: Age adjusted SPM voxel response data at the four local maxima within the 3,715 voxel 
suprathreshold cluster. 
Data has been extracted from the two-sample t-test at the FWEp p<0.05 threshold looking for voxels with 
reduced FDG uptake in the NF1 group compared to the normal controls subjects and using the optimal 
SPM pre-processing parameters. The voxel response data has been centered to the mean (the default setting 
within SP8) and the linear trend lines for each group is plotted accordingly. The lower FDG uptake in NF1 
patients compared to the normal control subjects identified on the SPM map is clearly depicted across the 
age range at each local maxima.  
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Figure 8.15 shows the SPM map of the one-sample t-test results detecting areas of 
increasing FDG uptake with age in the normal control subjects (from Chapter 4) 
alongside the SPM map of the same analysis in all of the NF1 patients. The SPM glass 
brain displays are shown along with the results overlayed on a single subject surfaced 
rendered brain (“SPM96” in SPM8) and overlayed on selected axial slices of the adult T1 
MRI template provided with SPM8. There are some features worth mentioning. Firstly, 
the overall pattern of increasing FDG uptake with age is similar in both groups, albeit 
with generally less extensive regions in the NF1 group. However, the overall pattern is 
similar with increasing FDG uptake most extensively occurring in the bilateral frontal 
lobes, with less extensive involvement of the cingulate gyrus, striatum, thalamus and 
cerebellum. The main difference is the absence of increasing uptake with age in the right 
cerebellum and inferior temporal lobes in the NF1 group. This apparent discordance was 
further investigated by plotting the SPM voxel response data from the left and right 
cerebellum in both groups (see Figures 8.16 and 8.17). Note that the cerebellum did not 
show evidence of reduced FDG uptake compared to the normal control subjects. Figure 
8.16 shows the similar positive linear relationship between FDG uptake and age in the 
left cerebellum. In the right cerebellum, Figure 8.17 shows the positive linear 
relationship between FDG uptake and age in the normal control subjects, and there is 
much more variability in FDG uptake in the NF1 patients across the age range. The 
scatter in the data from then NF1 patients in the right cerebellum is such that there is no 
longer evidence of a linear association with age and hence this was not highlighted in the 
SPM map in this group. It is likely that a similar phenomenon is occurring in the inferior 
temporal lobes and other regions with the NF1 patients did not show evidence of linearly 
increasing FDG uptake with age. 
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Figure 8.15: SPM maps of increasing FDG uptake with age in patients with NF1 and normal control 
subjects. 
Comparison of SPM results of the one-sample t-tests to show areas of increasing FDG uptake with age in 
the normal control subjects (left panel: A, B, C) and NF1 patients (right panel: D, E, F). The SPM results 
are shown in glass brain displays (A, D), overlayed on a single subject surfaced rendered brain (“SPM96” 
in SPM8; B, E), and overlayed on selected axial slices of the adult T1 MRI template provided with SPM8 
(the MNI coordinate of each slice in the z-axis are indicated; C, F). Both the normal control subjects and 
the NF1 patients show a similar regional pattern of increasing FDG uptake with age. In both groups the 
overall pattern of increasing FDG uptake with age occurs most extensively in the bilateral frontal lobes, 
with less extensive involvement of the cingulate gyrus, striatum, thalamus and cerebellum. However, there 
are apparent differences between the two groups including the absence of increasing uptake with age in the 
right cerebellum, small areas of the inferior temporal lobes and in the mid cingulate gyrus in the NF1 group. 
The NF1 group also has correlating but less extensive areas of increasing FDG uptake with age in the 
subcortical grey matter. These discordant regions likely relate to more variability in FDG uptake across the 
age range (see Results and Figures 8.16 and 8.17 for further explanation). 
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Figure 8.16: Left cerebellar voxel response in NF1 and normal controls. 
Voxel response at the left cerebellum for the NF1 patients and the normal control dataset is shown, from 
their respective one-sample t-tests to show areas of increasing FDG uptake with age. The locations of the 
voxels from which the data was taken are indicated on the marked panels in the lower right of the graph 
(SPM results overlayed on the single subject T1 MRI template provided within SPM8). Linearly increasing 
FDG uptake with age is seen in both groups in the left cerebellum and the linear regression lines are plotted. 
There was no evidence of a significant difference between the two groups in the left cerebellum on the 
two-sample t-test. 
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Figure 8.17: Right cerebellar voxel response in NF1 and normal controls. 
Voxel response at the right cerebellum for the NF1 patients and the normal control dataset is shown, from 
their respective one-sample t-tests to show areas of increasing FDG uptake with age. The location of the 
voxel from which the data was taken is indicated on the marked panels in the upper left of the graph (SPM 
results overlayed on the single subject T1 MRI template provided within SPM8). Linearly increasing FDG 
uptake with age is seen in the normal control group (the linear regression line is plotted) but no association 
with age is apparent in the NF1 patients (the mean voxel response is plotted. There is much more 
variability in the voxel response across the age range in the NF1 patients which in comparison to the 
normal control group is due to down-scatter of the voxel intensities across the age range. No evidence of a 
significant difference between the two groups in the right cerebellum was found on the two-sample t-test. 
 
8.6 Discussion 
It has been shown in this Chapter that when using an SPM analysis comparing children 
with NF1 to unaffected children, patients with NF1 have reduced FDG uptake in the 
thalamus and medial temporal lobe, bilaterally. These results correlate to the findings 
from Chapter 7 where qualitative and semi-quantitative (SUVmax) methods were used. 
Thalamic hypo-metabolism is consistent with previous SPM and non-SPM studies of 
cerebral FDG uptake in adults and children with NF1 [67, 121-123], however medial 
temporal lobe hypo-metabolism is a new, previously unreported finding. 
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As mentioned in the previous chapter, it can be hypothesised that medial temporal lobe 
hypo-function may be related to the memory and/or visuo-spatial processing difficulties 
experienced by children with NF1 [111-114]. There appear to not be any direct correlates 
to the medial temporal region on the very few functional MRI studied in NF1 which have 
shown an increased reliance on the inferior frontal and superior temporal areas during a 
reading task [147]; and more reliance on the posterior cortical regions [148] and 
decreased activation of the primary visual cortex [149] during visuo-spatial tasks in NF1.  
 
The FDG scans analysed in this chapter were conducted under a state of rest within a 
darkened room, supine and with minimal stimulation. They therefore resemble an 
approximate resting state assessment of cerebral metabolism. It is possible that the 
thalamic and medial temporal cortex hypo-metabolism form part of a resting state 
network that in children with NF1 is not as active as in non-affected children. No resting 
state connectivity studies have been published in children with NF1 to provide support 
for this hypothesis. 
 
There is evidence that temporal lobe epilepsy is associated with ipsilateral thalamic 
atrophy [150] suggesting a more direct link and the presence of temporo-thalamic 
networks that may be relevant in the thalamic and medial temporal hypo-metabolism in 
NF. Further, it is possible that including structural and/or functional imaging changes in 
the medial temporal lobes could strengthen the early evidence linking thalamic T2H to 
neuro-cognitive dysfunction in NF1 [117-120]. 
 
The reduced FDG uptake in the occipital lobes and the left cerebellum seen on the 
regional relative uptake (RU) analysis presented in Chapter 7 did not emerge on the 
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current SPM analysis. These discrepancies can be explained by the very different 
methods of analysis. The RU analysis was a qualitative estimate of FDG uptake within 
large, irregular regions of the cerebral cortex relative to maximal cortical uptake. The 
readers of these scans therefore subjectively pool the uptake observed at a voxel level 
within the larger lobar region to form an overall estimate of regional activity. The SPM 
analysis normalises voxel intensity to global mean voxel activity and performs a 
quantitative statistical comparison on each and every voxel across the whole brain 
volume (ie. a mass univariate voxel-wise approach). It is therefore plausible that small, 
non-significant, voxel-wise differences in FDG uptake could become larger, more 
apparent, lobar-wise differences when pooled subjectively by an individual reader. While 
both methods are valid, the SPM approach is inherently more quantitative, reproducible 
and with the strict pre-processing evaluation presented in this Chapter is less likely to 
produce false positive results. 
 
This Chapter has also shown the regional pattern of increasing cerebral FDG uptake with 
age occurring in children with NF1. This has not been reported previously. The pattern is 
similar to unaffected children, although the geographic extent of the involved cerebral 
regions were generally less extensive and did not include the right cerebellum and small 
areas of the inferior temporal lobes and the mid cingulate gyrus which were apparent in 
the normal control subjects. Data has been presented for the right cerebellum that shows 
significantly more variability in FDG uptake in NF1 than in the normal controls which 
accounts for the absence of a statistically significant linear association with age. The 
increased variability in FDG uptake appeared to be primarily due to down-scatter of the 
voxel intensities in NF1 across the age range. This effect is also likely to be responsible 
for the absence of a linear relationship in the small areas of the inferior temporal lobes 
and the mid cingulate gyrus, which were apparent in the normal controls; and the 
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generally smaller geographic extent of the involved cerebral regions elsewhere in the 
cortex and subcortical nuclei. This effect could be due to the presence of T2H in the 
cerebellum and also account for the variability elsewhere. Further analysis of the NF1 
dataset including cerebral MRI imaging is required to correlate the location of T2H to the 
regions of more variable FDG uptake and test this hypothesis. 
 
The major strengths of the current SPM analysis are the large sample size, robust nature 
of the control dataset, no previous chemotherapy or neurosurgery in the included NF1 
patients, dedicated brain PET acquisitions in all of the patients, use of a custom FDG-
specific normalisation template and rigorous iterative interrogation of the various SPM 
pre-processing parameters to reduce false positive results. These aspects far supersede 
the only two other published reports of SPM analysis in adult or pediatric NF1. 
 
There is literature supporting the use of custom created normalisation templates when 
analysing cerebral PET and structural MRI paediatric scans to avoid errors related to 
inadequate normalisation to adult based templates [6, 151]. There is also evidence that 
the use of normalisation templates different to the tracer used in the study participants 
leads to errors in the resulting SPM map [152] and that custom made FDG PET 
templates in SPM perform close to that of normalisation using structural MRI scans [45]. 
The two previously published studies of cerebral FDG scans in NF1 used the non-FDG, 
adult PET template provided with SPM8 and neither attempted to assess the effects of 
different template or scan smoothing parameters. 
 
The SPM analysis presented in this chapter applied strict statistical thresholds to limit the 
chance of identifying false positive hypo-metabolic regions in children with NF1. A 
stringent method to control for multiple comparisons was used, namely family-wise error 
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peak voxel correction (FEWp) with a threshold of p<0.05 [10]. This method of multiple 
comparison correction is generally believed to be extremely strict and may in fact reduce 
the chance of false positive results at a cost of reducing power. A cluster extent threshold 
of 20 voxels (0.16 cm3 of neural tissue in the scan after normalisation to the standard 
MNI space) was used to account for extremely small clusters that would not be 
biologically plausible. The surviving supra-threshold cluster involving the thalamus and 
medial temporal cortex bilaterally was 3,715 voxels in size (30 cm3 of neural tissue in the 
scan after normalisation to the standard MNI space). 
 
The normal control dataset used in the current study is the largest, paediatric aged control 
dataset reported and is comprised of children with no known neurological abnormalities. 
However, these subjects all had suspected or proven extra-cranial malignancies (see 
Chapter 3 for a full description of the normal subjects). While these subjects are more 
likely to have a true normal cerebral FDG distribution that children with neurological 
disorders and/or previous seizures, previous adult studies have shown various scattered 
regions of altered FDG uptake comparing adults with untreated lung cancer [79] and 
malignant lymphoma [80] to adults without cancer. Given the changes in regional 
cerebral FDG uptake that occur with age during childhood, it is reasonable to expect that 
a control dataset of paediatric patients with extra-cranial cancer is more appropriate than 
a control dataset of adult patients without cancer, especially when the analysis includes 
scans in young children. 
 
A limitation with any statistical analysis of FDG PET brain images, is how to deal with 
differences in global FDG uptake. The most common approach is to scale the image to a 
common threshold, usually global mean activity. While this method nicely accounts for 
global differences due to experimental factors such as variability in injected dose and 
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uptake times, it has the potential to bias the SPM results if there are biological causes for 
differences in global mean uptake between the two groups being compared. This effect 
has been elegantly described with simulation studies of cerebral blood flow using PET in 
where there was false identification of subcortical regions of increasing uptake due to 
reducing overall mean activity and static uptake in the subcortical regions [52-54]. 
Within the context of the SPM methodology used in the current chapter, spurious 
thalamic and medial temporal hypo-metabolism hypothetically could occur if there was 
increased uptake elsewhere producing an increase in the scaling factor, global mean 
activity. This is an unlikely situation because the semi-quantitaive, SUVmax analysis in 
Chapter 7 showed correlative evidence of thalamic and medial temporal cortex 
hypometabolism and also the available literature supports reduced thalamic FDG uptake 
in NF1 using other methods not requiring a global scaling procedure [121, 123]. 
 
Atlas based localisation methods were not used in the current analysis but instead 
localisation relied on the visual assessment of the resulting SPM maps superimposed on 
the T1 SPM template and also the FDG template created from the scans of the entire 
dataset itself. The only previous study published using SPM in children with NF1 used 
an adult Talairach based atlas to localise areas of supra-threshold clusters. These atlas 
based methods of localisation have the potential to over state the spatial precision of the 
results from function brain imaging studies [57] particularly when analysing pediatric 
brains. Notwithstanding these limitations, the qualitative assessment of the SPM results 
from our study appear to clearly localise hypo-metabolic regions close to but outside of 
the thalamus bilaterally, to the region of the medial temporal cortices. These appearances 
in combination to the thorough consideration towards minimising normalisation errors in 
pre-processing related and artefacts created by over-smoothing of the scans, provide 
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compelling evidence for hypo-metabolic regions occurring in the medial temporal lobes 
and thalamus in children with NF1. 
 
8.7 Conclusion 
This chapter has confirmed the suggestions on previous studies that children with NF1 
have reduced thalamic FDG uptake compared to unaffected children and in addition, it 
has shown for the first time in a robust voxel-wise SPM analysis that similarly reduced 
FDG uptake is seen in the medial temporal lobes. It has also for the first time 
demonstrated that the overall regional pattern of increasing FDG uptake with age in 
children with NF1, while similar to normal control subjects, has generally less extensive 
regional involvement and the absence of this relationship in the right cerebellum, small 
areas of the inferior temporal lobes and in the mid cingulate gyrus. 
 
Further analysis to identify the relationship of these metabolic abnormalities to neuro-
cognitive deficits and MRI structural lesions or T2H is the next step in understanding the 
importance of FDG PET imaging as a potentially important neurological biomarker in 
children with NF1. 
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9 CHAPTER NINE: THESIS SUMMARY AND 
CONCLUSIONS 
 
 
The first major aim of this thesis was to recruit and descriptively analyse a high quality 
dataset of dedicated cerebral FDG PET CT scans in neurologically normal children. This 
has been comprehensively achieved and Chapter 3 was the largest published report on 
normal cerebral FDG uptake during childhood. The major limitation common to the few, 
smaller previously published reports on this topic has been addressed and none of the 
normal control subjects included in this thesis had a previous neurological event or 
associated neurological abnormality. The findings were novel and showed conclusively 
that a relative pattern of cerebral FDG uptake similar to adults does not occur by one year 
of age but there are in fact changing patterns of regional FDG uptake that occur 
throughout childhood driven by different regional rates of age related increasing FDG 
uptake. 
 
The second major aim was to implement SPM analysis of the normal control dataset and 
also to demonstrate the use of SPM to compare patient scans to the dataset to identify 
regions of abnormal FDG uptake. The SPM analysis of the normal control dataset 
presented in Chapter 4 produced more regionally specific information of areas of the 
brain showing increasing cerebral metabolism with age. Whole brain, voxel-wise 
assessment is a particular strength of SPM analysis. SPM had not previously been used in 
this way with dedicated cerebral FDG scans in children. 
 
In combination, the qualitative, semiquantitative (SUV) and SPM analyses of the normal 
control dataset presented in Chapters 3 and 4 form the most comprehensive evaluation of 
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cerebral metabolic activity in neurologically normal children and provide a significant 
contribution to the paediatric neurological literature. The limitations of the analysis 
included the inability to control for the effect of the presence of an extra-cranial 
malignancy in many of the control subjects, a limitation unlikely to be able to be 
resolved, and the absence of data in children less than 11 months of age. This very young 
age group requires further investigation because extrapolating the data obtained from 
older children into the infant age group may not be valid. 
 
The thesis incorporated rigorous technical evaluation of the SPM method with Chapter 5 
devoted to determining specificity optimised SPM parameters to limit false positive 
findings. There was a considerable difference in the specificity optimised statistical 
thresholds required to limit false positive findings for hypo and hyper-metabolism. This 
finding implies that the topology of regional neural activity in children under states of 
minimal stimulation contain inconsistent areas of neuronal activation which maybe 
related to resting state networks. 
 
Chapter 6 proved that single-subject versus group SPM analysis of cerebral FDG scans in 
children with medically intractable epilepsy is clinically useful when applied with a 
suitable normal control dataset. The results are highly specific for predicting improved 
seizure control with localising a hypo-metabolic focus to the planned surgical resection 
site. The results in this thesis come from the largest reported group of FDG scans in 
children with epilepsy and highlight the importance of acquiring scalp surface EEG data 
during the uptake phase to correlate with the FDG imaging findings. 
 
Chapters 7 and 8 form the largest and most comprehensive evaluation of cerebral FDG 
scans in children with NF1. The results confirm the presence of thalamic hypo-
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metabolism in NF1 and have revealed new areas of cortical hypo-metabolism. The 
findings require correlation with further studies but localise the medial temporal lobes as 
another site of neuronal dysfunction in the brain of children with NF1. This finding may 
be related to the neurocognitive defects that profoundly affect children with this common 
genetic disorder. The SPM analysis presented in Chapter 8 is an example of a group 
versus group SPM comparison and this methodology can be applied to any clinical group 
of paediatric patients with neurological disorders. 
 
SPM analysis as demonstrated in this thesis has significant advantages over subjective 
visual assessment and semi-quantitative (SUV) analysis in that it is inherently 
quantitative when voxel intensities are proportionally normalised to whole brain activity 
and also reproducible, enabling longitudinal assessment in the same patients. The SPM 
technique involves highly technical pre-processing of FDG scans that, as demonstrated in 
Chapter 8, require an iterative approach to identify possible artefacts and a degree of 
understanding of biostatistical processes to correctly interpret the output SPM maps. 
With the availability of a suitable normal control dataset, such as the one described in 
this thesis, SPM analysis of paediatric cerebral FDG PET CT scans may become more 
widespread and has the ability to provide a means to detect and monitor abnormal 
neuronal metabolism in children with a range of neurological disorders. 
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